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Abstract
Assessment of human exposure to environmental chemicals is inherently subject to un-
certainty and variability. There are data gaps concerning the inventory, source, duration,
and intensity of exposure as well as knowledge gaps regarding pharmacokinetics in general.
These gaps result in uncertainties in exposure assessment. The uncertainties compound fur-
ther with variabilities due to population variations regarding stage of life, life style, and sus-
ceptibility, etc. Use of physiologically-based pharmacokinetic (PBPK) models promises to
reduce the uncertainties and enhance extrapolation between species, between routes, from
high to low dose, and from acute to chronic exposure. However, fitting PBPK models
is challenging because of a large number of biochemical and physiological parameters to
be estimated. Many of these model parameters are non-identifiable in that their estimates
cannot be uniquely determined using statistical criteria. In practice some parameters are
fixed in value and some determined through mathematical calibration or computer simula-
tion. These estimated values are subject to substantial uncertainties. The first part of this
paper illustrates the use of iteratively-reweighted-nonlinear-least-squares for fitting phar-
macokinetic (PK) models, highlighting some common difficulties in obtaining statistical
estimates of non-identifiable parameters and use bootstrap confidence interval to quantify
uncertainties.
Statistical estimation of parameters in physiologically based pharmacokinetic (PBPK)
models is a relatively new area of research. Over the past decade or so PBPK models have
become important and valuable tools in risk assessment as these models are used to de-
scribe the absorption, distribution, metabolism, and excretion of xenobiotics in a biological
system such as the human or rat. Because these models incorporate information on biolog-
ical processes, they are well equipped to describe the kinetic behaviors of chemicals and
are useful for extrapolation across dose routes, between species, from high-to-low-doses,
and across exposure scenarios.
vi
A PBPK model has been developed based on published models in the literature to de-
scribe the absorption, distribution, metabolism, and excretion of Dioxin and dioxin like
compounds (DLCs) in the rat. Data from the National Toxicology Program (NTP) two
year experiment TR-526 is used to illustrate model fitting and statistical estimation of the
parameters. Integrating statistical methods into risk assessments is the most efficient way to
characterize the variation in parameter values. In this dissertation a Markov Chain Monte
Carlo (MCMC) method is used to estimate select parameters of the system and to describe
the variation of the select parameters.
vii
1 Chapter One: Introduction / Literature Review
1.1 Background
TCDD (2;3;7;8-Tetrachlorodibenzo-p-dioxin; CAS 1746-01-6) or dioxin is a chlori-
nated hydrocarbon, and is the prototype of the polyhalogenated aromatic hydrocarbon
(PHAH) family, which includes dibenzo-p-dioxins (PCDDs), dibenzofurans (PCDFs),
biphenyls, and polychlorinated biphenyls (PCB). The most toxic compound in this fam-
ily is considered to be 2,3,7,8-tetrachlorodibenzo-p-dioxin or TCDD. Sometimes the term
dioxins also commonly refers to chlorinated dibenzo-p-dioxins and furans to chlorinated
dibenzofurans.
Dioxin is formed as an unintentional by-product of many industrial processes involv-
ing chlorine such as waste incineration, chemical and pesticide manufacturing and pulp
and paper bleaching. Specifically it was a common contaminant of the herbicide 2,4,5-
trichlorophenoxyacetic acid (Hamilton and Hardy, 1998). Dioxin and dioxin like chemicals
(DLCs) are found everywhere around us and we are all exposed to background levels. Soil
erosion and sediment transport in water and volatilization from the surfaces of soils and
water bodies with subsequent atmospheric transport and deposition are thought to be the
dominant mechanisms in the widespread environmental occurrence of PCBs (NRC, 2006).
Dioxin is notorious for being the primary toxic component of Agent Orange, a defoliate
famous for its use in the Vietnam war (Pirkle et al., 1989). It has also been found in
a number of the toxic waste sties, for example, underneath Love Canal in Niagara Falls
(Smith et al., 1983), NY and for accidental releases in Times Beach, MO (Umbreit, 1986)
and Seveso, Italy (Bertazzi et al., 1998). Soil contaminated with Dioxin and DLCS caused
the evacuation of Times Beach Missouri in 1983 and was the suspect in the death of local
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animals and a range of human illnesses. Times beach and Love Canal are two of the three
toxic waste sites that caused the creation of the Superfund law in 1980. (USDOJ, 1997)
Present day, the main sources of dioxin and dioxin like compounds releases into the
environment are from combustion and incineration sources, metal smelting, refining and
processing, chemical manufacturing and processing, biological and photochemical pro-
cesses, and existing reservoir sources that reflect past releases. PCB mixtures were com-
mercially produced and used in the electric power industry as dielectric insulating fluids in
transformers and capacitors and used in hydraulic fluids, plastics, and paints. These toxic
chemicals and chemical mixtures get into the soil (Freeman, 1986; McCrady, 1990) then
erosion and runoff transport them to bodies of water subsequently fish and other marine
life are exposed and the toxins bioaccumulate. This is believed to be the major mode by
which PCDD/PCDFs enter the aquatic food chain (Jensen, 2000).
In 1994 the National Institute for Occupational Safety and Health (NIOSH) classified
TCDD as an occupational carcinogen; thus exposure should be reduced to the lowest level
possible and there is no Permissible Exposure Limit (PEL) for dioxin (Hamilton and Hardy,
1998). Also the EPA has never published a Reference Concentration (RfC) or a Reference
Dose (RfD) for TCDD.
In general dioxin and dioxin-like compounds compounds have low vapor pressure, Low
water solubility, low rate of biotransformation and high lipophilicity. These properties give
dioxin and dioxin-like compounds (DLCs) high potential for bio-accumulation (Esposito et
al., 1980); they transport into and climb up our food chain. As a result, population exposure
to dioxin and DLCs mostly comes from food intake, specifically through the consumption
of fish, meat, and dairy products because dioxin and DLCs are fat-soluble (Schecter et al.,
2001).
These compounds share a common Ah receptor (AhR)-mediated mechanism of toxic
and biological responses (Safe, 1986; Birnbaum, 1994). They act via an Ah receptor in
both animals and humans. Exposure to dioxin and DLCs causes induction of proteins in
several tissues and binding alters gene expression. The Ah receptor is present in many
tissues in animals and humans most notably in the liver. Animal carcinogenesis has been
correlated with dioxin’s affinity for the Ah receptor (Steeland and Deddens, 2003).
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The most characterized biochemical response associated with TCDD exposure is the
induction of CYP1A1 (Whitlock, 1993), which involves the initial interaction of the ligand
with the multimeric cytosolic AhR complex (Chen and Perdew, 1994).
Evidence indicates that TCDD acts via an intracellular protein (the aryl hydrocarbon
receptor; Ah receptor), which functions as a ligand-dependent transcription factor in part-
nership with a second protein (known as the Ah receptor nuclear translocator; Arnt). There-
fore, from a mechanistic standpoint, TCDD’s adverse effects appear likely to reflect alter-
ations in gene expression that occur at an inappropriate time and/or for an inappropri-
ately long time. Mechanistic studies also indicate that several other proteins contribute
to TCDD’s gene regulatory effects and that the response to TCDD probably involves a
relatively complex interplay between multiple genetic and environmental factors (Poland,
1996; Limbird and Taylor, 1998).
The Seveso accident in 1976 caused a large, populated area north of Milan, Italy, to
be contaminated by 2,3,7,8- tetrachlorodibenzo-p-dioxin. In a follow up study the authors
followed the exposed population for chronic effects. They report the results of the mortality
follow-up extension for 1997 to 2001. The study cohort includes 278,108 subjects resident
at the time of the accident or immigrating/born in the 10 years thereafter in three contam-
inated zones with decreasing TCDD soil levels (zone A, very high; zone B, high; zone
R, low) also in a reference territory surrounding non-contaminated municipalities. Results
confirmed previous findings of excesses of lymphatic and hematopoietic tissue neoplasms
in the very high concentration zone (six deaths; rate ratio = 2.23, 95% confidence interval:
1.00, 4.97) and the high concentration (28 deaths; rate ratio = 1.59, 95% confidence inter-
val: 1.09, 2.33). These zones also showed increased mortality from circulatory diseases in
the years after the accident, from chronic obstructive pulmonary disease, and from diabetes
mellitus among females. Thus toxic and carcinogenic risk to humans after high TCDD
exposure is supported by the results of this study (Consonni et al., 2008).
TCDD exposure is widely recognized to produce severe chloracne (Cook et al., 1980).
It may also alter liver function. Long-term exposure is linked to impairment of the im-
mune system, endocrine system, and the reproductive system (ATSDR, 1998). Chronic
exposure at low levels has resulted in several types of cancer such as Cholangiocarcinoma
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and Hepatocellular adenoma in different animal species. Based on available animal data
and human epidemiological data, the WHOs International Agency for Research on Cancer
(IARC) classifies TCDD as ”carcinogenic to human”. The US Environmental Protection
Agency (USEPA) also classifies TCDD as a human carcinogen (EPA, 2002).
The major acute effects from exposure of humans to high levels of 2;3;7;8 TCDD
in air is chloracne, a severe acne-like condition that can develop within months of first
exposure. (ATSDR, 1998; EPA, 1997). Animal tests in species such as dogs, monkeys,
and guinea pigs have shown TCDD to have very high toxicity from oral exposure (ATSDR,
1998) .
The non cancerous Chronic Effects include Chloracne in humans while animal studies
have reported hair loss, loss of body weight, and a weakened immune system from oral
exposure (ATSDR, 1998). The ATSDR has calculated a chronic oral minimal risk level
(MRL) of 1e-09 milligrams per kilogram body weight per day (mg/kg/d) based on neu-
rological effects in monkeys. The MRL is an estimate of daily exposure to a dose of a
chemical that is likely to be without appreciable risk of adverse noncancerous effects over
a specified duration of exposure. The MRL is used by public health professionals as a
screening tool. (ATSDR, 1998)
While there has been some evidence of reproductive and developmental effects in hu-
mans, animal studies have reported developmental effects, such as skeletal deformities, kid-
ney defects, and weakened immune responses in the offspring of animals exposed TCDD
during pregnancy (ATSDR, 1998). More over reproductive effects, including reduced pro-
duction of sperm, and increases in miscarriages have been seen in animals exposed to
dioxin (ATSDR, 1998).
In human studies, mostly of occupational exposure by inhalation, there is evidence of
associations between Dioxin and lung cancer (Crump, 2003), soft-tissue sarcomas, and
lymphomas. While animal studies have found tumors in the liver, lung, tongue, and thy-
roid from oral exposure (ATSDR, 1998). For Dioxin exposure, the EPA has estimated the
inhalation cancer slope factor to be 1.5e-05 mg/kg/d and an inhalation unit risk estimate of
3.3e-05 pg/m3 (USEPA, 1985, 1997). Also the oral cancer slope factor is estimated to be
1.5e-05 mg/kg/d and an oral unit risk factor of 4.5 g/L (USEPA, 1985, 1997).
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TCDD is detectible in blood and adipose tissue of the general population (Kang et al.,
1991) yet the background exposure has not been associated with adverse effects. Dietary
intake is generally recognized as the primary source of human exposure to CDD/CDFs
(Rappe, 1992). Several studies estimated that over 90 percent of the average daily exposure
to CDD/CDFs are derived from foods (Rappe, 1992; Henry et al., 1992), mainly meat, dairy
products, and fish.
Table 1 shows a summary of Dioxin like chemical TEQ concentrations found in the
environment. Not only are toxic chemical mixtures found in air, water and food, part-per-
trillion levels of CDDs/CDFs have been found in everyday materials that are contaminated
with dust such as clothes dryer lint (2:4 to 6:0 ng I-TEQDF/kg); vacuum cleaner dust (8:3
to 12 ng I-TEQDF/kg); room air filters (27 to 29 ng I-TEQDF/kg); and house furnace filter
dust (170 ng I-TEQDF/kg) (Berry et al., 1993).
Because of the toxicity and the properties that allow the accumulation of Dioxin and
DLCs up the food chain Risk assessment is necessary to know at what dose these chemicals
are likely to cause harm. Dioxin and DLCs are not the only chemicals that are dangerous,
the number of chemicals manufactured is in the tens of thousands and it is important to
know at what dose these chemicals are likely to cause harm if in fact they are found to be
toxic. Thus the focus of risk assessment is establishing the safe dose of a chemical and
the probable toxic effects that may occur if that safe dose is exceeded. Risk assessment as
a process can be broken down into several steps: Hazard characterization, dose-response
assessment, exposure assessment, and risk characterization.
The first step in risk assessment is the hazard identification or characterization, which
is a review of all biological and chemical information on a possible toxic agent that may or
may not be a carcinogenic hazard. Physical and chemical properties, routes, and patterns of
exposure are all examined during the hazard characterization step. Metabolic and pharma-
cokinetic properties along with toxicologic effects are also included. Short and long-term
animal studies, and in some cases human studies are used to assess the hazard of a potential
carcinogen.
The weight of evidence of carcinogenicity is basically determined from long-term ani-
mal studies and epidemiological studies on humans with the aid of other information from
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short term tests, pharmacokinetic studies, and toxicity studies. The three steps to charac-
terizing the weight of evidence for carcinogenicity in humans are the characterization of
the evidence from human studies and animal studies, the combination of the characteriza-
tion of the two types of studies into an indication of the overall weight of evidence and the
evaluation of all supporting information.
The EPA has developed a classification of the weight of evidence yet this system is not
meant to be applied rigidly. The system for the characterization of the overall weight of
evidence for carcinogenicity includes five groups. Group A is designated for compounds
that are considered as carcinogenic to humans. While group B are for compounds that
are probably carcinogenic to humans and group C for those that are possibly carcinogenic.
Finally, group D are for compounds that are not classifiable as to human carcinogenicity
and group E are for those that show evidence no evidence of carcinogenicity for humans.
The EPA regards agents that fall into groups A and B are suitable for quantitative risk
assessments (USEPA, 2005). Those agents in group C may be suitable for quantitative risk
assessments but the decision to do so should be made on a case-by-case basis. Those agents
in groups D and E have no need for quantitative risk assessments.
After the hazard characterization step is completed usually the next step is to estimate
the excess cancer risk associated with a certain exposure. Of course estimates that are
derived based on human epidemiologic data are preferred over those derived from animal
data. The risk assessor must make a choice of mathematical model for the description of the
dose-response relationship and extrapolation. Thus there is no single mathematical model
or technique of estimation that is used as a gold standard for the low-dose extrapolation.
Low dose estimates obtained from animal data extrapolated to humans are confounded
by uncertainty factors that are different between species. Some of these factors are life span,
body size, genetic variation, pharmacokinetic effects such as metabolism and excretion.
Some of the common dosing scales includemg per kg body weight per day, parts per million
in the diet or water, and mg/m2 body surface area per day. Surface area is a good scale to
employ because many pharmacological effects scale according to surface area (Dedrick,
1973).
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The results of a dose-response assessment should be combined with estimates of the
exposures to which people are likely to be subjected in order to obtain quantitative estimate
of risk. Similar to dose-response assessment there is no single technique or procedure that
is appropriate for each and every case but the frequency, magnitude, and duration of the ex-
posure are the most important factors in estimating the concentration of the carcinogen to
which a subject is exposed. Often the cumulative dose received over a lifetime, expressed
as an average daily exposure prorated over a short period of time is used to measure the ex-
posure to a carcinogen. The risk assessor should always try to assess the level of uncertainty
associated with the exposure assessment and provide this so that there is an understanding
of the uncertainty of any final estimate.
Risk characterization is a report of the numerical estimates of risk and examination of
the significance of the estimate. Numerical estimates can be presented in different ways.
Possibilities include unit risk, excess lifetime risk due to a continuous constant lifetime
exposure, dose corresponding to a level of risk, individual or population risks (excess indi-
vidual lifetime risks or excess number of cancers per year in the exposed population). The
risk characterization should include the interpretation of the estimates in order to assess the
degree to which the quantitative estimates are likely to reflect the true magnitude of human
risk. Risk characterization should summarize the hazard identification, the does-response
assessment, exposure assessment, major assumptions scientific judgments and estimates of
the uncertainties in the risk estimates.
1.2 Toxic Equivalency Factors and Quantifying Toxicity
Since we are not exposed to any one single chemical or agent but a mixture of toxins in
the environment, in order to conduct risk assessment of these mixtures the toxic equivalency
factor (TEF) methodology has been developed.
Chemicals that are similar in structure and show similar physio-chemical properties and
cause similar adverse effects as Dioxin are considered ”dioxin-like”. The toxic potency (or
TEF) of each of these dioxin like chemicals is expressed relative to TCDD and these TEFs
are then used to quantify the toxicity of a mixture of chemicals relative to that of TCDD,
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expressed as a toxic equivalent concentration (TEC). Not only are the structures and physio-
chemical properties similar in DLCSs but like Dioxin they also invoke a common set of
toxic responses by a common aromatic hydrocarbon receptor (AhR) dependent mechanism
in vivo.
The current TEFs are qualitative values that specify an order-of-magnitude of potency
of a chemical compared with TCDD (NRC, 2006). They were established by a WHO
expert scientific panel that used a large data base of REP (relative potency) estimates from
in vivo and in vitro studies of biochemical and toxic effects. The TEF method takes the
concentration of the individual compounds present in the mixture and these are multiplied
by each specific TEF value, and the sum of all these products is expressed as the TCDD
toxic equivalent quotient.
TEQ= åiTEFiCi
In June 2005 a WHO-IPCS expert panel meeting was held to re-evaluate toxic equiv-
alency factors for Dioxin like compounds. It was concluded that a combination of un-
weighted distributions of relative effect potencies (REP), point estimates and expert judge-
ment. A TEF is derived for an individual PCDD, PCEF or PCB compound for producing
toxic or biological effect relative to a reference compound usually 2,3,7,8-TCDD or Dioxin.
The total Toxic Equivalent (TEQ) is defined as the sum of the products of the concentration
of each compound multiplied by it’s TEF value. The criteria for inclusion into the TEF
concept a compound must show a structural relationship to the PCDDs and PCDFs, bind
to the Ah receptor, elicit AhR mediated biochemical and toxic responses and finally be
persistent and accumulate in the food chain (Ahlborg et al., 1994).
The inherent uncertainty in the determination of REPs and sometimes high variation in
the REP values for a single congener are just two reasons for periodic evaluation of valid-
ity of the concept. There are gaps in the knowledge of even the most commonly studied
dioxin like chemicals such as 2,3,4,7,8-PeCDF and PCB126 (Haws et al., 2006). There
are multiple reasons for the variation in the REPS found in the literature for a single com-
pound. The different values can be caused by different dosing schemes, different endpoints
of interest, species, and also different methods used for calculating the REF value itself.
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Thus the variations in methodologies used to derive the different REP values introduces
uncertainties. The recommended method to calculate a REP is by divided the ED50 of the
reference compound by the ED50 of the congener under study (Van den Berg et al., 2006).
Among other considerations a study that aims to produce a REF should at the very
least administer the compounds under study by the same route, to the same species, strain,
gender, and age of animal (Van den Berg et al., 2006). The animal subjects should be
housed, fed, and maintained under consistent conditions. In vivo studies are preferred
over in-vitro studies because they retain and combine the toxicokinetic and toxicodynamic
properties.
The AH receptor’s role in the toxicological and biochemical effects associated with
dioxin and DLCs is considered to be necessary but not sufficient. There are further pro-
cesses regulated by the AH receptor and AH receptor gene expression. The induction of cy-
tochrome P450 proteins, CYP1A1 and CYP1A2, are the most studied processes associated
with dioxin exposure. According to the National Center for Biotechnology Information
(NCBI), these catalyze a number of reactions involved in drug metabolism and synthesis
of cholesterol, steroids, and other lipids. Although there is interaction with other chemi-
cals and other effects mediated by mechanisms that are independent of the AH receptor,
they are ignored in the TEF methodology. There have been observations of changes in
gene expression (Oikawa et al., 2001) and toxicity in Ah receptor knock out mice. (Lin et
al., 2001). It is not known to what extent other mechanisms influence the biochemical ef-
fects of Dioxin and DLCs. The National Academy of Sciences (NAS) has called for future
studies to consider AH receptor independent mechanisms when examining the toxicity and
carcinogenicity of DLCS.
There is considerable variability in the REP values that were used to obtain the WHO
TEFs and thus there is much uncertainty in the selection of TEFs values. Also the published
information on how they were originally derived was not entirely clear with respect to the
weighting schemes applied to the studies that provided the relative potency variables (Van
den Berg et al., 1998). Because of the uncertainty and variability inherent in the REPS and
TEFs the assumption of consistency of DLC REP values is necessary in the TEF
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methodology. This assumption requires the REP of a chemical to be equivalent for all end
points and all exposure scenarios.
1.3 History of PK and PBPK models
Pharmacokinetic (PK) models date back to the late 1930s and were first developed
by Torsten Teorell, a Swedish scientist whom some call the ”father of pharmacokinetics”
(Obrink, 1992). These first models were developed before there were relatively painless
ways to solve the sets of differential equations that explain such models. These models
were expanded in the latter half of the twentieth century to accommodate dose-dependent
elimination rates and flow-limited metabolism processes (Anderson, 2003). In the 1980’s
PK and physiologically based pharmacokinetic (PBPK) models were explored more be-
cause of the advancement in occupational toxicology and risk assessment and in the 1990’s
there was explosive growth in risk assessment applications of PK and PBPK models (An-
derson, 2003).
Scientists have used classic pharmacokinetic models, pharmacodynamic models, and
pseudophysiologic models for numerous applications but the main utility of these type of
models is to describe and study the distribution of xenobiotics in a biological system such
as the rat or the human. In the last few decades these models have grown into descriptive
physiologically based pharmacokinetic (PBPK) models. These PBPK models are used to
describe the absorption, distribution, metabolism, and excretion of xenobiotics.
Because these models incorporate information on biological processes they are better
equipped to describe the kinetic behaviors of chemical and are more amenable to extrapo-
lation across dosing routes, between species, from high-to-low-doses, and across exposure
scenarios (Clewell and Andersen, 1985; Anderson, 2003).
The first pharmacokinetic models specifically for Dioxin like compounds were devel-
oped in the 1980s. These models did not include processes such as specific binding of
TCDD with (non-Ah receptor) proteins, thus the estimated partition coefficients of interest
were biased. The estimated Liver:Blood partition coefficient appeared to be larger than the
Fat:Blood partition coefficient even though such chemicals are highly lipophilic.
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Many dioxin like compounds are highly lipophilic and are stored in the body fat; how-
ever it has been shown that hepatic binding processes are the reason that dioxin is concen-
trating in the liver. In the late 1980s Leung et al.(1989a,b) explored quantitative physiologic
models to study the role of the Ah-receptor in the concentration accumulation in the liver.
Although this was an improvement in the biological description of the mechanism of toxi-
city of dioxin like compounds. The binding to the Ah receptor alone could not account for
the sequestration in the liver of TCDD. Further studies eventually showed that existence of
non-Ah receptor binding sites and that these non-Ah receptor binding sites are microsomal
proteins with binding constants in the nano-molar range (Poland et al., 1989a,b). The Ah-
dioxin complex interacts with DNA to cause induction or repression of gene expression
(Anderson, 2003). Modeling advances in the 1990s (Kohn et al., 1993; Andersen et al.,
1993) expanded on these early models with the newer PBPK models for TCDD including
biological detail related to DNA binding, mRNA induction and protein synthesis.
The newest US EPA cancer guidelines discuss the use of biologically based models
in assessing dose response relationships. Hence one of the main uses of PBPK models is
in risk assessment. Yet in order to use these models in environmental risk assessment to
humans, it is necessary to extrapolate in the region of the lowest doses. This extrapolation
is done by adjusting estimates of risk to be conservative with the use of uncertainty fac-
tors but by employing uncertainty factors estimates of risks for humans may end up being
under-estimated. PBPK models can help address the uncertainty by describing multiple
biological, biochemical, and physiological processes.
Typically parameter estimates in these models are only presented as point estimates
with no margin of error or estimate of variation. Integrating statistical methods into in risk
assessments would be an efficient way to characterize the variation. Uncertainty enters
into risk assessment in many ways, in hazard identification the extrapolation from various
species to humans is a large contributor of uncertainty. In exposure assessment lack of
information on frequency, duration, and level of exposure introduce uncertainty. One im-
portant source of uncertainty is in the measure of the internal dose and specifically into an
organ, the biologically effect dose. With PBPK models, the intake and uptake process of
a chemical exposure is modeled as part of the absorption process. Since there are many
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studies that only report point estimates of physiological parameters such as oral absorption
rates and stomach emptying rates, there is no quantification of the variance.
In an oral exposure the administered dose enters the mouth (the intake process) and
is termed the potential dose then the chemical makes its way through the gastrointestinal
tract (the uptake process) and further metabolism creates the internal dose. The process of
forecasting tissue concentrations from cumulative exposure to low level exposures can be
more reliable if we can quantify the variation in physiological parameters.
This dissertation explores the difficulty of the integration of statistical methods of pa-
rameter estimation in PK and PBPK models so that estimates of the variation of key param-
eters can be obtained. Two of the main issues to deal with are complexity of the models and
non-identifiability of parameter values. PBPK models can be very complex with multiple
compartments and a large number of parameters, thus statistical estimation can be difficult
because of scarce data, parameter non-identifiability, and non-convergence among others.
1.4 Specific Aims
The first step in this dissertation research is to explore parameter identification issues
and incorporate statistical methods to estimate parameters in a simple two compartment
pharmacokinetic model describing the transfer of a mixture of TCDD, PCB-126, and
PeCDF. An oversimplfied PK model is used to illustrate and address parameter identifiabil-
ity and other issues in development and estimation of the parameters because identifiability
problems can only multiply and become more complex when adding equations and param-
eters into PK models. Fitting PK and PBPK models remains challenging due in particular
to a large number of biochemical and physiological parameters. Many of these model
parameters are unknown in value, are statistically non-identifiable, and have to be fixed.
Mathematical calibration or computer simulation are common methods used to determine
their value, and uncertainty quantification is inadequate. The first part of dissertation illus-
trates the use of iteratively-reweighted-nonlinear-least-squares for fitting PK models and
employs bootstrap confidence intervals to quantify variation in parameter estimates.
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The specific application involves a two-compartment model of rats chronically exposed
to dioxin over two years and the model permits dose-dependent kinetic parameters. We
show the use of simple graphs to identify region of non-identifiability and the use of the
bootstrap confidence interval. Insights gained here serve to advance statistical estimation of
general PBPK models and will fill some gaps in the literature by reporting on these issues.
The research then focuses on expanding this model by incorporating physiological in-
formation and leads to a second aim which is to examine assumptions employed in PBPK
methodology such as the assumption of constant proportional organ weights. In toxico-
logical experiments and pharmacological investigations the weight of an organ such as the
liver is typically assumed to be a constant proportion of body weight. Such an assumption
can have critical pharmacokinetic and pharmacodynamic impacts especially in the context
of therapeutic intervention or environmental exposure. Yet, there is limited literature on its
validity. The second part of this dissertation investigates how organ weights as a proportion
of body weight change with exposure conditions during growth period. This dissertation
will fill some gaps in the literature by examining organ weights, which are unlikely to be a
constant proportion of body weight in a growth period or under chronic exposure condition.
This non-constant relationship may have profound pharmacokinetic and pharmacodynamic
implications since physiological parameters such as organ blood flow rates, surface areas,
and permeability will be non-constant.
A third aim is to construct a PBPK model for chronic exposure to Dioxin (and two
other DLCs, one for the mixture as well) and integrate statistical methods for parameter
estimation. A markov chain monte carlo method is used to estimate key parameters and
quantify their variation. Furthermore the variability and sensitivity of these key parame-
ters to changes in other parameter values (held fixed) will be examined. Dose dependent
physiological parameters for elimination are incorporated into the model.
The PBPK model will incorporate the target compartments (organs) for each chemical
in a mixture of Dioxin and DLCs. In other words, there will be three ”responses” (one
response in three organs at the same time) hence three regression models (implicit explicit),
one for each response, namely, Yf at , Yliver, and Yblood . First, the differential equations for
all three responses simultaneously are derived. Then parameter estimation is done using
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statistical methods. The issue of parameter identifiability needs to be dealt as well as issues
related to assessment of model fitting, including model diagnostics and prediction.
It is clear that use of PBPKmodels in risk assessment requires research on model devel-
opment and implementation with respect to chronic exposure of low external doses. This
research fills a gap in the literature because most PBPK models are developed for acute or
short term exposure. Future work includes applying these PBPK models to verify the TEF
methodology. The World Health Organization (WHO) has suggested that the TEQ scheme
be reevaluated every 5 years.
1.5 Tables
Table 1: DLC TEQ WHO Concentrations in Environmental Media and Food.
Media n Mean(SD) References
Urban Soil, ppt 270 9.3 (10.2) EPA (2000a), Pearson et al.(1990)
Urban Air, pg/m3 106 0.12 (0.094) Hoff et al.(1992)
Water, ppq 236 0.00056 ( 0.00079) Meyer et al.(1989),Jobb et al.(1990)
Beef, ppt 63 0.18 (0.11) Winters et al.(1996)
Poultry, ppt 78 0.068 (0.070) Ferrario et al.(1997)
Marine Fish, ppt 158 0.26 (0.070) Fiedler et al.(1997), Jensen (2000)
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Table 2: Major Assumptions behind TEF approach.
Assumption Description
Role of AHR AHR mediates most toxicities produced
by TCDD and other PCDDs, PCDFs,
and coplanar PCBs that are APH agonists.
AHR Independent Mechanisms Effects mediated by other mechanisms
excluded (AHR independent) and interactions with
other chemicals are ignored.
Consistancy of DLC REP values The REP of a chemical in this group
is presumed to be equivalent for all end
points of concern and all exposure
scenarios.
Use Of TEFs for DLC body TEFs for animals exposed by dietary
burden intake are appropriate for assessment
of internal TEQ concentrations
and potential toxic effects.
Additivity of DLCs Mixtures exhibit additive toxicities
based on TEFs of individual chemicals
Rodent to Human Prediction REPs of dioxin and DLCS in rodents
is predictive of REPS in humans
Natural and Synthetic Non-DLCs Synthetic and non-natural non-DLC
AHR agonists agonists do not interfere with PCDD,
PCDF, and PCB dependent TEQ
predictions
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2 Statistical Estimation of Pharmacokinetic Models with
Non-identifiable Parameters
2.1 Introduction
Evaluation of human exposure to environmental chemicals requires analysis of pol-
lution inventory in the environment; the source, intensity, duration and routes of human
contact; and pharmacokinetics upon entering human body. Knowledge gaps and data gaps
inevitably generate uncertainties in exposure assessment estimates, which is compounded
with inherited variability in a general population (USEPA, 1992). The term variation refers
to differences in exposure due to susceptibility, life style and human activities. Uncertainty
refers to changes in our exposure estimates if we change our assumptions about gaps in
knowledge and data. Variations and uncertainties in exposure estimates contribute signifi-
cantly to the overall uncertainty in risk assessment, hence impact regulatory policies.
The promise that physiologically-based pharmacokinetic (PBPK) models can substan-
tially reduce uncertainties in exposure assessment has led to a growing body of research in
developing and applying PBPK models (USEPA, 2006; Barton et al., 2007; IPCS, 2008;
Thompson et al., 2008). PBPK models describe the process of absorption, distribution,
metabolism, and excretion of the chemical that enters the body, and measure target tissue
dose with appropriate dose metrics. A PBPK model may be used to predict tissue dose
based on exposure or to back-estimate the cumulative exposure based on tissue dose. A
PBPK model is a mechanism that can guide for more reliable extrapolations in estimates
between species, between exposure routes, from acute to chronic exposure, or from high to
low dose. Back-estimation of cumulative exposure based on a PBPK model may provide
useful reference levels for environmental monitoring and regulation.
PBPK models are typically developed on the basis of experiments of acute or sub-
chronic exposure in which a small number of animals are exposed at a few administered
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dose levels. Observation periods range typically from a few hours to a few weeks to yield
a small number of repeated measurements on the same subject or time-course data from
animals sacrificed at different sampling points. a PBPK model is complex involving many
target tissues where data are unavailable. As a result, the development and validation of
PBPK models are difficult. For example, it is unclear to what extend an acute exposure
model can be applied to chronic exposure.
Because a PBPK model involves a large number of physiological and biochemical pa-
rameters, simultaneous estimation of these parameters is unlikely, and many of them are
fixed at values that are uncertain and only a select few are calibrated or estimated through
mathematical simulation (Wang et al., 1997). The calibrated ones are nevertheless assumed
to be constant over time and exposure condition. In reality, however, a physiological or bio-
chemical parameter may change in value with exposure condition. Michalek et al.(2002)
reported, for example, that the TCDD elimination rate increased with the initial TCDD
concentration in both male and female participants of the Seveso cohort during the first
three years of follow-up,but from year 3 to year 16, the rate of increase subdued in size as
well as in statistical significance.
Still, the large number of parameters, complex model structure, and limited data often
result in ”non-identifiability” among parameters of which multiple, equally plausible esti-
mates cannot be distinguished using statistical criteria. We call this phenomenon hyper-
parameterization in the current context.
These issues have motivated us to explore statistical estimation of pharmacokinetic
(PK) models. A case for illustration is a 2-year experiment by the National Toxicology
Program (NTP) involving daily exposure of rats to a mixture of dioxin and dioxin-like
compounds (DLCs). This chapter (1) illustrates statistical estimation procedures in the
presence of parameter non-identifiability due to hyper-parametrization; (2) examines if ki-
netic parameters change in value under the chronic exposure conditions; and (3) evaluates
the applicability of linear kinetics to chronic exposure. We first describe the NTP exper-
iment providing the data, and then present a two-compartment PK model and the corre-
sponding nonlinear regression models. We discuss statistical model fitting using iteratively
reweighted non-linear least squares in conjunction with graphics to identify regions of non-
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identifiability. We also discuss the bootstrap confidence interval to quantify uncertainty and
variability in parameter estimates.
2.1.1 NTP’s Experiment with Two-Year Chronic Exposure to TCDD
TCDD (2;3;7;8-Tetrachlorodibenzo-p-dioxin; CAS 1746-01-6) is a by-product of cer-
tain chemical synthesis processes such as the production of herbicides. Exposure to TCDD
came to light in the use of the infamous ”agent orange” during the Vietnam war to defoliate
the rainforest (IOM, 2002). Today, the main sources of dioxins released into the envi-
ronment include, but are not limited to, combustion and incineration, oil refining, chem-
ical manufacturing and processing, and biological and photochemical processes (USEPA,
2000a), as well as existing reservoir sources from past releases.
Low water solubility, low rate of biotransformation, and high lipophilicity promote
dioxin and DLCs to transport into and climb up our food chain, which accounts for a high
potential for bioaccumulation (Esposito et al., 1980). As a result, environmental exposure
to dioxin and DLCs comes mostly from food intake, especially through the consumption
of fish, meat, and dairy products because dioxin and DLCs are fat-soluble (Schecter et al.,
2001).
TCDD is the most toxic in the class of chlorinated hydrocarbon compounds (Van den
Berg et al., 1994). Short-term exposure at sufficiently high levels may result in skin lesions
such as chloracne. It may also alter liver function. Long-term exposure is linked to im-
pairment of the immune system, endocrine system, and the reproductive system (ATSDR,
1998). Chronic exposure at low levels of has resulted in increased cancer incidences such
as cholangiocarcinoma and hepatocellular adenoma in different animal species. Based on
available animal data and human epidemiological data, the International Agency for Re-
search on Cancer (IARC) classifies TCDD as ”carcinogenic to humans.” The US Environ-
mental Protection Agency (USEPA) also classifies TCDD as a human carcinogen (NRC,
2006).
Given the likelihood of daily exposure to dioxin and DLCs from a variety of sources
and the associated potential health risk to humans, safeguard of these compounds in the
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environment is of critical importance to public safety. To this end, sound risk assessment
calls for better understanding of the human toxicokinetics of chronic exposure to dioxin
and DLCs. In the National Research Council’s evaluation of EPA’s reassessment of dioxins
(NRC, 2006), the committee specifically recommends the use of pharmacokinetics (PK)
and physiologically-based pharmacokinetics (PBPK) in exposure assessment.
The National Toxicology Program (NTP) of the National Institute of Environmental
Health Sciences conducted a series of studies to better understand the health consequences
of chronic exposure to dioxin and DLCs. In one of these studies, female Harlan Sprague-
Dawley rats were administered through gavage a mixture of TCDD, PeCDF, and PCB126,
once daily 5-days a week, up to 104 weeks (2 years). These three compounds make up
approximately half of the dioxin-like toxic activity found in human tissues (Walker et al.,
2005). The mixtures were prepared in a corn oil:acetone (99:1) solution at four concentra-
tion levels in the ratio of 1:2:10 parts TCDD:PeCDF:PCB126, with TCDD at levels of 3.3,
7.3, 15.2, and 33 ng/kg body weight, respectively. The mixture was determined accord-
ing to the World Health Organization (WHO) toxic equivalent factor (TEF)(WHO 2007),
so that each chemical would provide a third of the total dioxin toxic equivalent (TEQ) of
the mixture. These levels were also used to maximize statistical power to test for possible
interactions between the chemicals.
Eighty-one rats were randomly assigned to each dose group, in addition to a vehicle
control of corn oil/acetone solution only. Eight to ten rats per dose group were sacrificed
for biochemical (tissue concentration) and physiological evaluation at weeks 13, 30, and
52. The evaluation included thyroid hormone, cell proliferation, Cytochrome P450 ac-
tivity, 7-ethoxyresorufin-O-deethylase and acetanilide-4-hydroxylase activities in the liver,
and 7-ethoxyresorufin-O-deethylase activity in the lung. At week 104, all remaining ani-
mals were sacrificed for toxicological evaluation including carcinogenic outcomes. Among
these animals, again only eight to ten were used for tissue concentrations. These animals
were also weighted at baseline, weekly for 13 weeks, monthly thereafter, and at necropsy.
Clinical findings were recorded on day 29, monthly thereafter, and at necropsy. See Walker
et al.(2005) for more details on study design and clinical outcomes.
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In the present analysis, we are focused on PK models for tissue concentration of TCDD
in the fat and the liver. Table 2:5 summarizes the mean concentrations of TCDD in the
fat along with standard deviations. Table 2:5 is a summary of concentration in the liver.
TCDD concentration in each dose group clearly increases over time. Data variation shows
a generally increasing dose-time trend except for fat at week 30.
2.2 Methods
2.2.1 Two-Compartment Pharmacokinetic Model
Figure 1 shows a conceptual, two-compartment model: TCDD transfers from the liver
to the fat compartment at the rateKl f and from the fat to the liver at the rateK f l . Metabolism
takes place in the liver and TCDD is eliminated at the rate Ke. Administered daily dose
is assumed to enter the liver 100%. Although over-simplified, the model is adopted to
illustrate statistical estimation of PK models with hyper-parametrization.
The mass balance of this model is represented by the following differential equations:
dAL(t)
dt = W0D  (Ke+Kl f )AL(t)+K f lAF(t);
dAF (t)
dt = Kl fAL(t) K f lAF(t)
(1)
where AF(t) =WF(t)CF(t) and AL(t) =WL(t)CL(t) are the total amount of TCDD in fat
and the liver, respectively, with CF(t) and CL(t) being the respective tissue concentration,
andWL(t) andWF(t) the respective tissue weight;W0 is body weight at baseline; and D is
daily administered dose. In solving the equations above, we assume that tissue weight is a
constant proportion of body weightW (t) over time t (ILSI, 1994). Specifically fat weight
WF(t) = PfW (t) with Pf = 6:92% and the liver weight WL(t) = PlW (t) with Pl = 3:63%
(Wang et al., 1997).
The closed-form solution to equation (1) is given by
CF(t) =
W0
W (t)PF
DKl f
K f lKe
n
1  l2l1 l2 exp(l1t)+
l1
l1 l2 exp(l2t)
o
= W0W (t)Pf
mF(D; t;K)
CL(t) =
W0
W (t)PL
D
Ke
n
1  l2(l1+K f l)K f l(l1 l2) exp(l1t)+
l1(l2+K f l)
K f l(l1 l2) exp(l2t)
o
= W0W (t)Pl
mL(D; t;K)
(2)
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where
l1 = 12
n
K f l +Ke+Kl f  
q
K2f l 2K f lKe+2K f lKl f +K2e +2Kl fKe+K2l f
o
;
l2 = 12
n
K f l +Ke+Kl f +
q
K2f l 2K f lKe+2K f lKl f +K2e +2Kl fKe+K2l f
o
;
and K= (Ke;K f l;Kl f )T
2.2.2 Statistical Models
Although the PK models are often fit through mathematical optimization and calibra-
tion, statistical estimation is advantageous in that uncertainties and variations in the kinetic
parameters can be directly quantified through their interval estimates. To this end we con-
vert the PK model (2) into a bivariate nonlinear regression model with unknown parameters
K= (Ke;K f l;Kl f )T
YFi jk = CFi jk
Wi jk(t j)PF
Wi0k
= mFi j(Di; t j;K)+ eFijk
YLi jk = CLi jk
Wi jk(t j)PL
Wi0k
= mLi j(Di; t j;K)+ eLijk
(3)
where the responses Yi jk = (YLi jk;YFi jk)T are the per-baseline-body-weight TCDD con-
centration in the liver and fat, respectively, in the kth rat (k = 1; :::;ni j) of ith dose group
(Di = 3:3;7:3;15:2;33 ng/kg/day) at time t j (t j = 13;30;52;104 weeks). We choose the
concentrations per baseline body weight as the response variables to avoid treating weight
as a time-varying covariate in the mean mij = (mFij(Di; tj;K);mLij(Di; tj;K))T. We also as-
sume that the vector of errors eijk = (eFijk;eLijk)T follows a bivariate normal distribution
N(0;S2i j), where the variance-covariance matrix
Si j =
0@ s2Fi j sFLi j
sLFi j s2Li j
1A
may vary with dose level i or time j within the same dose group. The errors are independent
among rats.
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Empirical evidence suggests that there is an over-dispersion in relation to the mean. We
consider an variance-covariances structure with
sF(i j) = fFmFi j;
sL(i j) = fLmLi j;
sFL(i j) = r jfFfLmFi jmLi j;
(4)
with time-specific Pearson’s correlation coefficient r j at time j. This variance-covariance
structure captures the increasing variation in tissue concentrations with dose and/or time.
The approximate variance-covariance matrices provide appropriate weights to the nonlinear
least squares, and does not affect the unbiasedness of least square estimators.
It is important to note that the pharmacokinetics parameters may vary under chronic
exposure conditions. Michalek et al.(2002) reported that the TCDD elimination rate in-
creased significantly with the initial TCDD concentration in both male and female subjects
of the Seveso cohort during the first three years of follow-up; and the rate further increased
with a borderline significance in year 3-16 follow-up. To permit a dose-dependent kinetic
parameter, we introduce a regression type model between the kinetic parameters and ad-
ministered TCDD dose
logKm = am+ gmDi (5)
where m = e;fl; lf, and Di = 3:3;7:3;15:2;33 (ng/kg/day). This dose-dependent model is
labeled ”DD” in contrast with the dose independent (DI) model in which gm = 0.
2.2.3 Iteratively Re-weighted Nonlinear Least Squares
To estimate the kinetic parameters (K), we fit the bivariate nonlinear model to the
weight-scaled fat and liver concentration data simultaneously. The process relies on the
iteratively re-weighted nonlinear least squares (IRNLS) to minimize the sum squares of the
residuals
SSR=å
i jk
(yi jk mi j)TS 1i j (yi jk mi j)
with respect to the parameters (K). Because the variance-covariance (weight) matrices Si j
serve as weights, whose value must be updated at each iteration via updated estimation of
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the means and the dispersion parameters. The IRNLS process consists of the following
steps.
1. Obtain initial value K(0) for K. An appropriate starting value is critical to obtaining
solutions to an optimization problem that involves nonlinear parameters.
2. Use previous estimate K(l) (l = 0;1;2; : : :) to compute the predicted outcome yˆi jk =
mi j(Di; t j;Kˆ(l)). as well as estimate of the variance-covariance matrix Si j(Kˆ(l)). The
overdispersion parameters fF and fL are obtained from a linear regression of the
sample standard deviations against sample means (fˆF = :199 and fˆL = :200), and rˆ j
is sample correlation coefficient between the fat and liver measurements at time j.
As a proportion of the mean, the standard deviation is less sensitive to fluctuation of
SSR when the mean estimate deviates from the expected value.
3. Obtain updated IRNLS estimate Kˆ(l+1) that minimizes
SSR=å
i jk
(yi jk mi j)TS 1i j (Kˆ(l))(yi jk mi j):
A number of algorithms are available for this optimization. We used the Broyden-
Fletcher-Goldfarb-Shanno (BFGS) algorithm (Broyden, 1970; Fletcher, 1970) that is
a part of the function optim in R (R Development Core Team, 2008). The ”BFGS”
algorithm is a quasi-Newton method (also known as a variable metric algorithm)
capable of searching for a stationary point at which the gradient of the objective
function (i.e. SSR) is 0. The stationary point is then a candidate of local optimum.
4. Repeat steps (2) and (3) until a convergence criterion is met. We employed a weak
convergence criterion
jSSR(l+1) SSR(l)j
SSR(l)
< d (6)
when the current value of SSR is within a pre-specified tolerance level d > 0 of the
previous one. A negligible change in the SSR(l+1) from SSR(l) implies an overall
convergence of the IRNLS algorithm to a local minimum.
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2.2.4 Parameter Non-identifiability
It can occur that the objective function SSR attains its (nearly) minimum value within
a contiguous neighborhood in the parameter space. Geometrically, this local neighborhood
in the parameter space corresponds to an area where the surface of the objective function
is ”flat” - all points are equally acceptable estimates - a classic definition of parameter
non-identifiability (Neath and Samaniego, 1997). In this scenario, the parameters involved
cannot be uniquely determined. Non-identifiability can be structural in which the parame-
ters are functionally dependent, i.e. one might be a function of others. Even if structurally
identifiable, the parameters can still be non-identifiable when data do not provide suffi-
cient information about the model (Hengl et al., 2007). The complexity of a PBPK model
dictates a large number of parameters that are functionally important, and requires highly
informative data to uniquely determine the value of each and every of these parameters.
In practice, however, the depth of the data is always insufficient to meet this requirement,
giving rise to ”hyper-parametrization”.
The convergence criterion described above reflects our acceptance of non-unique esti-
mates of the parameters. We thus develop a ”clonal-expansion” algorithm in conjunction
with a graphic tool to identify the contiguous region of all acceptable estimates. Specifi-
cally, expand the initial region C d of acceptable estimates by including a new set K if the
convergence criterion and the following criterion is met:
jSSR(K) minC d SSR(K)j
minC d
SSR(K) < d
: (7)
To begin the clonal starts with the first set of estimates, then it either shifts to a better one
with smaller SSR or expands to include a new member whose SSR is within the tolerance
level d  of that of the signature member (the smallest SSR). We used d  = :005. The
contiguous region determines the scope of non-identifiable estimates from which we may
pick our final estimate of the parameters, hence the final model.
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2.2.5 Bootstrap Confidence Intervals
We use bootstrap confidence interval (Efron and Tibshirani, 1993) to report uncertainty
and variation of the parameters. The bootstrap methods are a simulation-based resampling
method that generates data to mimic the distribution underlying the original sample. Boot-
strap confidence intervals are particularly useful in the present case when point estimates
are not unique due to hyper-parametrization. Upon fitting the model, we obtain the resid-
ual vector, eˆi jk = yi jk  mˆi j. For each observed concentration yi jk we sample a residual eˆ(b)i jk
from the same dose-time group with replacement, and add it to the predicted concentration
to form a bootstrap sample data point,
y(b)i jk = mˆi j+ eˆ
(b)
i jk (i= 1; : : : ; I; j = 1; : : : ;J;k = 1; : : : ;ni j;b= 1;2; : : : ;B): (8)
This process yields a bootstrap copy of the original data set. The PK model is then fit to
this bootstrap sample to yield a copy of bootstrap estimate Kˆ(b) of the kinetic parameters.
We generated a total of B = 1000 copies for the dose independent model and B = 1342
for dose dependent case. (B=2000 were attempted, only copies of converging estimates for
K were included). The estimates of K are obtained through am and gm via the function
logKm = am+ gmD (m=e, fl, lf).
From the bootstrap sample of estimates we then construct a bias-corrected and acceler-
ated (BCa) percentile-intervals (Efron, 1986). The BCa confidence interval is given by
q bBaˆ1c < q < q
dBaˆ2e (9)
where the lower bound is the bBaˆ1cth smallest bootstrap estimate determined by the floor
of Baˆ1, and the upper bound is the dBaˆ2eth largest bootstrap estimate determined by the
ceiling of Baˆ2. The nominal levels aˆ1 and aˆ2 are defined as the normal probability
aˆ1 =F
"
zˆo+
zˆo  z1 a=2
1  aˆ(zˆo  z1 a=2)
#
and aˆ2 =F
"
zˆo+
zˆo+ z1 a=2
1  aˆ(zˆo+ z1 a=2)
#
;
where zˆo =F 1

åBb=1
I(qˆ (b)<qˆ)
B

is the bias correction factor when the bootstrap estimates
qˆ (b) deviate from qˆ in median, and aˆ is the acceleration factor which adjusts for the skew-
ness of the bootstrap sample estimates. Let qˆ( i) represent the estimate of q when the ith
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observation is omitted and q¯ represent the average of the qˆ( i). Thus estimated skewness
is aˆ = å
B
i=1(q¯ qˆ( i))3
6[(q¯ q( i))2]3=2
. These adjustments make BCa confidence interval transformation
invariant with better coverage than the standard percentile bootstrap confidence interval
(DiCiccio and Efron, 1996).
2.3 Results
2.3.1 Model Fitting and Parameter Estimate Identifiability
To fit the PK model, we designed a large number of starting value sets along a six-
dimensional grid corresponding to the six regression parameters in K. A non-structural
”hyper-parametrization” indeed occurred among K f l and Kl f . Using the ”clonal expansion”
algorithm in conjunction with the weak convergence criterion, we obtained a n= 1173 sets
of equally acceptable estimates for the dose-independent model and n = 1095 sets of esti-
mates for the dose-dependent model. These estimates are believed to be in a contiguous re-
gion corresponding to a near minimum value of the objective function SSR. The confirma-
tion is done by projection of the six-dimensional region onto all 15 possible 2-dimensional
planes (Figure 2). Although we do not know precisely the boundary of the contiguous re-
gion, we stopped expanding the grid points of starting values when convergence became
increasingly rare.
Figure 2 shows clearly that for K f l and Kl f the intercepts al f and a f l are almost per-
fectly related (the panel on row 3 and column 5), so are the slopes gl f and g f l (the panel
on row 4 and column 6). It reveals that within the 6-dimensional contiguous region of es-
timates corresponding to the flat maximum likelihood surface area, the estimates for al f
and a f l are linearly dependent, and those for gl f and g f l are also linearly dependent. This
is so despite the fact that the parameters are not linearly dependent in the model itself. A
limitation of the plot is that we do not know precisely the entire contiguous region of plau-
sible estimates and cannot say where exactly the boundaries lie. Thus a warning should be
noted in interpreting these values due to potential bias of not covering the entire contiguous
region. More biologic and or physiological information would be required to reduce the
uncertainty and resolve non-identifiability.
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Also noticeable in the scatter plot, the intercept and slope of Ke (row 1 and column 2)
reveals that a larger intercept is coupled with a smaller slope and vice versa, suggesting a
narrow range of plausible Ke estimates even though the elimination rate itself may increase
due to the value of the slope and the exposure condition. These results along with the
correlation between K f l and Kl f , indicate that the contiguous region has three edges along
which the parameter estimates are not distinguishable.
It is understandable that the concentrations observed in the liver and fat compartment
alone are insufficient conclude that the rate from the liver to fat (Kl f ) is different from the
rate from fat to the liver (K f l) even though in theory they are structurally different. External
and additional information pertaining to plausible values of these parameters are necessary
in order to resolve this problem of non-identifiability. Visual inspection of the scatterplots
alone cannot resolve the problem.
2.3.2 Parameter Estimation
Because we do not know precisely the entire contiguous region of estimates or the dis-
tribution within the region, it is not trivial to summarize these estimates. To a crude approx-
imation, we use the sample mean of all estimates in the contiguous region as the central
value, and then use it as the ”original” estimate to construct a BCa bootstrap confidence
interval to measure uncertainty and variation (Tables 3 and 4).
Table 5 shows the estimates of the regression coefficients am (intercept) and gm (slope)
along with their confidence interval for the kinetic parameters in the dose-dependent mod-
els (DD). The positive slope ge suggests the elimination parameter Ke is increasing with
exposure level. There is also some evidence that K f l and Kl f may be varying with exposure
with a positive slope g f l and negative slope gl f .
Table 6 summarizes the estimates of the kinetic parameters along with their 95% con-
fidence intervals for each expousre level. Again, Ke is increasing with exposure, so is K f l ,
whereas Kl f decreases with exposure. Note that the estimated value of Kl f is smaller than
that of K f l in both the dose-dependent and dose-independent models. TCDD bioaccumu-
lates due to its ability to bind to Ah receptors in the liver as well as its high lipophilicity.
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This simplified model does not consider binding in the liver and fat, nor uses partition co-
efficients to account for the lipophilicity. This is likely one reason why the estimate of K f l
is greater than Kl f .
Caution should be exercised in interpreting these summary values due to potential bias
of under-covering the entire contiguous region of non-identifiability. For example, it is pos-
sible that the boundary for the slopes for Kl f and K f l may extended beyond the range seen
in the plot (Figure 2), despite our further investigation (data not shown) found that beyond
this range convergence was increasingly unlikely, suggesting a practical approximation to
the true boundary. The biological meaning of such statistical averages is unclear. Use a
different ”average” value which is statistically equally admissible may lead to a different
confidence intervals as well.
Figure 3 displays the fitted model in the fat compartment under the DI model (solid
lines) and the DD (dotted lines) models, respectively. Each panel in the figure represents
a dose group in which a circle represents an individual animal’s observed value. Data for
the control group are omitted because of 0 administered dose and tissue concentration be-
low the detection limit. Within each dose group, the tissue concentration clearly increases
over time due to cumulative exposure. However, the rate of increase is subdued beyond 30
weeks, notably in the two highest dose groups, suggesting the tissue concentration reaches
an equilibrium. Across the panels, the concentration in fat also increases with the adminis-
tered dose level. It is important to note variation also increased as the mean concentration
level increases. This heteroscedasticity supports the employment of dose-time specific
weights in the iteratively re-weighted least-squares estimation.
Figure 4 displays the fitted model for TCDD concentrations in the liver. Both the model
and data show increasing concentration with exposure level and time. The data also show
increasing variation with the average concentration as well.
Comparison of the models with data suggests that both models impose an equilibrium
concentration whereas the data (by week 104) have yet to establish such an equilibrium,
especially in the two lower dose levels. Even at the highest dose level where empirical evi-
dence does suggest an equilibrium, it does not appear until about week 52 rather than week
30. The ascending to equilibrium is markedly rapid in the DI models (solid line) compared
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with DD models (dotted line). The DD models allow for a somewhat-delayed equilibrium
level, especially in the lowest two dose groups. The rapid ascent to the equilibrium by
the DI model resulted in overestimation of tissue concentration at the earlier times (e.g.
week 13), seen clearly in the highest dose group. This disparity in the timing of reaching
equilibrium can be viewed as evidence supporting for dose-dependent kinetic parameters.
Moreover, the adoption of the linear kinetics may have also contributed to the inadequate
model fitting. Whereas linear kinetics is often used for acute exposure studies, nonlinear
kinetics as well as binding of TCDD in fat could be more appropriate (Wang et al., 1997).
2.4 Conclusion
In this paper we have illustrated statistical estimation of multiple-compartment PK
model using iteratively re-weighted non-linear least squares in conjunction with bootstrap
confidence intervals. Our application of the models to the NTP two-year experiment of
chronic exposure to TCDD mixtures showcased a common challenge in modeling biolog-
ical systems - parameter non-identifiability. That is when a biological system involves a
large number of parameters yet there are insufficient data or information to ascertain the
values of these parameters. As a result, there will be a contiguous region within which all
values are equally acceptable estimates under statistical criteria. While common statistical
methods can be used to identify the region of non-identifiability, specific choice within the
region will be difficult to justify by statistical criteria alone, and is subject to substantial
uncertainty. We have used weak convergence criterion and graphic tools to identify the
region, and use the choice of sample averages. While conventional statistical estimation
remains useful, biological information will be critical to reduce the uncertainty and resolve
the non-identifiability.
Because our nonlinear regression models are based on linear kinetics common in char-
acterizing acute exposure studies, it is possible that such models may not be adequate to
describe data of chronic exposure condition. Our PK models impose an equilibrium earlier
than the data indicated, suggesting a nonlinear kinetics as well as exposure-altered kinetic
parameters may be warranted. Although our model is an oversimplification of the underly-
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ing PBPK models such as the one proposed by Wang et al.(1997) which involves multiple
compartments and nonlinear kinetics for TCDD-AhR binding, we still found evidence that
some key kinetic parameters may change over exposure conditions, including the elimina-
tion rate and transfer rates between compartments.
Although data in additional tissue compartments may help remove non-identifiability
among some parameters, new compartment and new parameters also will be introduced.
As a result, parameter non-identifiability will remain an issue for statistical modeling, hin-
dering the adoption of statistical estimation. To promote statistical modeling of complex
biological systems, new and more effective methods should be promoted. Methods such as
Markov chain Monte Carlo (MCMC) is useful in this regard. Work is ongoing for statistical
estimation of PBPK models for dioxin, following the PBPK models of Wang et al.(1997,
2000) and Emond (2004). Statistical modeling of complex biological systems must in-
corporate existing biological information to construct a model and to form a prior for the
model parameters. Choice of priors in MCMC deserves attention as artificially informative
prior can essentially lead to arbitrary and as uncertain as the prior. Statistical estimation
is increasingly hybrid in that it will incorporate computational, mathematical, and graphic
tools.
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2.5 Tables
Table 3: Mean (SE) TCDD concentrations in the fat (pg/g)c.
Dose Level
Week Control 3.3 ng/kg 7.3 ng/kg 15.2 ng/kg 33 ng/kg
13 13a 305:4(12:9) 563:2(44:2) 704:7(52:6) 1399:2(103:3)
30 -b 326:7(12:3) 646:5(14:8) 1292:0(37:9) 2610:0(96:9)
52 -b 345:3(20:5) 687:6(44:4) 1098:9(75:6) 2706:3(95:0)
104 12:600:40 553:2(33:9) 856:6(116:3) 1616:0(107:7) 2823:8(208:6)
a Based on one observation; b Level below the limit of quantitation (LOQ) of 5 pg/g;
c Number of sacrificed animals at each time point per dose group: Week 13:
10,10,10,10,10; Week 30: 10, 10, 10, 10, 10; Week 52: 8, 8, 8, 8, 8; Week 104: 8,
10, 10, 10, 10.
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Table 4: Mean(SE) TCDD concentrations in the liver (pg/g)b.
Dose Level
Week Control 3.3 ng/kg 7.3 ng/kg 15.2 ng/kg 33 ng/kg
13 0:74(0:26) 613:6(33:1) 1675:5(84:3) 3625:0(166:7) 6660:0(402:9)
30 0:13a 727:2(47:6) 1789:9(130:9) 3383:0(200:9) 8508:0(495:0)
52 0:14a 779:6(32:8) 2048:8(103:8) 3836:2(181:3) 9503:8(647:3)
104 4:62(3:68) 1260:8(100:7) 2611:0(141:7) 4640:0(336:9) 10518:8(929:6)
a Based on one observation; b Number of sacrificed animals at each time point per dose
group: Week 13: 10,10,10,10,10; Week 30: 10, 10, 10, 10, 10; Week 52: 8, 8, 8, 8, 8;
Week 104: 8, 10, 10, 10, 10.
Table 5: Estimates (95% BCa bootstrap CIsa) of regression coefficients.
Coefficient Intercept (am) Slope (gm)
log(Ke) -2.9903 (-3.0690, -2.9678) 0.00998 (0.0082, 0.0244)
log(K f l) -4.1314 (-4.1657, -4.1296) 0.0059 (0.0052, 0.0095)
log(Kl f ) -4.3558 (-4.5207, -4.3502) -0.0061 (-0.0076, -0.0038)
a Sample mean of all acceptable estimates was used as the original estimate for bootstrap
sampling.
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Table 6: Estimates (95% BCa bootstrap CIsa) for kinetic parameters.
Dose-Independent Dose Dependent model
Model 3.3(ng/kg) 7.3(ng/kg) 15.2(ng/kg) 33(ng/kg)
Ke 0.0583 0.0519 0.0540 0.0584 0.0697
CI (0.0561, 0.0604) (0.0477, 0.0557) (0.0493, 0.0614) (0.0526, 0.0745) (0.0609, 0.1150)
K f l 0.1109 0.0164 0.0168 0.0176 0.0195
CI (0.1083, 0.1138) (0.0158, 0.0166) (0.0161, 0.0172 ) (0.0168, 0.0186 ) (0.0184, 0.0220)
Kl f 0.0752 0.0126 0.0123 0.0117 0.0105
CI (0.0730, 0.0772) (0.0106, 0.0128) (0.0103, 0.0126) (0.0097, 0.0122) (0.0085, 0.0114)
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2.6 Figures
Figure 1: Schematic representation of the pharmacokinetic model.
CL,CF are concentrations, D is dose, and Ke, K f l , and Kl f are kinetic parameters.
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Figure 2: Scatter plots of plausible estimates of the model parameters.
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Figure 3: TCDD concentration in fat (concentration per unit baseline bw).
Constant (solid line) and dose-dependent (dotted lines) kinetic parameter models for TCDD.
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Constant (solid line) and dose-dependent (dotted lines) kinetic parameter models for TCDD.
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3 Body and Organ Weight Growth of Female SD Rats
exposed to a Mixture of DLCs
3.1 Introduction
Pharmacokinetics (toxicokinetics) and pharmacodynamics (toxicodynamics) are the
main tools to study xenobiotics in a biological system of a mammal species. In the last few
decades these models have grown into physiologically based pharmacokinetic (toxicoki-
netic) or pharmacodynamic (toxicodynamic) models by integrating realistic characteristics
of a biological system (Clewell and Andersen, 1985; Anderson, 2003). Organ weight is one
fundamentally important characteristic of any biological system. Because organ weight is
often not directly measurable, estimation is required. One common approximation is to
assume that the organ weight is constant fraction of the total body weight. For example,
the International Life Science Institute and the EPA’s Office of Health and Environmental
Assessment suggests that the rat liver is 3.66% of the total body weight and the lungs are
0.5% of the body weight (Brown et al., 1997). In most PBPK models an organ’s weight
is assumed to be a constant fraction of body weight, and the potential exposure or growth
effects on this relation is ignored. This is the case in PBPK models of Dioxin (Wang et
al., 1997; Emond, 2004). These authors considered body weight growth equations, but did
not consider exposure effect that might alter body weight or organ weight growth. Organ
weight may hold well as a constant portion of total body weight in an acute study of short
duration in which body and organ weight change is negligible. But over a longer period of
active growth or significant environmental interference such as chronic exposure to toxins,
the organ and body weights and their relation may not hold.
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The assumption of constant organ to body weight ratio must be verified. Invalidity
in the assumption can have critical impact on pharmacokinetics and pharmacodynamics
especially in a sub-chronic or chronic toxicological study, including incorrect estimation
of the total amount of the agent in the target tissue (Brown et al., 1997). Body and organ
weights and organ volumes are some of the most important physiological parameters in
PBPK models, and they affect many physiological parameters, including but not limited to
breathing rate, cardiac output rate, and organ perfusion rate, which in turn influence blood
flow velocities, surface areas, and permeability.
The literature appears limited on the relationship between organ and body weights.
Schoeffner et al.(1999) investigated the organ weights and fat volume of Fischer344 rats
and Sprague-Dawley (SD) rats at 4, 6, 8, 10, 12, 14, and 40 weeks as the animals aged. The
relative weight of the liver, spleen, kidneys, and lungs decreased between 4-week and 14-
week in age. This implies that even in short term studies of acute or sub-chronic exposure,
the constant organ weight fraction to body weight may not hold. In youngest rats (4-8
weeks old) the percent of body fat ranged from 5.2% to 5.8%, while in rats aged 10-14
weeks fat ranged from 6.1% to 6.5%, although the increase was not statistically significant.
This paper investigates how organ weight might change as a fraction of body weight
under chronic exposure during an active growth period. We show that the growth of body
weight of SD rats was affected by exposure to a dioxin mixture, and the organ weight was
changing as well relative to body weight over time and across exposure level.
3.2 Methods
3.2.1 The NTP 2-Year Carcinogenicity Study of Dioxin and DLC Mixture
Body weight and organ weight data of female Harlan Sprague-Dawley rats were de-
rived from a NTP 2-year carcinogenesis study of mixture of dioxin, PeCDF, and PCB126.
TCDD (2;3;7;8-tetrachlorodibenzo-p-dioxin; CAS 1746-01-6) or dioxin is a chlorinated
hydrocarbon, and is the prototype of the polyhalogenated aromatic hydrocarbon (PHAH)
family, which includes dibenzo-p-dioxins (PCDDs), dibenzofurans (PeCDFs), biphenyls,
and polychlorinated biphenyls (PCB). TCDD is the most toxic compound in this family.
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The National Toxicology Program (NTP) of the National Institute of Environmental
Health Sciences (NIEHS) conducted a series of studies to better understand carcinogenicity
of chronic exposure to dioxin and DLCs. In one of these studies, female Harlan Sprague-
Dawley rats were administered a mixture of TCDD, PeCDF, and PCB126. The mixture was
administered through gavage, once daily 5 days a week, up to 104 weeks (2 years). The
mixtures were prepared in a corn oil:acetone (99:1) solution at four concentration levels
in the ratio of one part TCDD, two parts PeCDF, and ten parts PCB-126, with the dose of
TCDD being 3.3, 7.3, 15.2, and 33 ng/kg body weight respectively. Eighty-one rats were
randomly assigned to each dose group, in addition to a vehicle control of corn oil/acetone
solution only. Eight to ten rats per dose group were sacrificed for biochemical (tissue
concentration) and physiological evaluation, at weeks 13, 30, and 52. The animals were
weighted at baseline, weekly for 13 weeks, monthly thereafter, and at necropsy. Organ
weights were only collected at week 13, 30, and 52. The sampling scheme of the 2-year
study is shown in Table 7. See Walker et al.(2005) for more details on study design and
outcomes.
3.2.2 Body Weights
The overall baseline mean weight of the rats is 180.8 grams and the baseline mean
weights for each dose group were 179.1, 180.0, 181.4, 181.3, and 182.1 grams in the con-
trol, 10, 22, 46, and 100 ng TEQ/kg bw dose groups respectively. The mean body weight
by time and dose is displayed in table 2. For example the mean weight at the last time point
of 104 weeks was 360.8, 380.5, 365.5, 329.4, and 287.0 grams for the control and dose
groups respectively.
Figure 5 summarizes body weight at the time of sacrifice using boxplots. The boxplots
show that the variation in the weights at the 104 week time point is greatest in the two
lowest dose groups. Body weight growth does not seem to be slowed in the two lower dose
groups compared to the control group; but the weights at the highest group were noticeably
lower than the control group at all four sacrifice times. The individual rats growth curves
also demonstrate this trend and are shown later. We show that exposure to dixoin and the
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mixture of PCB126 and PeCDF cause a reduction in the maximum weights and growth
periods of the rats at the higher exposure levels.
3.2.3 Organ Weights
Weights of the liver, lung, spleen, right kidney, thyroid, and right ovary were obtained
at week 13, 30, and 52 upon sacrifice. The means and standard deviations of the observed
weights are presented in Table 8. We also report the mean ratio of organ weight to body
weight by dose and time in Table 9.
The mean liver weight increases as dose level increases, as well as with time. At week
13 the mean liver weight in the control group is 9.33g and increases to 10.72g in the highest
dose group. At week 52 the range in mean liver weight is 10.38g to 12.42g across the dose
levels.
In terms of proportions, at week 13 the control group’s liver weight on average is 3.12%
of total body weight, but this increased to 3.59% in the lowest dose (10 TEQ ng/kg) group,
and to 4.12% in the highest dose (100 TEQ ng/kg) group. This trend suggests an increasing
portion of liver weight in body weight when exposure level increases. There is a similar
pattern in the ratios at weeks 30 and 52. Over time the general trend is also increasing
based on these crude ratios. A formal analysis of these trends is done through the use of
regression models.
Similar patterns are observed in the ratios of the lung to body weights and kidney to
body weights. In the lung the mean relative weights range from 0.61% in the control group
at week 13 to 0.71% in the highest dose group at week 13. At week 52 the range is 0.69%
to 0.83%. While the relative kidney weight is also increasing (although not monotonically)
in dose and time, from 0.26% in the control group at week 13 to 0.29% at week 52.
The change in the weight of the spleen over exposure level is opposite that of the liver,
lungs, and kidney. At week 13 the mean spleen weight is 0.58g in the control group de-
creasing to 0.47g in the highest dose group. At week 52 the range is 0.54g to 0.43g over the
dose levels. The mean spleen weight is decreasing in time. In the control group the mean
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spleen weight is 0.56g at 13 weeks and decreases to 0.49g at 52 weeks. The thyroid and
ovary weights also decrease in time yet changes over exposure level are not monotonic.
3.2.4 Body Weight Growth Model
To investigate and quantify the relationship between organ weights and body weight we
first conduct a nonlinear regression model of body weight growth as mediated by exposure
level. Body weight growth was described using a Michaelis-Menten-like kinetic function.
To capture the between-subject variation in weight growth, we introduced random-effects
into the coefficients which measures individual deviation in the regression coefficient from
the average value. This is a statistical nonlinear mixed-effects model.
Let Yi jk be the body weight of k-th rat in the ith dose group at time j, where Di (i =
1;2;3;4;5) corresponding to 0, 10, 22, 46, and 100ng TEQ /kg bw. Figure 6 is a plot in
which each panel (dose group) displays individual rats’ weight growth over time. The rats’
weight were measured once a week for the first 13 weeks and then once a month thereafter
until sacrifice. The plot suggests an increasing trend of body weight that is suppressed
somewhat by the increasing exposure level in both the growth period and peak weight.
Moreover the between-subject variation is visibly increasing over time, but stays roughly
the same over exposure level. These observations suggested the Michaelis-Menten kinetics
function for the mean weight
mi j = W0+

Vmaxt j
Km+t j

(10)
whereVmax and Km are functions of dose to permit the exposure effect on maximum growth
as well as on rate of growth:
Vmax = exp(Va+Vb Di) (11)
Km = exp(Ka+Kb Di) (12)
Note that the coefficient Km is the time when half-maximal growth is achieved. The
complete statistical model for body weight growth is therefore
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Wi jk = m
 
Di; t j;W0;Vmax;Km

+ ei jk (13)
where the error term ei jk  N
 
0;s2I

To capture the increasing variation in body weight
as the animal grew older, we proposed s = exp(b t). For simplicity the errors from the
same subject were considered independent, hence the variance covariance matrix involves
the identity matrix I. To further allow for between-subject variation, random effects are
introduced so thatW0, and Ka, Kb can be replaced with
W0+ g1k
Ka+ g2k
and
Kb+ g3k
respectively.
3.2.5 Organ and Relative Organ Weight Models
Wemodeled the relationship between organ weight and body weight through regression
models with exposure level and time as mediation effects. Two approaches were consid-
ered. The first is a linear model in which organ weight is thought of as a function of body
weight with adjustment by animals age and exposure level.
Thus we initially fit a model of the form.
Yi jk = b (Di; t j)Wi jk =
 
b0+b1 Di+b2  t j

Wi jk+ ei jk (14)
where Yi jk represents the weight of the organ of interest for the kth rat in the ith dose group
and week t j (i= 1 : : :5 and j= 1;2;3). The model can be extended to include nonlinear term
(e.g. quadratic term) or cross product of dose and time along the classic linear regression
framework. The function b (Di; t j) is the mean relative weight of the organ of interest and
it is this quantity that will be derived and reported.
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The second approach is a variation of the first model in which we directly model the
ratio of an organ weight to body weight.
log Yi jkWi jk = b0+b1 Di+b2  t j+ ei jk (15)
This model can also be expanded to include nonlinear term or cross-product of dose
and time. This second approach is attractive in its ability to deal with hetereocadesticity -
variance is not constant over dose or time. In both models, we can consider
ei jk  N(0;s2i jI)
where we allow si j to be distinct between dose levels and time points, including the more
formal function si j = exp(l1 Di+l2  t j).
3.3 Results
3.3.1 Body Weight
Regression estimates and standard deviations of the random effects of the nonlinear
mixed-effects model for body weight growth are presented in Table 10. The regression
coefficients for the slopes (Vb and Kb) of the dose terms in the maximum weight (Vmax)
and half-life of growth (Km) equations are both highly significant (p-value< 1.00e-04) and
negative. The values of -9.81e-03 and -0.02 for Vb and Kb respectively confirm the reduced
maximum weight and shortened growth spurt of the rats. The standard deviations of the
random effects of the slope and intercept of the Km term are small, 4.89e-03 and 4.07e-05
for Ka and Kb respectively, indicating small between subject variability.
Using the regression model we can calculate the value of Vmax and Km for each dose
group and these are presented in Table 11. The model suggests that body weight growth
was reduced by approximately 28% in the highest dose group compared to the control
group. The growth spurt reached it’s half maximum value earlier in the highest dose group,
about 46% earlier then the control group.
In this case, ignoring the dependence of body weight on exposure would cause mis-
leading estimates of other related parameters. Especially in the context of a PK or PBPK
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model. Examining subject growth in body weight should be done on a case by case basis
in applications of model building and risk assessment.
3.3.2 Organ Weight as a fraction of body weight
The regression coefficients and associated summary statistics for the organ weight mod-
els are displayed in Table 12. The only organ model to have a significant quadratic dose
effect was the liver model and it is denoted as b3. Since both of the dose terms are highly
significant in the liver model, we have evidence that exposure modifies the weight of the
liver relative to the body weight. The dose coefficient is 2.28e-04 (p-value = 2.63e-13) and
the quadratic coefficient is -1.33e-06 (p-value = 1.73e-06), thus the relative liver weights
are increasing as dose increases. Given that the sign of the dose coefficient is positive and
the sign of the quadratic term is negative, the change in relative liver weight is increasing
yet the rate of growth slowed as dose increased. Liver weight as a fraction of body weight
also changes over time. Given the observations and these results we conclude liver weight
is not a constant proportion of body weight over the first two years of life for SD rats. The
predicted values of the relative weights from all the organ models are found in Table 13.
In the lung and spleen models there is a dose effect. In the lung model the estimated
coefficient for dose is 9.57e-06 (p-value = 4.28e-05), which implies an increase of 9.57e-06
in the relative lung weight for every unit increase in the dose level. The coefficient for dose
in the spleen model is -1.08e-06 (p-value = 2.95e-02), this means we observe a decreasing
effect as dose increases, opposite to that of the liver and lung as time is held constant.
The same models were fit to the kidney, thyroid, and ovary weight data. In the kidney
model the dose coefficient is borderline significant (9.55e-07, p-value = 7.72e-02) but in
the thyroid and ovary models dose is not statistically significant. Although the dose terms
are not significant, the regression coefficients in the thyroid and ovary models are negative,
implying a decreasing effect on the size of the organ as dose increases.
In all the organ models, time is highly significant. The relative weight of the liver,
lung, and kidney as a fraction of body weight increase with the animal’s age; however, in
the spleen, thyroid, and ovary the relative weight is decreased over time. In the lung for
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example, the mean relative weight is increasing by 1.43e-05 per week and the spleen is
decreasing by -7.62e-06 per week.
3.3.3 Organ-Body Weight Ratios
The observed liver weight to body weight ratios were plotted by dose and time point
and is displayed in Figure 7. The ratio is directly modeled on a log-scale. The regression
coefficients and associated summary statistics are displayed in Table 14. The predicted
values from all of the organ-body ratio models are found in Table 15. The only organ
model to have a significant quadratic dose term is the liver model and it is denoted as b3.
Since both dose terms are highly significant in the liver model, we have evidence that
exposure modifies the ratio of liver to body weight. The dose coefficient is 6.11e-03 (p-
value = 2.30e-13) and the quadratic dose coefficient is -3.59e-05 (p-value = 1.13e-06), thus
the relative liver weights are increasing as dose increases but the rate of change slowed as
dose increased (as indicated by the negative value of the coefficient for the quadratic term).
Given the signs of the dose coefficients, the change in the log of the ratio is increasing
yet concave with a downwards curvature as dose increases and time is held constant. By
exponentiating the intercept b0 we estimate that the liver is approximately 3.06% of the
body weight at baseline.
The observed relative liver weight ranged from 3.12% in the control group to 4.12% in
the highest dose group at week 13 and at the end of one year the mean ranged from 3.21%
for the control group to 4.32% for the highest dose group. The mean predicted values are
not far from the observed mean values. The quadratic liver model predicted 3.13% in the
control at week 13 and 4.28% for the highest dose group at the end of one year. A difference
of only .04% in the highest dose group at week 52.
Not only did time and dose modify the growth trajectory for the relative liver weights
but an increasing effect was seen in the lung and a decreasing effect in the spleen. Growth
over time was statistically significant in all organs. Both the time and dose terms are highly
significant in the relative weight model for the lung and spleen. For the lung, the estimate
of the dose effect is 1.42e-03 (p-value = 7.72e-06). For the spleen, the estimate of the dose
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effect is -6.95e-04 (p-value = 8.50e-03), suggesting a decreasing relative weight as dose
increases.
The same analysis was conducted on the relative weights of the kidney, thyroid, and
ovary. The dose effects are not statistically significant at the 5% level in the these organs.
There is very little change in the relative right kidney weights over the one year time span.
At week 13 in the control group the mean relative weight was .26% while in the highest
dose group the mean was .29%. At the end of one year, the control group’s mean was .30%,
while the highest dose group’s mean was .31%.
Although not statistically significant, the dose effects on the relative weight of the thy-
roid and ovary are negative; suggesting a decreasing trend in the relative weight, this is
opposite from the effect observed in the liver.
The two different models (equations 14 and 15) give similar predictions of relative
organ weights. For the liver, the models predict the week 13 control group means to be
3.10% and 3.13%, in the highest dose group at week 13 the predictions are 4.05% and
4.03%. At the end of one year the model predictions are almost equal to each other, in
the control group the models predict 3.34% and 3.33% and in the highest dose group the
predictions are 4.29% and 4.28%. Given the similar predictions the model in equation 15
is favored because of its ability to deal with hetereocadesticity, as it models the log of the
organ to body weight ratio.
3.4 Discussion and Conclusions
Using the assumption of organ weight being a constant proportion of body weight can
cause ”pharmacokinetic bias” when predicting amounts or concentrations. Since PBPK
models attempt to describe or predict the way the body absorbs, distributes, metabolizes,
and excretes chemicals or drugs; any measurement of concentration or amount of substance
in an organ will be biased when using a constant proportion as the organ weight, especially
in chronic exposure scenarios.
Sprague-Dawley rat strains are commonly used to evaluate adverse effects as a result
of environmental exposure to toxic chemicals and PBPK models are commonly based on
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animal experiments. This paper illustrates that organ weights may change disproportional
to body weight over the growth period or under chronic exposure to DLCs. Thus in PBPK
models physiological parameters such as organ volumes and organ weight may be affected
by exposure conditions and should not be assumed to be a constant proportion of body
weight. Organ volumes and adipose tissue content can substantially influence the disposi-
tion of drugs and chemicals in physiologically based pharmacokinetic models (Sotaniemi,
1992).
There is strong evidence that liver and lung weights, as a proportion of body weight,
increase with the exposure level and growth age of the animals. The proportion of other
organs such as the spleen to body weight also changed statistically significantly. Since
organ weights are unlikely to be a constant proportion of body weight in the first year of
growth or under chronic exposure condition, this non-constant relationship may have pro-
found pharmacokinetic and pharmacodynamic implications. This is because physiological
parameters such as organ blood flow rates and surface areas will be non-constant. The
use of accurate physiological values in PK/PBPK models is essential for meaningful pre-
dictions of the pharmacokinetic behavior. Also the increased use of monte carlo analysis
in conjunction with PBPK modeling requires that appropriate ranges of the physiological
values in question be determined in order to develop valid probability distributions (lipton
et al., 1995) for parameters. Our results in this paper not only confirm the likelihood of or-
gan weight change in disproportion to body weight, but also illustrate the range of relative
weights when experiment subjects are exposed to mixtures of DLCs.
Allometric equations within PBPK models are often used to describe the change in car-
diac output. For example in Emonds (2004) PBPK model for developmental exposures to
TCDD in the rat, an equation of the formQc(ml=h)=QCC 60 ((BodyWeight)=1000)(0:75)
is employed for predicting the cardiac output, where QCC = 311.4 ml=min=kg. If body
weight is assumed to grow independently of exposure, then in cases where exposure or ther-
apeutic intervention modifies or inhibits the growth trajectory, cardiac output predictions
will be biased. We have also shown that assuming body weight growth is not modified by
exposure can lead to over estimating the body weight of animals in high dose groups. This
can have a direct effect on cardiac output and blood flow rates. Cardiac output and blood
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flow rates are important physiologic parameters in any PBPK model, they help determine
the total amount and rate at which blood is moved in the organism.
Every substance has a different density and will have a different volume to weight con-
version, in PBPK models the density of each organ is usually considered to be 1 (Brown
et al., 1997), thus no conversion from mass to volume is used and Density = MassVolume . Fur-
thermore, this implies that the weight is assumed to be the volume. Consider the formula
for amount of a chemical (i.e., in the Liver) with respect to concentration and volume, we
have AL = CLVL . If we let VˆL be an estimate of liver volume when assuming liver weight is a
constant proportion of body weight and letVL(t;d) be an estimate of liver volume based on
a model using body weight that includes exposure and time as modifiers of the relationship,
then in the context of the observed results of the NTP study (the relative weight of the liver
increases with exposure), using VˆL would cause over-estimation of AL for a given CL since
VˆL <VL(t;d).
This paper has demonstrated that the assumption of organ weights being a constant
proportion of body weight is not valid and can possibly bias estimates of concentrations or
amounts of chemicals when using PBPK models. We have also demonstrated that growth
in SD rats is slowed by exposure to the dioxin and dioxin like compounds and that expo-
sure effects must be incorporated into the growth equations of PBPK models in hopes of
eliminating bias and improving accuracy.
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3.5 Tables
Table 7: Sampling scheme of the 2-year NTP study of TCDD mixture.
Administered Dose Level
(ng TEQ / kg)
Week Control 10 22 46 100
14 10 10 10 10 10
30 10 10 10 10 10
52 8 8 8 8 8
104 8 10 10 10 8
50
Table 8: Observed mean (SD) of the organ and body weights (g) by time and dose.
Administered Dose Level (ng TEQ / kg)
Organ Week Control 10 22 46 100
Whole Body 0 179.11(9.98) 179.96(7.40) 181.39(9.94) 181.33(7.88) 182.12(6.41)
13 298.77(23.61) 280.44(20.59) 281.99(12.98) 277.42(17.93) 259.83(19.21)
30 290.47(18.96) 297.00(14.71) 299.50(21.06) 293.79(25.23) 294.65(17.86)
52 323.94(13.08) 307.86(24.70) 316.35(25.13) 320.05(30.45) 287.46(14.26)
104 360.75(54.91) 380.47(68.73) 365.51(66.36) 329.43(58.92) 287.01(47.05)
Liver
13 9.33(0.83) 10.07(0.87) 9.78(1.06) 10.11(1.01) 10.72(1.16)
30 8.94(1.19) 10.69(0.86) 10.65(0.71) 11.56(1.63) 11.99(1.34)
52 10.38(0.79) 11.27(1.10) 11.30(1.16) 14.09(2.00) 12.42(1.36)
Lung
13 1.83(0.27) 1.86(0.31) 1.85(0.23) 1.93(0.35) 1.85(0.16)
30 1.91(0.33) 1.89(0.28) 2.07(0.22) 2.12(0.33) 2.10(0.24)
52 2.25(0.46) 2.12(0.23) 2.16(0.26) 2.35(0.31) 2.38(0.26)
Kidney
13 0.77(0.06) 0.82(0.06) 0.79(0.03) 0.77(0.04) 0.76(0.06)
30 0.82(0.06) 0.91(0.08) 0.84(0.06) 0.86(0.08) 0.84(0.05)
52 0.96(0.08) 0.92(0.08) 0.91(0.08) 1.01(0.07) 0.88(0.07)
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Table 8 continued. Observed mean (SD) of the organ and body weights (g) by time and dose.
Administered Dose Level (ng TEQ / kg)
Organ Week Control 10 22 46 100
Spleen 13 0.58(0.04) 0.56(0.08) 0.56(0.07) 0.52(0.04) 0.47(0.06)
30 0.51(0.06) 0.50(0.06) 0.51(0.04) 0.52(0.07) 0.48(0.07)
52 0.54(0.03) 0.49(0.07) 0.50(0.05) 0.55(0.16) 0.43(0.05)
Thyroid
13 2.65e-02(2.68e-03) 2.47e-02(2.91e-03) 3.13e-02(6.41e-03) 2.78e-02(7.93e-03) 2.29e-02(4.61e-03)
30 2.34e-02(4.25e-03) 2.39e-02(6.40e-03) 2.69e-02(3.57e-03) 2.41e-02(3.35e-03) 2.61e-02(3.67e-03)
52 2.27e-02(9.18e-03) 1.85e-02(2.62e-03) 2.01e-02(3.09e-03) 1.76e-02(2.92e-03) 1.61e-02(2.10e-03)
Ovary
13 6.40e-02(1.08e-02) 6.00e-02(1.89e-02) 5.60e-02(1.35e-02) 5.60e-02(1.35e-02) 5.30e-02(1.64e-02)
30 5.00e-02(8.16e-03) 5.60e-02(1.43e-02) 5.40e-02(1.35e-02) 5.90e-02(1.59e-02) 5.50e-02(8.50e-03)
52 5.37e-02(1.19e-02) 5.12e-02(6.41e-03) 4.88e-02(6.41e-03) 6.38e-02(1.85e-02) 4.50e-02(9.26e-03)
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Table 9: Observed mean (SD) of the relative organ weighta by time and dose (Expressed as percentage).
Administered Dose Level (ng TEQ / kg)
Organ Week Control 10 22 46 100
Liver 13 3.12(0.12) 3.59(0.21) 3.47(0.32) 3.64(0.24) 4.12(0.24)
30 3.07(0.26) 3.60(0.15) 3.56(0.17) 3.92(0.32) 4.06(0.29)
52 3.21(0.22) 3.66(0.18) 3.58(0.32) 4.40(0.45) 4.32(0.42)
Lung
13 0.61(0.06) 0.66(0.09) 0.66(0.07) 0.70(0.12) 0.71(0.05)
30 0.66(0.09) 0.64(0.10) 0.69(0.08) 0.72(0.10) 0.72(0.08)
52 0.69(0.13) 0.69(0.09) 0.70(0.16) 0.74(0.10) 0.83(0.11)
Kidney
13 0.26(0.02) 0.29(0.01) 0.28(0.01) 0.28(0.02) 0.29(0.01)
30 0.28(0.02) 0.31(0.03) 0.28(0.02) 0.29(0.02) 0.29(0.01)
52 0.30(0.02) 0.30(0.03) 0.29(0.02) 0.32(0.05) 0.31(0.02)
53
Table 9 continued. Observed mean (SD) of the relative organ weighta by time and dose (Expressed as percentage).
Administered Dose Level (ng TEQ / kg)
Organ Week Control 10 22 46 100
Spleen 13 0.19(0.01) 0.20(0.02) 0.20(0.02) 0.19(0.01) 0.18(0.01)
30 0.18(0.02) 0.17(0.01) 0.17(0.01) 0.18(0.02) 0.16(0.02)
52 0.17(0.01) 0.16(0.02) 0.16(0.01) 0.17(0.05) 0.15(0.02)
Thyroid
13 8.80e-03(1.03e-03) 8.80e-03(1.03e-03) 1.12e-02(2.30e-03) 1.02e-02(3.22e-03) 9.00e-03(1.49e-03)
30 7.90e-03(1.52e-03) 8.00e-03(2.31e-03) 8.90e-03(1.37e-03) 8.20e-03(1.4e-03) 9.00e-03(1.63e-03)
52 6.88e-03(2.70e-03) 6.25e-03(1.04e-03) 6.25e-03(1.04e-03) 5.62e-03(9.2e-04) 5.50e-03(7.60e-04)
Ovary
13 2.10e-02(3.16e-03) 2.00e-02(8.16e-03) 2.00e-02(6.67e-03) 2.10e-02(5.68e-03) 2.10e-02(5.68e-03)
30 1.90e-02(3.16e-03) 2.00e-02(4.71e-03) 2.10e-02(3.16e-03) 2.00e-02(4.71e-03) 1.90e-02(3.16e-03)
52 1.75e-02(4.63e-03) 1.87e-02(3.54e-03) 1.63e-02(5.18e-03) 2.00e-02(7.56e-03) 1.50e-02(5.35e-03)
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Table 10: Regression coefficients and statistics for Nonlinear mixed effects body weight
model.
Term Estimate Std. Error t value Pr(> jtj) SD of random
effect estimates
Wint 185.22 1.36 136.11 <1.00e-04 9.89e-02
Va -0.20 0.01 -30.38 <1.00e-04 -
Vb -9.81e-03 1.00e-03 -21.25 <1.00e-04 -
Ka 1.86 0.07 24.92 <1.00e-04 4.89e-03
Kb -0.02 2.8e-03 -6.65 <1.00e-04 4.07e-05
s j = exp(b  t j) with the estimate bˆ = 0:012.
Table 11: Estimates of Vmax and Km by dose level.
Administered Dose level Vmax Km
ng TEQ / kg bw
Control 0.82 6.33
10 0.79 5.95
22 0.76 5.52
46 0.70 4.76
100 0.59 3.41
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Table 12: Regression statistics of organ weight models.
Organ Term Estimate Std. Error t value Pr(> jtj)
Liver (quadratic model)
b0 3.02e-02 6.91e-04
b1(Dose) 2.28e-04 2.81e-05 8.11 2.63e-13***
b2(Week) 6.23e-05 1.64e-05 3.79 2.26e-04***
b3
 
Dose2

-1.33e-06 2.66e-07 -5.00 1.73e-06***
Lung
b0 6.12e-03 1.93e-04
b1(Dose) 9.57e-06 2.26e-06 4.23 4.28e-05
b2(Week) 1.43e-05 5.02e-06 2.85 5.10e-03
Kidney
b0 2.69e-03 4.56e-05
b1(Dose) 9.55e-07 5.36e-07 1.78 7.72e-02
b2(Week) 5.26e-06 1.19e-06 4.42 1.96e-05
Spleen
b0 2.03e-03 4.19e-05
b1(Dose) -1.08e-06 4.93e-07 -2.20 2.95e-02
b2(Week) -7.62e-06 1.09e-06 -6.97 1.23e-10
Thyroid
b0 1.09e-04 3.56e-06
b1(Dose) -1.82e-08 4.19e-08 -0.43 6.67e-01
b2(Week) -8.78e-07 9.29e-08 -9.45 1.23e-16
Ovary
b0 2.18e-04 8.32e-06
b1(Dose) 1.32e-08 9.77e-08 0.14 8.93e-01
b2(Week) -9.74e-07 2.17e-07 -4.49 1.49e-05
Yi jk = b (Di; t j)Wi jk
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Table 13: Means (SE) of estimated relative weight based on organ weight regression models
Administered Dose Level (ng TEQ / kg)
Organ Week Control 10 22 46 100
Liver (quadratic model)
13 3.10e-02(5.52e-04) 3.33e-02(4.37e-04) 3.54e-02(4.47e-04) 3.87e-02(5.70e-04) 4.05e-02(6.74e-04)
30 3.21e-02(4.64e-04) 3.43e-02(3.15e-04) 3.64e-02(3.25e-04) 3.97e-02(4.78e-04) 4.16e-02(6.03e-04)
52 3.34e-02(5.77e-04) 3.57e-02(4.61e-04) 3.78e-02(4.65e-04) 4.11e-02(5.80e-04) 4.29e-02(6.91e-04)
Lung
13 6.30e-03(1.44e-04) 6.40e-03(1.33e-04) 6.52e-03(1.25e-04) 6.75e-03(1.25e-04) 7.26e-03(1.93e-04)
30 6.55e-03(1.10e-04) 6.64e-03(9.58e-05) 6.76e-03(8.35e-05) 6.99e-03(8.37e-05) 7.50e-03(1.69e-04)
52 6.86e-03(1.51e-04) 6.96e-03(1.40e-04) 7.07e-03(1.32e-04) 7.30e-03(1.32e-04) 7.82e-03(1.98e-04)
Kidney
13 2.76e-03(3.41e-05) 2.77e-03(3.16e-05) 2.78e-03(2.95e-05) 2.81e-03(2.96e-05) 2.86e-03(4.57e-05)
30 2.85e-03(2.61e-05) 2.86e-03(2.27e-05) 2.87e-03(1.98e-05) 2.90e-03(1.98e-05) 2.95e-03(4.00e-05)
52 2.97e-03(3.57e-05) 2.98e-03(3.32e-05) 2.99e-03(3.13e-05) 3.01e-03(3.13e-05) 3.06e-03(4.68e-05)
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Table 13 continued. Means (SE) of estimated relative weight based on organ weight regression models.
Administered Dose Level (ng TEQ / kg)
Organ Week Control 10 22 46 100
Spleen
13 1.93e-03(3.13e-05) 1.92e-03(2.90e-05) 1.90e-03(2.72e-05) 1.88e-03(2.72e-05) 1.82e-03(4.20e-05)
30 1.80e-03(2.40e-05) 1.79e-03(2.09e-05) 1.77e-03(1.82e-05) 1.75e-03(1.82e-05) 1.69e-03(3.68e-05)
52 1.63e-03(3.28e-05) 1.62e-03(3.06e-05) 1.61e-03(2.88e-05) 1.58e-03(2.88e-05) 1.52e-03(4.30e-05)
Thyroid
13 9.72e-05(2.66e-06) 9.70e-05(2.47e-06) 9.68e-05(2.31e-06) 9.64e-05(2.31e-06) 9.54e-05(3.57e-06)
30 8.23e-05(2.04e-06) 8.21e-05(1.77e-06) 8.19e-05(1.55e-06) 8.14e-05(1.55e-06) 8.05e-05(3.13e-06)
52 6.30e-05(2.79e-06) 6.28e-05(2.60e-06) 6.26e-05(2.45e-06) 6.21e-05(2.45e-06) 6.11e-05(3.65e-06)
Ovary
13 2.05e-04(6.21e-06) 2.05e-04(5.75e-06) 2.06e-04(5.39e-06) 2.06e-04(5.40e-06) 2.07e-04(8.34e-06)
30 1.89e-04(4.76e-06) 1.89e-04(4.14e-06) 1.89e-04(3.61e-06) 1.89e-04(3.61e-06) 1.90e-04(7.30e-06)
52 1.67e-04(6.50e-06) 1.67e-04(6.06e-06) 1.68e-04(5.71e-06) 1.68e-04(5.71e-06) 1.69e-04(8.52e-06)
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Table 14: Regression statistics for organ weight relative to body weight.
Organ Term Estimate Exp(Est) Std. Error t value Pr(> jtj)
Liver (quadratic model)
b0 -3.49 3.06e-02 1.82e-02
b1(Dose) 6.11e-03 1.01 7.52e-04 8.13 2.30e-13
b2(Week) 1.59e-03 1.00 4.37e-04 3.63 4.00e-04
b3
 
Dose2

-3.59e-05 1.00 7.04e-06 -5.10 1.13e-06
Lung
b0 -5.10 6.09e-03 2.61e-02
b1(Dose) 1.42e-03 1.00 3.05e-04 4.65 7.72e-06
b2(Week) 2.18e-03 1.00 7.00e-04 3.11 2.26e-03
Kidney
b0 -5.91 2.70e-03 1.51e-02
b1(Dose) 3.45e-04 1.00 1.76e-04 1.96 5.17e-02
b2(Week) 1.78e-03 1.00 4.03e-04 4.42 2.01e-05
Spleen
b0 -6.19 2.05e-03 2.23e-02
b1(Dose) -6.95e-04 1.00 2.60e-04 -2.67 8.50e-03
b2(Week) -4.55e-03 1.00 5.98e-04 -7.60 4.10e-12
Thyroid
b0 -9.09 1.13e-04 4.12e-02
b1(Dose) -2.75e-04 1.00 4.80e-04 -0.57 5.68e-01
b2(Week) -1.15e-02 1.00 1.10e-03 -10.50 3.69e-19
Ovary
b0 -8.45 2.13e-04 4.22e-02
b1(Dose) -5.83e-05 1.00 4.92e-04 -0.12 9.06e-01
b2(Week) -4.97e-03 1.00 1.13e-03 -4.39 2.21e-05
log Yi jkWi jk = b0+b1 Di+b2  t j
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Table 15: Estimated means (SE) of relative organ weights.
Administered Dose Level (ng TEQ / kg)
Organ Week Control 10 22 46 100
Liver (quadratic model)
13 3.13e-02(1.46e-02) 3.32e-02(1.13e-02) 3.52e-02(1.14e-02) 3.84e-02(1.48e-02) 4.03e-02(1.69e-02)
30 3.21e-02(1.25e-02) 3.42e-02(8.40e-03) 3.61e-02(8.60e-03) 3.95e-02(1.27e-02) 4.14e-02(1.51e-02)
52 3.33e-02(1.57e-02) 3.54e-02(1.27e-02) 3.74e-02(1.28e-02) 4.09e-02(1.59e-02) 4.28e-02(1.79e-02)
Lung
13 6.27e-03(1.95e-02) 6.36e-03(1.80e-02) 6.47e-03(1.67e-02) 6.69e-03(1.65e-02) 7.22e-03(2.55e-02)
30 6.50e-03(1.54e-02) 6.60e-03(1.34e-02) 6.71e-03(1.16e-02) 6.94e-03(1.13e-02) 7.50e-03(2.24e-02)
52 6.82e-03(2.16e-02) 6.92e-03(2.03e-02) 7.04e-03(1.92e-02) 7.28e-03(1.90e-02) 7.86e-03(2.71e-02)
Kidney
13 2.77e-03(1.12e-02) 2.78e-03(1.04e-02) 2.79e-03(9.65e-03) 2.81e-03(9.53e-03) 2.87e-03(1.47e-02)
30 2.85e-03(8.85e-03) 2.86e-03(7.71e-03) 2.88e-03(6.70e-03) 2.90e-03(6.53e-03) 2.95e-03(1.29e-02)
52 2.97e-03(1.25e-02) 2.98e-03(1.17e-02) 2.99e-03(1.11e-02) 3.01e-03(1.09e-02) 3.07e-03(1.56e-02)
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Table 15 continued. Estimated means (SE) of relative organ weights.
Administered Dose Level (ng TEQ / kg)
Organ Week Control 10 22 46 100
Spleen
13 1.93e-03(1.67e-02) 1.92e-03(1.54e-02) 1.90e-03(1.43e-02) 1.87e-03(1.41e-02) 1.80e-03(2.18e-02)
30 1.79e-03(1.31e-02) 1.78e-03(1.14e-02) 1.76e-03(9.94e-03) 1.73e-03(9.68e-03) 1.67e-03(1.92e-02)
52 1.62e-03(1.85e-02) 1.61e-03(1.73e-02) 1.59e-03(1.64e-02) 1.57e-03(1.62e-02) 1.51e-03(2.32e-02)
Thyroid
13 9.70e-05(3.08e-02) 9.68e-05(2.84e-02) 9.65e-05(2.64e-02) 9.59e-05(2.61e-02) 9.45e-05(4.01e-02)
30 7.98e-05(2.42e-02) 7.96e-05(2.11e-02) 7.93e-05(1.83e-02) 7.88e-05(1.78e-02) 7.77e-05(3.54e-02)
52 6.20e-05(3.41e-02) 6.18e-05(3.20e-02) 6.16e-05(3.02e-02) 6.12e-05(2.99e-02) 6.03e-05(4.27e-02)
Ovary
13 2.00e-04(3.15e-02) 2.00e-04(2.91e-02) 2.00e-04(2.71e-02) 1.99e-04(2.67e-02) 1.99e-04(4.11e-02)
30 1.84e-04(2.48e-02) 1.84e-04(2.16e-02) 1.84e-04(1.88e-02) 1.83e-04(1.83e-02) 1.83e-04(3.62e-02)
52 1.65e-04(3.50e-02) 1.65e-04(3.28e-02) 1.65e-04(3.10e-02) 1.64e-04(3.07e-02) 1.64e-04(4.38e-02)
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Figure 5: Boxplots of weight at time of sacrifice (by dose and time).
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Figure 7: Scatter plot of relative liver weights (by dose and time).
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4 Statistical Estimation of PBPK Model Parameters.
4.1 Introduction
Statistical estimation of parameters in physiologically based pharmacokinetic (PBPK)
models is a relatively new area of research. Over the past decade or so PBPK models have
become important and valuable tools in risk assessment as these models are used to de-
scribe the absorption, distribution, metabolism, and excretion of xenobiotics in a biological
system such as the human or rat. Because these models incorporate information on biolog-
ical processes, they are well equipped to describe the kinetic behaviors of chemicals and
are useful for extrapolation across dose routes, between species, from high-to-low-doses,
and across exposure scenarios (Clewell and Andersen, 1985; Anderson, 2003).
A PBPK model has been developed based on published models in the literature to de-
scribe the absorption, distribution, metabolism, and excretion of Dioxin and dioxin like
compounds (DLCs) in the rat. Data from the National Toxicology Program (NTP) two
year experiment TR-526 are used to illustrate model fitting and statistical estimation of
the parameters. Typically, parameter estimates in these models are only presented as point
estimates with no margin of error or estimate of variation. Integrating statistical methods
into risk assessments is the most efficient way to characterize the variation. In this chapter
a Bayesian approach via a Markov Chain Monte Carlo (MCMC) algorithm applied to a
PBPK model described by a system of ordinary differential equations is used to estimate
select parameters and to describe the variation of the select parameters of the system. A
future aim will be to use this model and data from NTP’s study to evaluate the toxic equiv-
alency methodology with PBPK models.
Figures 8 and 9 describe the conceptual structure of the PBPK model. The model
contains 4 main compartments: fat, liver, blood, and the rest of the body. The target organs
for this research are the fat and liver. There are also equations for the lumen and stomach
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which are used to introduce the xenobiotics into the system and the parameters in these
two equations will not be estimated as there are a number of previous studies that provide
information such as a stomach emptying rate and absorption rate.
4.2 Model Equations Specified by a System of ODEs
4.2.1 The Data - Doses and Amounts
The NTP of the National Institute of Environmental Health Sciences (NIEHS) con-
ducted a series of studies to better understand the health consequences of chronic exposure
to dioxin and DLCs. In one of these studies, female Harlan Sprague-Dawley rats were ad-
ministered through gavage a mixture of TCDD (CAS NO. 1746 01 6), 2;3;4;7;8-penta
chlorodibenzofuran (PeCDF) (CAS NO. 57117  31  4), and 3;3N;4;4N;5-pentachloro
biphenyl (PCB 126) (CAS NO. 57465  28  8), once daily 5 days a week, for up to 104
weeks (2 years). The mixtures were prepared in a corn oil:acetone (99:1) solution at four
concentration levels in the ratio of one part TCDD, two parts PeCDF, and ten parts PCB-
126. The dose of TCDD was 3.3, 7.3, 15.2, and 33 ng/kg body weight, respectively. These
doses were established using the World Health Organization (WHO) toxic equivalency fac-
tor (TEF) values. The mixture study was designed so each chemical would provide a third
of the total dioxin toxic equivalent (TEQ) of the mixture. These levels were also used to
maximize statistical power to test for possible interactions between the chemicals. These
three chemical compounds make up approximately half of the dioxin-like toxic activity
found in human tissue (Walker et al., 2005).
This study was designed with a chronic exposure scenario. The dosing schedule for
the rats in the NTP Tr526 study was 5 times a week (Monday through Friday) for up to
104 weeks. The actual amount of chemical feed to each rat is determined by the rats
body weight. There were 5 dose groups in the study including a control group, which was
removed for parameter estimation. Body weights were measured for the first 13 weeks then
about once every 3-4 weeks after that.
The body weights were used to calculate a dose per day and for each rat there is one dose
vector of input, each element of which is a daily dose. Initial attempts to input individual
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dosing vectors made computing time to predict the expected concentrations for each rat in
the study far too long to be practical. To speed up simulation, the average dose by dose
level and time group is used and the predicted value will be repeated as many times as
necessary to match the number of observed values at each time point. There were 8 to 10
observations at each design point. To further speed up computing time the dosing data is
input into the model on a weekly scale as opposed to daily. The sum of the five doses per
week was used as input and this further reduced computing time to a manageable level.
Dose units are nanograms per kilogram of body weight per day (ng/kg bw/day) and
the measured concentrations are in picograms per gram of tissue (pg/g) while organ and
body weights are measured in grams (g). Multiplying the weight of the organ at the time
of sacrifice (observation time) by the concentration of the chemical yields the amount. The
amounts are then divided by 1000 to get the mass in nanograms, which is consistent with
the units of the doses.
Figures 14, 15, and 16 show the observed amounts in the fat, liver, and blood compart-
ments. In these figures the control groups are not included as the amounts in the control
groups are negligible and they will not be considered when fitting the model as the expected
outcomes are zero. The dose is increasing from right to left over the panels as well as time
increasing within each panel, observed time points are 13, 30, 52, and 104 weeks. The
obvious pattern is that amounts are increasing as dose level increases. Also, within each
dose level, amounts in the tissues increase with time, and the variability of the amounts
increase with time as well.
After an oral dose TCDD and DLCs are delivered to the blood via the lymphatic
system as well as from the GI tract. The differential equations that are commonly used
in PBPK models to describe the absorption of DLCS (Wang et al., 1997; Emond, 2004,
2006) through the stomach and lumen are below. Fortunately, a closed form solution to this
subsystem of two differential equations exists and was used in the numerical solution. The
solution is found in equation 16.
dALum
dt (ng=week) = KstASt KabsALum
dASt
dt (ng=week) = KstASt +Dose
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at t = 0;ALum = ASt = 0:
Where Kabs and Kst are the absorption rate and the stomach emptying rate respectively.
Solving the two differential equations for the lumen and stomach we can use the equation
below for the amount in the lumen.
ALum = DoseKabs  

Dose
Kabs Kst

e Kst t +

Dose
Kabs Kst  
Dose
Kabs

e Kabst (16)
where ASt and ALum are the amounts of TCDD in the stomach and lumen.
4.2.2 Body Weight over time and Cardiac Output
Body weight over time is modeled with a type of Michaelis Menten kinetics equa-
tion. There is considerable variation in the weights especially as time increases; therefore a
nonlinear mixed effect model for the weights over time with a variance function was used
to predict the mean weight. Details are found in the previous chapter and the estimated
regression coefficients are found in table 10.
BWt = BWt0+BWt0  VmaxtKm+t (17)
Body weight is a very important parameter in PBPK modeling. Cardiac output and
organ volumes are often calculated using the body weight, so the consequences of a poor
fit to the weight data are possibly very far reaching though-out the model. Since wasting
occurs in rats exposed to Dioxin and DLCS (Tuomisto, 1999), Vmax and Km are functions
of dose, where Vmax =Va+Vbdose and Km = Ka+Kbdose.
Once the weight is predicted then the cardiac output can be predicted using an allomet-
ric type of equation. The cardiac output is used in turn to calculate the tissue blood flows
as fractions of the total cardiac output and tissue permeabilities. Again the weight of the
rat plays a very important role in a PBPK model. Using a sub-system or sub-model for
the rat weights including dose as a factor is an improvement over Wang’s 1997 model and
Emond’s 2004 and 2006 models. Only time and not dose level is considered as a covariate
in these previously published models.
Qc(ml=week) = QCCAR 10080  ((BWt)=1000)(0:75) (18)
where QCCAR = 311.4 ml/min/kg
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4.2.3 Liver Compartment
The liver compartment follows the membrane influenced condition and two differ-
ential equations are used in describing the compartment. Equation 19 describes the change
in the amount of chemical in the liver tissue. Equation 20 describes the change in the Liver
blood amount. At time zero the amount is considered to be zero. The input to the liver
tissue is the liver blood and the outputs are the elimination of the free liver concentration
and output of free concentration back to the blood compartment.
In the liver tissue blood sub-compartment the inputs are the amounts from the blood,
liver tissue blood, and the amount in the lumen while the outputs are the amounts in the
liver blood and the free liver concentration.
Liver tissue (intra-cellular sub-compartment):
dAL
dt (ng=week) = ML(CLB CL f ) KeAL f (19)
CL = ALWL ; at t = 0, AL = 0
Liver Tissue Blood (Extra-cellular sub-compartment):
dALB
dt (ng=week) = QL(CB CLB) ML(CLB CL f )+(1 a)KabsALum (20)
CLiB = ALBWLB ; at t = 0, ALB = 0
Where CB, CLB, and CL f are the blood, liver blood, and free liver concentrations. ML is the
liver permeability and QL is the liver tissue blood flow rate. The empirical parameter a is
the fraction of the dose entering the system circulation via the lymphatic flow and Kabs is
the absorption rate constant of TCDD from lumen to the system circulation. Ke is the dose
dependent elimination from the liver. ALum, AL, ALB are amounts of TCDD in the luman,
liver, and liver blood respectively.
The free liver concentration is described by a non linear function solved by using the
bisection method. The two right most terms on the right side of the equation are the amount
of TCDD bound to the Ah receptor and the amount of TCDD bound to the CYP1a2 protein,
respectively.
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CL f (ng=gliver) = 1PL
h
CL  CAhLiCL fKAhd+CL f  
CCYP1A2CL f
KCYP1A2d+CL f
i
(21)
where CAhLi is the Ah receptor level, CL f is the free liver concentration, KAhd is the
TCDD-AH dissociation constant,CCYP1A2 is the concentration of CYP1A2 in the liver and
KCYP1A2d is the TCDD-CYP1A2 dissociation constant. Calculation of free concentration in
liver is done by numerically solving the non linear equation. More details are found in the
numerical methods section. The total concentration is the sum of the specific bound and
free concentrations, ie. Total concentration = Specific bound + Free concentration. The
non linear components of the equation are the specific bound terms.
4.2.4 Adipose Tissue Compartment
The adipose tissue follows the membrane limited condition. Membrane-limitations
are likely for large molecules, which is the case when the resistance of convection is neg-
ligible compared to the membrane transfer resistance. Two differential equations describe
the fat compartment. The input into the tissue is from the fat blood and the output is the
concentration in the fat divided by a partition coefficient. Elimination of TCDD from the
adipose tissue does not occur.
Tissue amount (intra-cellular sub-compartment):
dAF
dt (ng=week) = MF(CFB  CFPF ) (22)
CF = AFWF ; at t = 0, AF = 0
Fat tissue blood (extra-cellular sub-compartment):
dAFB
dt (ng=week) = QF(CB CFB) MF(CFB  CFPF ) (23)
CFB = AFBWFB ; at t = 0, AFB = 0
Where CB is the blood concentration and CFB is the TCDD concentration in the adipose
tissue blood. MF is the adipose tissue permeability and Q f is the adipose tissue blood flow
rate. AFB and AF are the amounts in the fat tissue blood and fat respectively. The input into
the fat tissue blood is from the blood and the amount in the fat tissue. The output is the
amount in the fat blood multiplied by a permeability parameter.
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4.2.5 Blood Compartment
The rate of change of the amount of chemicals in the blood is described by one dif-
ferential equation. The inputs are from the lumen, fat, liver and rest of the body compart-
ments. There is a urinary clearance term Ku which is one parameter that will be considered
as linearly dose dependent, and an intercept and slope will be both be estimated.
d(AB)
dt (ng=week) = QL(CLB CB)+QF(CFB CB)+QR(CRB CB)
+aKabsALum KuAB
(24)
at CB = ABWB ; at t = 0, AB = 0
where Kabs is the oral absorption rate and ALum is the amount in the lumen. Ku is the dose
dependent elimination from the blood also known as urinary clearance. QF , QL, and QR
are the blood flow rates for the adipose tissue, liver, and rest of the body. CLB,CB,CFB,CRB
are the TCDD concentrations in the liver tissue blood, blood, adipose tissue blood, and the
rest of the body respectively.
4.2.6 System of ODEs
All of the equations above are solved simultaneously with the details found in the nu-
merical methods section. The predicted amounts from the ODE system, specifically the
amounts in the liver, fat, and blood are the means of the statistical model specified later.
Physiological parameter descriptions, abbreviations, and values can be found in tables 16
and 17.
There are sub-equations in the liver compartment that describes the binding and induc-
tion of enzymes. These are found in appendix B. Acetanilide-4-hydroxylase ativity (Ah)
activity was measured in the liver (nmol/min/mg) and is used in describing the process of
binding with the Cytochrome P450 1A2 (CYP1A2) protein. Also ethoxyresorufin deethy-
lase (EROD) activity was measured in the liver (pmol/min/mg). EROD is considered a
biomarker for CYP1A1 activity and the equations describe the change in amount in the
liver compartment just as Wang et al.(1997) and Anderson (1997). Since the amount of
CYP1A2 varies with the TCDD, the specific binding to CYP1A2 also varies. This results
in a non-linear binding. The change of CYP1A2 with time is described by the model for a
70
stimulation process proposed by Dayneka et al.(1993). The process of TCDD specifically
bound is simplified using the equilibrium binding equation.
4.3 Methods
One characteristic of the objective is to develop a model of appropriate measure of
tissue amount and examine how statistical methodology can be integrated into the modeling
process. There is a need for clear strategies to incorporate statistical methodology into risk
assessment and PBPK modeling and to address the uncertainty and variability in parameter
estimation.
The R system and its programming language is a powerful tool used in the building,
application, and analysis of dynamic models. Frequently used in combination with object
orientated programming languages such asC++ or Fortran, R is becoming being used for
model simulations in different fields such as epidemiology and microbiology.
Denoting the system of ordinary differential equations (ODE) similar to the documen-
tation for the simecol package developed for the R language (Petzoldt and Rinke, 2007) we
have:
x˙(t) = f(t;x(t);u(t);p)
y(t) = g(t;x(t);u(t);p)
(25)
where x(t) is the state of the system, and x˙ is its first derivative, t is time, u(t) is the input
function. p is a vector of constant parameters. The functions f and g are the state transition
function and the observation function respectively. In this setting x(t) is the output from
the LSODA function (the ODE solver) and g would be the objective function such as the
sum of squares.
Since there is no easy way to obtain an explicit solution to the function f when the
dynamic system becomes large or complicated, a numeric solution is obtained by using
a algorithm. Dynamic systems and continuous models require interpolation of input data
especially when using ODE solvers. There are functions in the base package of R that
conduct interpolation and ”approxfun” is utilized. The function ”approxfun” returns a
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function performing (linear or constant) interpolation of the given data points. For a given
set of x values, this function will return the corresponding interpolated values. The inputs
are time and dose thus when the ODE solver picks up a time other then the exact dosing
time there is an interpolated value that is used as input for the integration.
When using numerical integration to solve a dynamic system of ODEs over a certain
time period, the method must jump from time point to the next successive time point in
a discrete manner. One needs to specify starting values of the concentrations or amounts
ie. the initial conditions at time t0. Then at each point in time the value of the derivatives
are estimated. These are the rates of change of the amounts and the numerical integration
uses the previous values of the amounts plus the rates of change to estimate the value of
the amounts at the next time point of interest. Figure 10 is a flowchart that describes the
numerical integration. A compact expression of the update for each time point can be
written as follows.
At+Dt = f

At ;
dAt
dt
;Dt

(26)
where A is an amount and D is a very small change. Since a closed form solution of most
PBPK models is intractable, a numerical solution to the system of differential equations
must be utilized. When parameter estimation is attempted a numerical solution to the PBPK
model will be calculated at every iteration, thus the numerical solution must be as fast as
possible to avoid excessive computer usage and waiting time.
The R function lsoda provides an interface to the Fortran ODE solver of the same name
and the system of ODEs is written in R. The solver is only one component of the simulation
step. The simecol package has been developed to give users an interactive environment
to implement, modify, and simulate dynamic models without writing long and complex
programs. The package uses an object oriented approach, which provides a flexible way to
implement simulation models of different types.
4.3.1 Calculation of free concentration in liver
In PBPK models the system of nonlinear ODEs can be very complex, involving nu-
merous equations with a large number of parameters and the analytical solutions are not
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available. This can happen because many biological phenomenons are described with non
linear terms such as binding. When modelers encounter these types of situations a numeri-
cal method must be used.
Since there is at least one non-linear function in f another numerical algorithm must be
used to solve it. The calculation of the free concentration in the liver is defined as Free
concentration = Total concentration - Specific bound.
CLi f (ng=gliver) =
1
PL

CL  CAhLiCL fKAhd +CL f  
CCYP1A2CL f
KCYP1A2d +CL f

(27)
The root finding algorithm known as the Bisection method is used to solve the equation
for the free liver concentration. We can denote it asCL f (tjCL(t); p) whereCL is the current
total liver concentration and p are the kinetic parameters involved in the binding process.
1. The numerical solution can run up to the point where CL f is needed
2. Take the current liver concentration CL(t) and the specified parameters to calculate
the free concentration. Use the bisection method, root will be in (0;CL).
3. Thus CLiFree(tjCL(t); p) =CL f (t).
4. Use CL f (t) in the binding equations and continue the numerical solution.
4.3.2 Statistical model
The statistical model can be written as 3 separate equations, one for each major com-
partment, liver, fat, and the blood. Each is a function of dozens of parameters, dose, and
time. Each also has an error term distributed normally.
YL = AL (q ;d; t)+ eL eL  N
 
0;s2L

YF = AF (q ;d; t)+ eF eF  N
 
0;s2F

YB = AB (q ;d; t)+ eB eB  N
 
0;s2B
 (28)
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The responses Yi jk = (YLi jk;YFi jk;YBi jk)T are the amounts of TCDD in the liver, fat,
and blood compartments, respectively, in the kth rat (k = 1; :::;ni j) of ith dose group
(di = 3:3;7:3;15:2;33 ng/kg/day) at time t j (t j = 13;30;52;104 weeks). Denote the mean
by mij = (mFij(d; t;q);mLij(d; t;q);mBij(d; t;q))T. The error terms are a combination of
measurement errors and model error prediction.
There are dozens of physiological and biochemical parameters in the model but six
have been chosen to be estimated. The remaining parameters will be fixed at values found
in previously published papers (Anderson, 1997; Emond, 2004, 2006; Safe, 1988; Wang
1997). A dose dependent elimination rate from the liver Ke is defined as a linear function of
dose (Ke = ae+beDose) thus both the slope and intercept will be estimated. Similarly,
urinary clearance Ku is also linearly dose dependent with intercept au and slope bu. The
fat and liver partition coefficients will also be estimated.
4.3.3 Bayesian approach for parameter estimation via MCMC analysis
When the number of parameters to estimate in a model increases, non-identifiability
problems become more and more complex; and trying to use common optimization tech-
niques with the method of least squares is not efficient. Also the method of least squares
only produces point estimates while using MCMC methods can generate estimates of the
means and variances of the probability distributions of physiological parameters of interest.
MCMC methods can be used to sample values for parameters from complex proba-
bilistic models. In a high dimensional space sampling is an important step for simulating,
estimating parameters, and optimization. Prior distributions are specified for each param-
eter of interest and the hyperparameters of the prior distributions can be specified from
published studies and literature.
In the current PBPK model there are over three dozen parameters. We will only choose
a subset of them to illustrate the algorithm. We will consider estimating six key parameters
grouped in two tiers. In the first tier we have elimination from the liver Ke (for all doses
simultaneously as a function of dose Ke = ae+beDose and urinary clearance Ku, also
linearly dose dependent with intercept au and slope bu. These parameters help determine
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the amount in the tissue and tissue blood sub-compartments of their respective compart-
ments. They also indirectly affect the concentration in other compartments and between
the tissue blood compartment and the tissue compartment.
The second tier of parameters consists of two partitions coefficients. PF is the partition
coefficient for the fat compartment and for the liver compartment, we denote it by PL. These
parameters help determine the amounts in the tissue blood and tissue sub-compartments of
their respective compartments.
Most, if not all PBPK models reported in the literature for exposure to Dioxin and
dioxin like compounds are for acute exposure scenarios and only a few have been used
to describe a sub-chronic exposure (defined as up to a few months). This PBPK model
is chronic in nature as it attempts to describe the absorption, distribution, elimination and
excretion over a two year exposure period, the parameter values in the literature can only
be used as initial guesses as to the true parameter values for this chronic exposure model.
Since these existing parameter values are not well defined for the current problem and/or
unmeasured, there is a need to estimate these values. However, there are many problems
or challenges to this including non-identifiable parameters, the estimation of the variation,
uncertainty in the parameters, and the effect of these uncertainties on predicted outcomes
is unknown.
This PBPK model like other complex dynamic systems includes non-identifiable pa-
rameters which cannot be uniquely determined with a high degree of precision (Vajda et
al., 1989). Such non-identifiability is usually self inflicted by related parameters, mean-
ing the effect of modifying the value of one parameter can be reversed or partially undone
by modifying some other parameter or parameters. This type of over-parametrization is
commonplace for complex models in PBPK and ecological modeling; it is nearly unavoid-
able (Mieleitner and Reichert, 2006). In order for the parameter estimation algorithm to
converge, with estimates of decent precision, the parameter set must be identifiable.
Bayesian probabilistic methodology has been reported as a method to quantitatively
address both variability and uncertainty in PBPK modeling (Jonsson and Johanson, 2003).
However, this has not been done yet in chronic studies of exposure to Dioxin and DLCS
with PBPK models.
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Figure 11 is a flow chart that describes the process of the estimation of the model pa-
rameters. First, the numerical solution of the PBPK model is calculated, then the simulated
values are compared with the observed values and a value of the objective function is re-
alized. MCMC sampling is done to pick up a set of parameter values and then the process
starts over after accepting or rejecting the new set of parameter values.
The MCMC algorithm is summarized as follows.
1. Initial chain t = 0 with initial values of q 0. Where q 0 = (a0e , b 0e , a0u , b 0u , P0f , P
0
Li)
2. Pick up a proposal set of parameters q . This new set q  is accepted as q t+1 if
u<
P(q )Q(q t ;q )
P(q t)Q(q ;q t)
(29)
where u is a value drawn from U[0;1] and Q is a multivariate normal proposal distri-
bution. P is the posterior distribution which is proportional to a function of the sum
of squared residuals between the observed values and the model predictions with the
current value of q and the sum of squares of the differences between the current value
of q and the prior distribution means.
P
 
q jy;s2 µ exp 0:5SS(q)s2 +SSpiror(q )
with
SS(q ) =å
i jk
(yi jk mi j)TS 1i j (yi jk mi j)
and
SSpiror(q ) =å
i

q  q 0
jq 0j=10

If this new set of parameter values q  is not accepted stay at the same place and
q t+1 = q t .
3. Then return to the numerical solution to the PBPK model using as parameter values
q t+1.
The MCMC sampler was implemented using the flexible modeling environment (FME)
package written in the R statistical software language (Soetaert and Petzoldt, 2010). The
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MCMC scheme for drawing samples from the posterior distributions of parameters to be
estimated in the models was obtained by iterating the algorithm above. After collecting
the final samples we drew statistical inference for the parameters q . After 38,000 burn in
iterations every 10th sample was retained out of the next 50,000. The number of iterations
was stopped at 88,00 total due to the traceplots indicating convergence in all six parameters.
All prior distributions for the parameters we estimated are normal with the standard
deviation being set at 10% of the mean. Details are shown in table 18. Furthermore, all
the prior distributions for the inverse of error variances are gamma distributions denoted as
P
 
s 2i jy;q
 Gn2 ; SS(q)2  where i is the index of parameters.
To conduct a sensitivity analysis additional MCMC scenarios were run to estimate pa-
rameters when fixing selected parameters at different values, such as body fat composition,
bioavailability, and cardiac output. The results are in the next section. The above algorithm
is used but one difference is that the standard deviations of the prior distribution of each
parameter is now 50% of the mean for the intercepts and partition coefficients and 25% of
the mean for the slopes of the dose dependent elimination terms Ke and Ku.
4.4 Results
MCMC analysis allows for advantages in PBPK modeling, including but not limited
to the use of experimental data and results from previous published efforts as starting val-
ues or prior distributions, the capability to update multiple variables simultaneously; and
the ability to separately consider parameter variability (i.e., population heterogeneity) and
uncertainty (i.e., lack of information, which can be addressed by collection of additional
data).
4.4.1 Model fit and estimated parameters
Figures 12 and 13 show the traceplots and the histograms of the MCMC analysis. When
the horizontal line on each plot of the trace plots is stabile we consider convergence reached.
This line is the cumulative average of the parameter estimate. The histograms show the
distribution of each parameter and all look normally distributed with the exception of PL,
77
the liver partition coefficient. This looks to have a bimodal distribution with tails similar to
a normal distribution. This is a clear example of parameter non identifiability, there are two
modes in this distribution with the approx values of 24.8 and 25.5. Usually in the literature
partition coefficients are reported as whole numbers and the mean of this distribution is
25.25 so we can use a value of 25 when reporting this parameter.
Table 18 displays the means and standard deviations of the prior distributions of the
MCMC parameters and table 19 displays the estimated posterior means and associated
95% CIs. The mean of the intercept and slope of the elimination term in the liver are 2.536
and -0.00106 respectively. After transformation exp(intercept+ dose slope), this gives
values of 12.42, 12.16, 11.66, and 10.61 for each dose group respectively. The negative
slope indicates we have a decreasing elimination rate from the liver. The range of the slope
of the liver elimination is -1.42e-03 to -7.60e-04 and the 95% CI for the slope is (-1.27e-03,
-8.70e-04). Since zero is not included we can conclude the slope is statistically different
from zero and the elimination from the liver slows as the dose increases. This is consis-
tent with Emonds (2004) PBPK model where the half life is increasing with increasing
exposure.
The estimated values of the intercept and slope of the urinary clearance term are 0.5189
and 0.0001. These give values of 1.683, 1.686, 1.693, and 1.708 for the four dose groups
respectively. These are very close to the point estimate reported by Emond (2004) for the
use in a PBPK model, Emond reports a value of .01 1/hr which in terms of weeks is 1.68
1/week. The positive slope indicates we have an increasing urinary clearance. The range of
the slope of the urinary clearance in the MCMC estimates is 6.19e-05 to 1.38e-04 and the
95% CI for the slope is (8.08e-05, 1.19e-04). Although close to zero the lower bound is
positive thus we can conclude the slope is statistically different from zero and increasing.
The mean value of the partition coefficient for the fat compartment is 200.8 with a 95%
CI of (187.8, 213.9). This is higher than used in Wang’s model (1997) where the value
is 100. However, published partition coefficient values from different studies reveal that
they can range from 80 to 260 (Murphy et al., 1995). Leung et al.(1990a) used a value of
350. So this value of 200.5 is biologically plausible. The mean partition coefficient for the
liver is 25.25 with a 95% CI of (24.2, 26.0). This is also higher than reported values in the
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literature. Wang et al.(1997) and Emond et al.(2004) use a value of 6, but again this values
can range in the literature from 3.3 (Murphy et al., 1995) to 20 (Leung et al., 1990a).
4.4.2 Sensitivity in Parameters
A number of MCMC simulations scenarios were run to estimate parameters when fixing
select parameters such as body fat composition, bioavailability, and cardiac output. The
parameter estimates are found in table 20. Twelve different scenarios were considered.
Combinations of bioavailability at 50, 60 and 75% with percentage of body fat being either
0.069% or 0.169% (the latter is in line with a human being), and cardiac output being fixed
at either 311 or 342 ml/min/kg.
As the value of the bioavailability increases there is an increasing trend in the inter-
cept of the liver elimination (ae). When cardiac output and fat percentage are held at 311
ml/min/kg and 16.9%, the value of ae is 2.29, 2.49, and 2.53 for bioavailability values of
50, 66 and 75 respectively. Thus a 33% reduction in the bioavailability results in a 9.5%
change in the intercept. When the cardiac output and percentage of body fat is held at those
same levels the slope of the dose dependent parameter be is -0.0053, -0.0034, and -0.0040
for bioavailability values of 50, 66 and 75 respectively.
There is a decreasing trend in the intercept of the urinary clearance when bioavailabil-
ity increases and cardiac output and fat percentage are held at 342 ml=min=kg and 6.9%
respectively. The value of au is 0.57, 0.55, and 0.49 for bioavailability values of 50, 66 and
75 respectively. When the cardiac output and percentage of body fat is held at those same
levels the slope of the dose dependent parameter bu stays constant to four decimal places.
The values of the partition coefficients for the liver (Pl) in the different scenarios is
constant and the value of Pf is consistent but different when the fat percentage is 6.9%
compared with 16.9%. When fat percentage is 6.9%, Pf varies between 194 and 196; but
when fat percentage is 16.9%, Pf varies between 78 and 80. This difference in the Pf is
expected as both of these parameters are in the equations of the fat compartment and both
directly influence the amount of chemicals in the compartment.
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A few notes must be made about the limitations of the simulations and the parameter
estimates presented. First, the length of the runs for each MCMC is limited, due to ex-
cessive computation time a maximum of 140;000 was obtained. It is difficult to declare
convergence of the parameter estimates with relatively short runs when there is still large
variability in the trace plots. The exception are the trace plots for the partition coefficients,
these show a stabile cumulative mean. This may be attributed to relatively wide prior
distributions as specified by standard deviations being 50% for the intercepts of the dose
dependent parameters and the partition coefficients, while the standard deviations of the
slopes of the dose dependent parameters is 25%. The acceptance rate range from between
22.3% and 29.8% for the twelve different scenarios.
4.4.3 Uncertainty in Fixed Parameters
PBPK models often contain a large number of parameters. In order to estimate the
parameters in which we do not have values for, other parameters need to be fixed. This
introduces uncertainty into the model which is unavoidable. Bioavailability is a parameter
for which multiple values have appeared in the literature. In Sprague-Dawley rats given just
one single oral dose of 1.0 ug [14C]-2,3,7,8-TCDD/kg bw in a acetone:corn oil mixture,
the fraction absorbed ranged from 66% to 93% (Rose et al., 1976). In a study under a
repeated oral dosing of rats at 1.0 ug/kg/day for 5 days per week for seven weeks, the
gastrointestinal absorption of TCDD was observed to be approximately that observed for
a single oral exposure (Rose et al., 1976). Yet oral exposure of Sprague-Dawley rats to a
larger dose of TCDD in acetone:corn oil (50 ug/kg) resulted in an average absorption of
70% of the administered dose (Piper et al., 1973) also Diliberto et al.(1996) reported an
88% absorption of TCDD following oral exposure.
The estimated values inWang’s 1997 study showed that the estimated fraction of TCDD
absorption was 90, 85, 80, 80, 70, and 70% following a single exposure to a dose from 0.01,
0.1, 0.3, 1.0, 10.0, to 30 ug TCDD/kg bw. On the nanogram scale, this ranges from 10 to
30,000 ng TCDD/kg bw. These results indicate that bioavailability may be dose dependent
and decreasing as the administered dose increases. The doses in the NTP study data used
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in this paper are on the nanogram scale and at the very low end, ranging from only 3.3
to 33 ng TCDD/kg bw/day. Given all these different published values of bioavailability
uncertainty is introduced when fixing this parameter as a constant. Using this informa-
tion the bioavailability for this model was set at 88% to do the parameter estimation for
which the results are presented. Future analysis will include a sensitivity analysis on the
bioavailability parameter and possibly estimating a dose dependent bioavailability.
The cardiac output parameter provides more uncertainty in the model. In studies with
acute or sub-chronic exposure to dioxin like compounds the cardiac output may not need to
vary, yet cardiac output cannot be expected to be a single fixed value for all subjects as there
is evidence of variation in cardiac output due to age and gender in rats and humans. For
example, average resting cardiac output is 5.6 L/min for a human male and 4.9 L/min for a
female (Guyton, 2006). Delp et al.(1998) studied the effects of age and body composition
on cardiac output in Fischer-344 rats and concluded that cardiac output changes with age.
They grouped the rats by age into three categories: juvenile (2-mo-old), adult (6-mo-old),
and aged (24-mo-old) rats. Cardiac output was found to be lower in juvenile rats (51  4
ml/min) than in adult (106  5 ml/min) or aged (119  10 ml/min) groups. Since the NTP
study is a chronic study conducted over two years starting with rats with an average age of
8 weeks a constant cardiac may not describe the biological process well.
In fact each fixed parameter adds a layer of uncertainty which cannot be avoided. Pa-
rameters such as permeabilities (as fraction of tissue blood flow) and partition coefficients
for the fat, liver, and the rest of body have numerous values published yet the true values
are unknown.
4.5 Discussion and Conclusion
PBPK models describe the absorption, distribution, metabolism, and excretion of xeno-
biotics in the body. The key factors in the absorption of Dioxin and dioxin like chemicals
are the gastric non absorption rate (ie. stomach emptying rate), the oral absorption rate,
and the bioavailability. The main factors of the distribution and metabolism are the cardiac
output, tissue blow flows and tissue volumes. Tissue permeability and partition coefficients
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also help determine how chemicals are distributed in tissue and tissue blood compartments.
Finally, elimination depends on the diffusion in and out of the fat tissue, metabolism, se-
questration in the liver, and elimination from the liver and urinary clearance.
Figure 14 displays the model fit in the Liver compartment. The model, with the param-
eter estimates found in table 19 fits the data in the liver compartment best in the two highest
dose groups. The four panels from right to left display the four dose groups in increasing
order. The model overestimates the early time point observations in the two lowest dose
groups. Similar to the liver compartment, the model does not fit the data obtained from the
fat compartment perfectly. It under estimates the amount in the lowest dose group at the last
time point, 104 weeks. From figure 15 we see that the predicted curve for the highest dose
group (33 TCDD ng/kg bw) over estimates the amount at the early time points. The model
fits the second highest dose group (7.3 ng/kg bw) best upon visual inspection. Finally in
the blood compartment the predicted values of the model describe the observed data well
with the exception of the two earliest time points in the highest dose group.
There are two possible explanations for the overestimation of the amounts at the early
time points. The parameter values or the structure of the equations. In most of the com-
partments the equations do not have a nonlinear kinetic component. In the fat and blood
compartment there are only linear kinetics describing the rate in change of the amounts.
Adding non linear components to the model may improve the overall fit, also using differ-
ent target tissue proportions of body weight by dose and time point groups would improve
model fit but both of these would increase the number of parameters necessary to estimate.
One limitation to this model is the lack of data at time points before 13 weeks and lack
of information between one year and two year measurement of tissue concentrations.
The PBPK model presented in this paper is one of the first PBPK models for chronic
exposure to Dioxin for a period of two years time. Previously models (Wang et al., 1997;
Emond, 2004) used data from studies which observation time ranged from only a few hours
up to 30 weeks and are considered sub-chronic at best.
Although other published models have shown a dose-dependent elimination of TCDD
(Andersen, 1993; Kohn, 2001) this is one of only a few PBPK models to present evidence
using a PBPK model that kinetic parameters are dose dependent with a chronic exposure
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scenario, which would be the closest to the actual type and duration of environmental ex-
posure of such chemicals to humans.
Emond et al.(2006) modified their 2004 model to include an inducible elimination term
in the liver based on induction of CYP1A2. Still there is a lack of understanding of the
enzymes metabolizing TCDD and the role of other processes and hepatotoxicity in the
pharmacokinetics of TCDD. A dose-dependent elimination of dioxins can influence expo-
sure assessments in epidemiologic studies assessing the potential adverse health effects of
dioxins and mixtures of dioxin like chemicals.
In the past epidemiologic studies that have addresses the relationship between TCDD
exposure and adverse health effects using a first-order elimination rate from current mea-
sured body concentrations to back-calculate TCDD body burdens at the time of initial ex-
posure (Crump et al., 2003; Steenland et al., 2001). Emond et al.(2005) suggest that using a
model with dose-dependent elimination can result in nonlinear relationships between mea-
sured and predicted body burdens. Applying PBPK models that include dose dependent or
inducible elimination rates to the epidemiologic data may result in quantitatively different
relationships between exposure and adverse health effects observed in these studies.
Future research will include sensitivity analysis with the current model and testing of
the current TEF methodology by applying this model to the other chemicals in the NTP
study. One purpose of building this model is to test the Toxic equivalency factor method
of quantifying the toxicity of a mixture of chemicals. The NTP study from which the data
used in this paper was designed to generate results that could allow the testing of the TEQs.
This model will be fit to the other two dioxin like chemicals in the study, PeCDF, and PCB
126 and also the TEQ of all three chemicals.
Applying the models separately to dioxin, furan, and PCB, as well as to the mixture of
the three based on TEQ we can assess if the TEQmethodology holds true. For example, we
predict the internal dose of the mixture (TEQ) by the PBPK model for the mixture, and call
this the predicted internal dose of the mixture. Also separately we predict the internal dose
of dioxin, furan, and PCB using the PBPK models for each of these compounds, and then
obtain the mixture of the internal doses of the three compounds and denote this mixture
as the predicted internal doses. We can then check the consistency or agreement between
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the predicted internal dose of the mixture with the mixture of the predicted internal doses.
While the true TEQ has to be tested against health outcome using PBPD models, this will
be a first step in verification using PBPK models.
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4.6 Tables
Table 16: Physiological Parameters for the PBPK model for DLCs in Rat.
Parameter Abbreviation Value Reference
QACCR QACCR 311.4 ml/min/kg Emond (2004)
Tissue blow flows (frac of cardiac output)
Total Qc ml/week Calculated
Liver QL .1830 Emond (2004)
Fat QF .0693 Emond (2004)
Rest of Body QR .7487 Emond (2004)
Tissue weights (fraction of Bw)
Blood WBo 0.0760 Wang (1997)
Liver Wlo 0.0362 Emond (2004)
Fat WFo 0.0690 Emond (2004)
Rest of Body WRo 0.7290 Emond (2004)
Tissue Blood weights (fraction of organ)
Liver WliBo 0.2660 Emond (2004)
Fat WFBo 0.0503 Emond (2004)
Rest of Body WRBo 0.0300 Emond (2004)
Permeability (fraction of tissue blood flow)
Fat MF 0:091 Emond (2004)
Liver MLi 0:350 Emond (2004)
Rest of Body MR 0:0298 Emond (2004)
Partition coefficient
Fat PF 100 Wang (1997)
Liver PL 6 Wang (1997)
Rest of body PR 1.5 Wang (1997)
Gastric non absorption rate KS 0.36 1/hr Roth et al.(1993)
Oral Absorption rate KAbs 0.20 1/hr Wang (1997)
Elimination Liver Ke Estimating
Urinary Clearance Ku 0.01 ml/hr Emond (2004)
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Table 17: PBPK model parameters for binding and enzyme activity.
Parameter or Variable Abbreviations Value Reference
CYP1a2 associated ACOH activity
TCDD-AH Dissociation KAhd 0.1 nM Gasiewicz (1984)
TCDD-CYP1A2 Dissociation
KCYP1A2d 0.1 nM Gasiewicz (1984)
Ah receptor level CAhLi .35 nM Safe (1988)
ACOH Basal induction rate K0ACOH 160 nM/hr Webber (1993)
Degradation rate K2ACOH 0:1 liter/hr Wang (1997)
16:8 liter/wk
Maximum Induction Fold InACOH 0:4 nmol/g/hr Anderson (1997)
TCDD-Ah-DNA ICACOH 130 nm Tritscher (1992)
Hill coefficient h .6 Wang (1997)
CYP1a1 associated EROD activity
Basal induction rate K0EROD 160 nM/hr Webber (1993)
1100 pM/hr adjusted
Degradation rate K2EROD 0:1 liter/hr Wang (1997)
16:8 liter/wk
Maximum Induction Fold InEROD 0:365 nmol/g/hr Anderson (1997)
365 pmol/g/hr
TCDD-Ah-DNA ICEROD 130 nm Anderson (1997)
1300 pm Anderson (1997)
Units converted to weeks where necessary in the model.
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Table 18: Specified prior distributions and starting values.
Parameter Abbreviation Prior distribution Hyper-parameters
Ke Intercept ae N(a0e ;(ja0e j=10)2) 2.550
Ke Slope be N(b 0e ;(jb 0e j=10)2) 0.001
Ku Intercept au N(a0u ;(ja0u j=10)2) 0.518
Ku Slope bu N(b 0u ;(jb 0u j=10)2) 0.001
Fat partition coefficient
Pf N(P0f ;(jP0f j=10)2) 190
Liver partition coefficient
Pl N(P0l ;(jP0l j=10)2) 26
Table 19: Estimated posterior means and 95% equal-tail credible intervals.
Parameter Abbreviation Mean 95% CI
Ke Intercept ae 2.536 (2.494, 2.578)
Ke Slope be -1.061e-03 (-1.266e-03, -8.74e-04)
Ku Intercept au 0.519 ( 0.5092, 0.5284 )
Ku Slope bu 1.0014e-04 (8.082e-05, 1.19e-04)
Fat partition coefficient
Pf 200.8 (187.8, 213.9)
Liver partition coefficient
Pl 25.2 (24.2 , 25.9)
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Table 20: Estimated posterior means and 95% equal-tail credible intervals for sensitivity analysis.
bio cardiac output Fat % ae be au bu Pf Pl
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342
0.169
2.35 -3.34e-03 0.39 1e-04 79 25
(2.27, 2.47) (-4.761e-03, -2.209e-03) (0.27, 0.50) (5.00e-05, 1.50e-04) (72.7, 86.1) (24.3, 26.6)
0.069
2.47 -3.93e-03 0.49 1e-04 193 25
(2.36, 2.56) (-4.62e-03, -3.258e-03) (0.38, 0.58) (5.10e-05, 1.48e-04) (177.7, 209.6) (24.2, 26.4)
311
0.169
2.53 -4.03e-03 0.34 1e-04 79 25
(2.41, 2.65) (-5.01e-03, -3.19e-03) (0.21, 0.51) (4.90e-05, 1.48e-04) (73, 85.8) (24.2, 26.4)
0.069
2.56 -5.15e-03 0.43 1e-04 191 25
(2.45, 2.66) (-5.75e-03, -4.55e-03) (0.35, 0.5) (5.10e-05, 1.5e-04) (175.3, 207.7) (24.2, 26.4)
60
342
0.169
2.40 -4.36e-03 0.36 1e-04 80 25
(2.3, 2.49) (-5.34e-03, -3.75e-03) (0.29, 0.48) (5.10e-05, 1.49e-04) (73.6, 86.2) (24.1, 26.1)
0.069
2.53 -5.34e-03 0.55 1e-04 194 25
(2.48, 2.61) (-5.89e-03, -4.93e-03) (0.47, 0.59) (5.00e-05, 1.46e-04) (178.3, 209.1) (24.1, 26.1)
311
0.169
2.49 -3.39e-03 0.68 1e-04 79 26
(2.4, 2.58) (-4.05e-03, -2.62e-03) (0.55, 0.85) (5.30e-05, 1.48e-04) (72.4, 86.1) (24.4, 26.7)
0.069
2.34 -4.69e-03 0.28 1e-04 193 25
(2.21, 2.47) (-6.08e-03, -3.75e-03) (0.19, 0.39) (4.9e-05, 1.46e-04) (177.8, 208.4) (24.2, 26.2)
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2.35 -6.26e-03 0.39 1e-04 78 25
(2.25, 2.43) (-7.08e-03, -5.53e-03) (0.34, 0.44) (5.10e-05, 1.5e-04) (72.4, 85.1) (24.1, 26.1)
0.069
2.32 -5.06e-03 0.57 1e-04 195 25
(2.16, 2.46) (-5.89e-03, -4.33e-03) (0.5, 0.65) (4.90e-05, 1.48e-04) (179.9, 209.4) (24, 26)
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0.169
2.29 -5.33e-03 0.48 1e-04 79 25
(2.25, 2.33) (-6.223e-03, -4.63e-03) (0.4, 0.55) (5.20e-05, 1.47e-04) (72.9, 85.7) (24.1, 26.1)
0.069
2.34 -5.52e-03 0.50 1e-04 194 25
(2.26, 2.44) (-6.45e-03, -4.86e-03) (0.39, 0.62) (5.10e-05, 1.52e-04) (179.4, 208.5) (24.1, 26.1)
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4.7 Figures
Figure 8: Conceptual PBPK model for mixture of Dioxin and DLCs in SD rat.
Figure 9: Specific binding processes in the liver.
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Figure 10: Flow chart for numerical integration
Figure 11: Flow chart computer algorithm.
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Figure 12: Traceplots of MCMC parameter estimates.
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Figure 13: Histograms of MCMC parameter estimates.
92
0
5 0
1 0
0
1 5
0
Dose = 3.3
T o
t a
l  A
m
o u
n t
 i n
 L
i v
e r
 c
o
m
p a
r t m
e n
t
0 30 52 104
Dose = 7.3
0 30 52 104
Dose = 15.2
0 30 52 104
Dose = 33
0 30 52 104
Figure 14: Model fit - Liver compartment.
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Figure 15: Model fit- Fat compartment.
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5 Overall Discussion and Conclusions
In human health risk assessment, exposure assessment, especially in the context of
Dioxin and DLCs, is inherently variable and uncertain as there are little or no human data
to estimate the internal dose of a toxicant in a target tissue. Use of physiologically based
pharmacokinetic (PBPK) models to estimate the internal dose (Anderson, 1995; Clark,
2004) has been proposed to reduce uncertainties, especially regarding interspecies, route to
route, high to low dose, and acute to chronic exposure extrapolation. PBPK models quan-
tify the internal dose in target tissues by using appropriate dose metrics and considering the
process of absorption, distribution, metabolism, and excretion of chemicals that enters the
body. There has been growing efforts in developing, validating, and applying PBPK mod-
els in risk assessment. PBPK models have been used to describe and study the distribution
of chemicals in the body for decades but they have only been applied to toxicology and risk
assessment since the 1980s when models were developed for polychlorinated biphenyls
and other persistent lipophilic compounds (Anderson, 1995).
Traditionally, PBPK models are based on animal studies using a small number of sub-
jects under acute or subchronic exposure. Because PBPK models typically involve a large
number of physiological and biochemical parameters, information from published literature
is often utilized to fix selected parameters as if they are known. Statistical estimation of un-
known parameters is often not performed, instead mathematical simulation is relied upon.
Moreover, kinetic parameters are typically assumed to be constants, free of exposure level.
The first part of the dissertation research focused on a simple pharmacokinetic model to de-
scribe internal tissue (fat and liver) concentrations of dioxin (2,3,7,8-tetrachlorodibenzo-p-
dioxin), a human carcinogen, using single-point time course data from a 2-year chronic ex-
posure study. Statistical estimation was conducted via nonlinear re-weighted least squares
method and the fitted models are used to examine whether the kinetic parameters are dose-
dependent. The statistical modeling process is an attempt to gain insights in statistical
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estimation of PBPK models with multiple tissue compartments and their application in risk
assessment.
We fit the PK model using statistical approaches such as iterative re-weighted least
squares and bootstrap confidence intervals to quantify the variation and uncertainty in the
parameter estimates. It is evident that even in the simple case of a two compartment PK
model that there are no unique solutions to the mathematical equations that describe the
model. Employing weighted least squares is important as variability of the tissue concen-
trations increases with dose and time. Extrapolating to large PBPK models with multiple
compartments and dozens of parameters will only increase the complexity of the problem.
This research fills a gap in the literature in more than one way. It explores and highlights
the uncertainty in the mathematical solution of differential equations that govern PK and
PBPK models, while showing that physiological parameters can vary by exposure level
and should not be treated as constants during long term studies. These are two avenues of
model development that need to be traveled to improve risk assessment and the modeling
process that risk assessment relies upon.
In 2004 the National Research Council (NRC) reviewed the EPA’s Exposure and
Human Health reassessment of 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) and related
compounds. Recommendations were made for improvement in the quantitative approaches
used to characterize risk. These recommendations included improving the way uncertainty
and variability are handled and communication of the methods used to do so.
PBPKmodels for exposure assessment can be used to enhance quantification and reduc-
tion of uncertainties concerning inter-species, high-to-low dose, route-to-route extrapola-
tion (Wang et al., 2000; Anderson 2003). Within the context of pharmacokinetic modeling,
uncertainties can be categorized as model uncertainty or parameter uncertainty. The choice
of model for pharmacokinetic analysis is termed as model uncertainty as it is structural in
nature. Model uncertainty is examined through analysis with alternative model assump-
tions or choices to give a range of outputs (Krupnick et al., 2006).
In the present context, the decision to exclude a pathway or a tissue compartment in
the PK model, or whether to treat some of the kinetic parameters as dose-dependent or
constant are examples of model uncertainty. Our choice of a two-compartment PK model
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for the TCDD tissue concentrations obviously is an over-simplification, hence it is a source
of significant uncertainty and the analysis of dose-dependent kinetic parameters versus
constant parameters illustrates a case of structural uncertainty.
Parameter uncertainty arises from errors or difficulties in either measuring data or ap-
plying data from the measured source. Measurement errors and population variations are
among sources of parameter uncertainty. Among parameter uncertainty, some elements
such as systematic bias are unknown and cannot be quantified; inherent uncertainty such as
population variation (variation) can be quantified, but is irreducible. The overall parameter
uncertainty is conveniently and efficiently quantified with bootstrap confidence intervals.
In this paper we have illustrated statistical estimation of multiple tissue compartment
PK models, through which, we also have quantified parameter uncertainty using confi-
dence intervals. In particular, we have investigated parameter uncertainty associated with a
structural relationship - whether kinetic parameters are dose-dependent.
Nonlinear PK models make conventional methods for estimating standard errors and
confidence intervals difficult and less reliable. In contrast, the bootstrap bias corrected
intervals utilize the sampling distribution of the bootstrap samples, are less dependent on
conventional assumptions such as symmetry, and thus are robust. The applicability of boot-
strap methods in deriving confidence intervals for PBPK models is particularly meaningful
as conventional approaches might be extremely difficult when PBPK models are defined
by a set of differential equations without a closed-form solution.
Although the purpose of the early research is to demonstrate statistical approach to PK
modeling and parameter uncertainty, the ultimate objective was to expand this approach
to PBPK modeling. This required the incorporation of all relevant tissues, a large number
of physiological, biochemical, and kinetic parameters. In such settings the PBPK models
are typically hyper-parameterized in the sense that available data are likely insufficient for
statistically estimating all parameters. Current practice is to fix selected parameters, and
estimate or calibrate the remaining parameters based on mathematical simulations.
A significant part of any PBPK model is to model the size or weight of the animal,
because typically, if not always, organs volumes and weights and other physiological pa-
rameters such as cardiac output are based directly on the weight of the animal.
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Since there is uncertainty and variation in all parameter values there is variation in phys-
iological parameters such as organ weight or volume and we must model the rat growth.
The female Harlan Sprague-Dawley rat weight data from the 2-year carcinogenesis study
conducted by the NTP/NIEHS was used to model the organ and body weight growth. Body
weight growth was modeled using a Michaelis-Menten-like kinetic function in conjunction
with random-effects for between-subject variation and was incorporated into the PBPK
model.
The results of the weight growth modeling indicate that the estimated slopes of theVmax
and Km parameters are dose dependent and they decrease with increasing dose level. This
is more evidence that kinetic parameters are not constant over exposure level. Also, this
suggests that without incorporating exposure effects into the weight function of a PBPK
model can result in over estimation of the weight, which in turn would cause other param-
eters dependent on the body weight to be overestimated as well. Examining the growth of
an experimental subject over time should be done on a case by case basis. In this experi-
ment exposure to the mixture of TCDD, PCB126, and PeCDF, reduced body weight growth
and shortened the growth period. According to the estimates of Vmax and Km for the con-
trol group and the highest dose group, body weight growth was reduced by approximately
27%. Also the growth period was shortened by approximately 46%. These estimates are
calculated from the percent change from the control group.
The organ weights were also modeled as a function of body weights while adjusting for
animals’ age and exposure level. Similar models were developed for other organs including
lung, spleen, and ovary. There is strong evidence that liver weight as a proportion of body
weight increased with the exposure level and growth age of the animals and thus are not
constant with respect to body weight. The proportion of other organs (ie. lung, spleen) to
body weight also changed statistically significantly.
The final section of the dissertation describes the development and parameter estima-
tion of a PBPK model. An algorithm for estimating the parameters of a dynamic system
described by a system of differential equations using a markov chain monte carlo method
was presented, illustrated using data from the NTP study.
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The PBPK model presented is one of the first for chronic exposure to Dioxin for a
period of two years time. Previously models (Wang et al., 1997; Emond 2004) used data
from studies which observation time ranged from only a few hours up to 30 weeks and are
considered sub-chronic at best.
Although other published models have shown a dose-dependent elimination of TCDD
(Andersen, 1993; Kohn, 2001), the model presented is one of only a few PBPK models to
present evidence that kinetic parameters are dose dependent in a chronic exposure scenario,
which would be the closest to the actual type and duration of environmental exposure of
such chemicals to humans.
Emond et al.(2006) modified their 2004 model to include an inducible elimination term
in the liver based on induction of CYP1A2. Still there is a lack of understanding of the
enzymes metabolizing TCDD and the role of other processes and hepatotoxicity in the
pharmacokinetics of TCDD. A dose-dependent elimination of dioxins can influence expo-
sure assessments in epidemiologic studies assessing the potential adverse health effects of
dioxins and mixtures of dioxin like chemicals.
Future research will include sensitivity analysis with the current model and test-
ing of the current TEF methodology by applying this model to the other chemicals in
the NTP study. The NTP TR526 study was designed to generate results that could
allow the testing of the TEQs. This model will be fit to the other two dioxin like
chemicals in the study, 2;3;4;7;8-pentachlorodibenzofuran (PeCDF) and 3;3N;4;4N;5-
pentachlorobiphenyl (PCB 126) and also the TEQ of all three chemicals.
Applying the models separately to dioxin, furan, and PCB, as well as to the mixture of
the three based on TEQ we can assess if the TEQmethodology holds true. For example, we
predict the internal dose of the mixture (TEQ) by the PBPK model for the mixture, and call
this the predicted internal dose of the mixture. Also separately we will predict the internal
dose of TCDD, PeCDF, and PCB using the PBPK models for each of these compounds
and then obtain the mixture of the internal doses of the three compounds and denote this
mixture as the predicted internal doses. We can then check the consistency or agreement
between the predicted internal dose of the mixture with the mixture of the predicted internal
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doses. While the true TEQ has to be tested against health outcome using PBPD models,
this will be a first step in verification using PBPK models.
One implication of this dissertation within the context of existing methodology is that
it has shown that uncertainty in the solutions to the systems of equations that make up
the PBPK model should be dealt with using a range or confidence interval generated by a
resampling technique as the bootstrap method or a probability distribution through markov
chains. Another implication of this dissertation is that tissue compartment volumes in
PBPK models should not be considered as always proportional to body weight.
Implications and plans for future research based on this dissertation include further re-
finement of the PBPK model, examining the difference in predictions when using different
dosing schemes, for example an individual dosing vectors for input vs average dose vector
by dose and time; and examining the results when simulation is on different time scales,
such as days vs weeks. Computing time is a large factor/obstacle.
Long term pharmacokinetic studies designed with more frequent measures of tissue
conentrations/amounts, although expensive, would be ideal for constructing PBPK models
in which to test the toxic equivalence methodology. This research utilized data from only
4 time points months apart. Tissue concentrations were measured at 13, 30, 52 and 104
weeks. Since the PBPK model built in this dissertation was applied on a weekly scale,
weekly observations would have provided more information for parameter estimation.
The take home message from this research should include the fact that there is a large
amount of uncertainty in the current state of science of PBPKmodeling and risk assessment
employing PK and PBPK models. No one single model will describe the exact distribu-
tion, absorption, metabolism and elimination of TCDD and DLCS, our current level of
knowledge of the molecular processes involved includes much too uncertainty.
Also from a mathematical and statistical point of view, the non identifiability of the
actual parameter values used in PBPK models adds variability to the uncertainty. Only
recently, over just the last decade or so, scientists have begun to realize that kinetics are not
constant. This research reinforces that fact by showing elimination in a PBPK model fit to
tissue amounts in a chronic exposure study change as dose (and concentration) increases.
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The statistical estimation of parameters in a PBPK model built for risk assessment
or for testing assumptions of methods used in risk assessment, such as the toxic equiva-
lence method, must incorporate a multidisciplinary approach instead of a strict biological
or mathematical approach. The approach must include expert knowledge of toxicology,
biology, mathematics, statistics, and last but not least computer science to implement the
algorithms in a convenient and efficient manner.
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Denote the amount of a chemical in the liver and the fat by AL(t) =WL(t)CL(t) and
AF(t) =WF(t)CF(t), where W is the organ weight C is the organ-specific concentration,
we the following set of ordinary differential equations (ODE) to describe the mass balance:
dAL(t)
dt
= WoD  (Ke+Kl f )AL(t)+K f lAF(t);
dAF(t)
dt
= Kl fAL(t) K f lAF(t);
with baseline body weightW0, administered dose D, and kinetic parameters K. The general
solution to the ODE can be written as
A(t) = A0+b1 exp(l1t)h1+b2 exp(l2t)h2
where A(t) = (AL(t);AF(t))T , A0 = (a0L;a0F)
T , and b1 and b2 are coefficients solved from
the system with the initial value A(0) = 0. Further, l1 and l2 are the eigenvalues, and
h1 = (h11;h21)T and h2 = (h21;h22)T are the corresponding eigenvectors of the matrix of
the ODE coefficients.
The eigenvectors are
h11 =
 K f l+Ke+Kl f 
q
K2f l 2K f lKe+2Kl fK f l+K2e+2KeKl f+K2l f
 2Kl f
h12 =
 K f l+Ke+Kl f+
q
K2f l 2K f lKe+2Kl fK f l+K2e+2KeKl f+K2l f
 2Kl f
h21 = h22 = 1
and the eigenvalues are given by
l1 =  :5K f l  :5Ke  :5Kl f
+:5
q
K2f l 2K f lKe+2K f lKl f +K2e +2Kl fKe+K2l f
l2 =  :5K f l  :5Ke  :5Kl f
 :5
q
K2f l 2K f lKe+2K f lKl f +K2e +2Kl fKe+K2l f
Note l1 l2 =
q
K2f l 2K f lKe+2K f lKl f +K2e +2Kl fKe+K2l f
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To solve for the steady state amounts a0L and a0F , the steady-state equations0@ 0
0
1A =
0@  (Ke+Kl f ) K f l
Kl f  K f l
1A0@ a0L
a0F
1A+
0@ W0D
0
1A
give the solution a0L =
W0D
Ke
, and a0F =
Kl fW0D
K f lKe
The solution to b1 and b2 is from the initial
condition A(0) = 0.
0 =
W0D
Ke
+

 b2 
Kl fW0D
K f lKe

h11 b2h12
0 =
W0D
Ke
  Kl fW0D
K f lKe
h11+b2(h12 h11)
Specifically,
b1 =
W0D(K f l Kl fh12)
KeK f l(h12 h11) and b2 =
W0D(Kl fh11 K f l)
KeK f l(h12 h11)
Thus the solution to ODE is
AF(t) =
Kl fW0D
K f lKe
+
W0D(K f l Kl fh12)
KeK f l(h12 h11) exp(l1t)+
W0D(Kl fh11 K f l)
KeK f l(h12 h11) exp(l2t)
AL(t) =
W0D
Ke
+
W0D(K f l Kl fh12)
KeK f l(h12 h11) exp(l1t)h11+
W0D(Kl fh11 K f l)
KeK f l(h12 h11) exp(l2t)h12
Utilizing the relationships
h12 h11 =  (l1 l2)Kl f ; K f l Kl fh11 = l1; K f l Kl fh12 = l2
as well as
(K f l Kl fh11)
(h12 h11) =
 l1Kl f
l1 l2 ;
(K f l Kl fh12)
(h12 h11) =
 l2Kl f
l1 l2 ; and A(t) =W (t)C(t)
we have the simplified version given in (3).
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In the NTP Tr526 experiment, information was collected on individual animal tissue
chemistry at weeks 13, 30, 52. Acetanilide-4-hydroxylase Activity (A4H, Ah) activity was
measured in the Liver (nmol/min/mg) and is used in describing the process of binding with
the CYP1A2 protein. Also Ethoxyresorufin deethylase (EROD) activity was measured in
the liver (pmol/min/mg). EROD is considered a biomarker for CYP1A1 activity.
For the Ah (CYP1A2) binding in the liver the change in concentration as Wang 97 and
Anderson 97 did. Since the amount of CYP1A2 varies with the TCDD, the specific binding
to CYP1A2 also varies. This results in a non-linear binding. The change of CYP1A2
with time is described by the model for a stimulation process proposed by Dayneka et
al.(1993). The process of TCDD specifically bound is simplified using the equilibrium
binding equation. Amount of TCDD occupied by Ah receptor. CAhLi is not observed in
TR-526.
CAH TCDD(ng=gliver) =
CAhLiCL f
KAhd+CL f
Amount of acetanilide-4-hydroxylase (ACOH):
dAACOH
dt (nmol=week=gliver) = (SACOH(t)K0ACOH  K2ACOHCACOH))WL
at t = 0, CACOH(t) =CACOHBS
Stimulation function
SACOH(t) = 1+ InACOH

ChAH TCDD
ChAH TCDD+IC
h
ACOH

Amount of TCDD occupied by CYP1A2:
CCYP TCDD(ng=gliver) =
f (CACOH)CL f
KCYP1A2d+CL f
A link between acetanilide-4-hydroxylase (ACOH) concentration,CACOH , and
CYP1A2, is assumed to be linear.
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CCYP1A2 = f (CACOH) = KACOHcypCACOH
Two bind relationships are described by the two ”equations” below. TCDD binds with
the Ah receptor, which in turn binds to DNA sites. Thus there are two different disassocia-
tion constants KAhd2 and Kd .
KAhd2
AhR+TCDD  ! [AhR TCDD]
Kd
[AhR TCDD]n+DNAn  ! [AhR TCDD DNA]n
Kmx is the maximum CY1A2 synthesis rate and K0 is the basal synthesis rate as a
fraction of KMx; h is the coefficient in the Hill model (h > 0). Denote AA2 as the total
CYP1A2 amount in the intra-cellular domain, and AA2 =WLiPLiCA2
CA2BS is the Basal level ofCA2. While K0 is the zero order basal rate for CYP1A2 synthesis
and K2 is the first order constant rate for CYP1A2 degradation. Note that when TCDD= 0
then CL f = 0 andCAh TCDD = 0, thus CA2 will not vary, hence dAA2dt = 0.
We need a value for Kmx so we can use an estimate of a basal synthesis rate to get K0 as
a fraction for Kmx. We can use Ahli = :35 nmol as reported in Safe (1988) and KDah = 7:5
nm for CyP1A2 from Anderson et al.(1997).
Biding to CYP1A1 (EROD activty) is described using the same form of equilibrium
binding equation as the CYP1a2 binding process. All the parameter notations are the same
with an Er prefix in the subscript.
Amount of EROD:
dAEROD
dt (pmol=week=gliver) = (SEROD(t)K0EROD K2ERODCEROD))WL
at t = 0, CEROD(t) =CERODBS also K0EROD = K2ERODCERODBS
Stimulation function for EROD:
SEROD(t) = 1+ InEROD

ChAH TCDD
ChAH TCDD+IC
h
EROD

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KErmx is maximum CY1A1 synthesis rate and KEr0 is the basal synthesis rate as a
fraction of KMx. Denote AEr as the total CYP1A1 amount in the intra-cellular domain, and
AEr =WLPLCEr. CErBS is the Basal level of CEr. While KEr0 is the zero order basal rate
for CYP1A1 synthesis and KEr2 is the first order constant rate for CYP1A1 degradation.
Note that when TCDD= 0 then CL f = 0 and CEr TCDD = 0, thus CEr will not vary, hence
dAEr
dt = 0.
The data from the control group in the TR526 data will provide baseline and max syn-
thesis values for the binding process. KErmx so we can use an estimate of a basal synthesis
rate to get KEr0 as a fraction for KErmx. We can write the amount of Ah receptor occupied
by TCDD as:
CEr TCDD = (AhLiCL f )=(KErd2+CL f )
With Ahli = :35 nmol as reported in Safe (1988).
The last set of equations describes the rate of change in the rest of the body.
Rest of Body tissues (Intra-cellular sub-compartment):
dAR
dt (ng=week) = MR(CRB  CRPR )
CR = ARWR ; at t = 0, AR = 0
Rest of body tissue blood (Extra-cellular sub-compartment):
dARB
dt (ng=week) = QR(CB CRB) MR(CRB  CRPR )
CRB = ARBWRB ; at t = 0, ARB = 0
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#CLOSED FORM SOLUTION FOR THE 2 COMP PK MODEL
#These are used in the functions for the fat and liver amounts.##
eta11fun<-function(K){K[2]/(.5*(-K[2]+K[1]+K[3]+sqrt((K[2]^2)-
2*K[2]*K[1]+2*K[3]*K[2]+(K[1]^2)+2*K[1]*K[3]+(K[3]^2))))}
eta12fun<-function(K){K[2]/(.5*(-K[2]+K[1]+K[3]-sqrt((K[2]^2)-
2*K[2]*K[1]+2*K[3]*K[2]+(K[1]^2)+2*K[1]*K[3]+(K[3]^2))))}
lambda1fun<-function(K){(.5*(-K[2]-K[1]-K[3]+sqrt((K[2]^2)-
2*K[2]*K[1]+2*K[3]*K[2]+(K[1]^2)+2*K[1]*K[3]+(K[3]^2))))}
lambda2fun<-function(K){(.5*(-K[2]-K[1]-K[3]-sqrt((K[2]^2)-
2*K[2]*K[1]+2*K[3]*K[2]+(K[1]^2)+2*K[1]*K[3]+(K[3]^2))))}
# fat model ######################################################
FATmodelY2 <- function(theta,tdymat,dosedep=FALSE,
fixedfl=TRUE,fixedlf=TRUE){
#fat concentration must be the 3 rd column of the tdymat
#time is col 1 and dose is col2.
if(!dosedep) K1<-exp(theta[1]+0*tdymat[,2]) else
K1<-exp(theta[1]+theta[2]*tdymat[,2])
if(fixedfl) K2<-exp(theta[3]+0*tdymat[,2]) else
K2<-exp(theta[3]+theta[4]*tdymat[,2])
if(fixedlf) K3<-exp(theta[5]+0*tdymat[,2]) else
K3<-exp(theta[5]+theta[6]*tdymat[,2])
eta12<-eta12fun(c(K1,K2,K3))
eta11<-eta11fun(c(K1,K2,K3))
lambda1<-lambda1fun(c(K1,K2,K3))
lambda2<-lambda2fun(c(K1,K2,K3))
tempvec <- (tdymat[,2]/(K1*K2))*(K3+((K2-K3*eta12)/(eta12-eta11))
*exp(lambda1*tdymat[,1])
-((K2-K3*eta11)/(eta12-eta11))*exp(lambda2*tdymat[,1])) #fat
return(tempvec)} #end of fat function
## Liver model ###############################################
LivermodelY2 <- function(theta,tdymat,dosedep=FALSE,
fixedfl=TRUE,fixedlf=TRUE){
# LIVER concentration must be the 4th column of the tdymat!!!
#time is col 1 and dose is col2.
if(!dosedep) K1<-exp(theta[1]+0*tdymat[,2]) else
K1<-exp(theta[1]+theta[2]*tdymat[,2])
if(fixedfl) K2<-exp(theta[3]+0*tdymat[,2]) else
K2<-exp(theta[3]+theta[4]*tdymat[,2])
if(fixedlf) K3<-exp(theta[5]+0*tdymat[,2]) else
K3<-exp(theta[5]+theta[6]*tdymat[,2])
eta12<-eta12fun(c(K1,K2,K3))
eta11<-eta11fun(c(K1,K2,K3))
lambda1<-lambda1fun(c(K1,K2,K3))
lambda2<-lambda2fun(c(K1,K2,K3))
tempvec2<-(tdymat[,2]/K1)*(1+(((K2-K3*eta12)/((K2)*(eta12-eta11)))
*eta11*exp(lambda1*tdymat[,1]))
-(((K2-K3*eta11)/((K2)*(eta12-eta11)))*eta12*exp(lambda2*tdymat[,1])))
return(tempvec2)
}#end of liver function
## ##################################################################
## function to convert theta to K ###################################
theta2k <- function(theta, d, dosedep=FALSE){ #old version of function
#input: theta = parameter estimates on log scale, d = doses.
if(!dosedep){
if(length(theta)!=3) stop("Theta is not of length 3.")
K1<-exp(theta[1])
K2<-exp(theta[2])
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K3<-exp(theta[3])
return(c(K1, K2, K3))
}else{ if(length(theta)!=6) stop("Theta is not of length 6.")
K1<-exp(theta[1]+theta[2]*d)
K2<-exp(theta[3]+theta[4]*d)
K3<-exp(theta[5]+theta[6]*d)
return(as.matrix(data.frame(Ke=K1, Kfl=K2, Klf=K3)))
} } #end o'function
theta2k2 <- function(theta, d, dosedep=FALSE,fixedfl=TRUE,
fixedlf=TRUE)#input:theta=parameter estimates log scale,d=doses.
# is Kfl fixed = fixedfl, Is Klf fixed = fixedlf
if(!dosedep) K1<-exp(theta[1]+0*d) else K1<-exp(theta[1]+theta[2]*d)
if(fixedfl) K2<-exp(theta[3]+0*d) else K2<-exp(theta[3]+theta[4]*d)
if(fixedlf) K3<-exp(theta[5]+0*d) else K3<-exp(theta[5]+theta[6]*d)
return(as.matrix(data.frame(Ke=K1, Kfl=K2, Klf=K3)))
}#end o'function
## ###################################################################
## Calculate the weight matrices from RESIDUALS.######################
newweightmat <- function(theta,tdymat,dosedep=T,fixedfl=F,fixedlf=F){
# input: theta = parameter estimates. tdymat = DATA. and options
if(!dosedep) pke<-1 else pke <-2 #is Ke dose dependent?
if(fixedfl) pkfl<-1 else pkfl<-2 #is Kfl fixed?
if(fixedlf) pklf<-1 else pklf<-2 #is Klf fixed?
p<-pke+pkfl+pklf ; #total # of parameters.
fittedy <- FATmodelY2(theta,tdymat, dosedep=dosedep,fixedfl=fixedfl,
fixedlf=fixedlf) #pred fat
fittedy2<-LivermodelY2(theta,tdymat, dosedep=dosedep,fixedfl=fixedfl,
fixedlf=fixedlf)#pred liver
res.f <- tdymat[,3]-fittedy #fat residuals
res.l<- tdymat[,4]-fittedy2 #liver residuals
resids<-data.frame(res.f,res.l) #dataframe of residuals
nt<-sort(unique(tdymat[,1])) #unique times
nd<-sort(unique(tdymat[,2])) #unique doses
lnd<-length(nd) #number of unique doses
lnt<-length(nt) #number of unique times
pred<- data.frame(fittedy ,fittedy2)
#save weight matrices in an array.
#will use as input to weighted objective function and unlist and convert
# to matrix when needed
saveweights<-array(data = list(matrix(c(1,0,0,1),nrow=2),
matrix(c(1,0,0,1),nrow=2),
matrix(c(1,0,0,1),nrow=2),matrix(c(1,0,0,1),nrow=2),
matrix(c(1,0,0,1),nrow=2),matrix(c(1,0,0,1),nrow=2),
matrix(c(1,0,0,1),nrow=2),matrix(c(1,0,0,1),nrow=2),
matrix(c(1,0,0,1),nrow=2),matrix(c(1,0,0,1),nrow=2),
matrix(c(1,0,0,1),nrow=2),matrix(c(1,0,0,1),nrow=2),
matrix(c(1,0,0,1),nrow=2),matrix(c(1,0,0,1),nrow=2),
matrix(c(1,0,0,1),nrow=2),matrix(c(1,0,0,1),nrow=2)),dim = c(4,4))
allcors<-rep(c(0.80973,0.94639,0.96306,.90011),4)
ocormat<- matrix(allcors,nrow=4,ncol=4,byrow=F)
for(i in 1:lnt) { #times loop
for( j in 1:lnd){ #doses loop
temp<-pred[tdymat[,1]==nt[i]&tdymat[,2]==nd[j],];
corFL<-ocormat[i,j];#cor(temp[,1],temp[,2]);
SDf<-.19901*mean(temp[,1]);
varf<-SDf*SDf;
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SDl<-.19980*mean(temp[,2]);
varl<-SDl*SDl;
covFL<-corFL*.19901*.19980*mean(temp[,1])*mean(temp[,2]);
etestmat<-matrix(c(varf,covFL,covFL,varl),nrow=2); #put in matrix
#var & cov of residuals in temp data frame
saveweights[i,j]<- list(etestmat)
}#end dose loop
} #end time loop
return(saveweights)
}#End o'function to calculate weight matrices.
## OBJECTIVE FUNCTIONS #############################################
#USED FIRST TO GET INITIAL ESITMATES FROM STARTING VALUES
# for 8 groups.. observed times 1,2,3 together by the 4 dose groups
vs time 4 by the 4 dose groups.
mult.model.obj.newweightmat <- function(theta,tdymat,dosedep=T,
fixedfl=F,fixedlf=F){
#input: theta = parameter estimates, tdymat = DATA... options...
if(!dosedep) pke<-1 else pke <-2 #is Ke dose dependent?
if(fixedfl) pkfl<-1 else pkfl<-2 #is Kfl fixed?
if(fixedlf) pklf<-1 else pklf<-2 #is Klf fixed?
p<-pke+pkfl+pklf ; #total number of parameters
fittedy <- FATmodelY2(theta,tdymat, dosedep=dosedep,fixedfl=fixedfl,
fixedlf=fixedlf) #pred fat
fittedy2<-LivermodelY2(theta,tdymat, dosedep=dosedep,fixedfl=fixedfl,
fixedlf=fixedlf)#pred liver
res.f <- tdymat[,3]-fittedy #fat residuals
res.l<- tdymat[,4]-fittedy2 #liver residuals
resids<-data.frame(res.f,res.l) #dataframe of residuals
nt<-sort(unique(tdymat[,1])) #unique times
nd<-sort(unique(tdymat[,2])) #unique doses
lnd<-length(nd) #number of unique doses
lnt<-length(nt) #number of unique times
pred<- data.frame(fittedy ,fittedy2)
#save weight matrices in an array.
#will use as input to weighted objective function and unlist and
# convert to matrix when needed
saveweights<-array(data = list(matrix(c(1,0,0,1),nrow=2),
matrix(c(1,0,0,1),nrow=2),
matrix(c(1,0,0,1),nrow=2),matrix(c(1,0,0,1),nrow=2),
matrix(c(1,0,0,1),nrow=2),matrix(c(1,0,0,1),nrow=2),
matrix(c(1,0,0,1),nrow=2),matrix(c(1,0,0,1),nrow=2),
matrix(c(1,0,0,1),nrow=2),matrix(c(1,0,0,1),nrow=2),
matrix(c(1,0,0,1),nrow=2),matrix(c(1,0,0,1),nrow=2),
matrix(c(1,0,0,1),nrow=2),matrix(c(1,0,0,1),nrow=2),
matrix(c(1,0,0,1),nrow=2),matrix(c(1,0,0,1),nrow=2)),dim = c(4,4))
allcors<-rep(c(0.80973,0.94639,0.96306,.90011),4)
ocormat<- matrix(allcors,nrow=4,ncol=4,byrow=F)
savemat<- matrix(0,nrow=lnt,ncol=lnd)
for(i in 1:lnt) { #times loop
for( j in 1:lnd){ #doses loop
temp<-pred[tdymat[,1]==nt[i]&tdymat[,2]==nd[j],];
corFL<-ocormat[i,j];#cor(temp[,1],temp[,2]);
SDf<-.19901*mean(temp[,1]);
varf<-SDf*SDf;
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SDl<-.19980*mean(temp[,2]);
varl<-SDl*SDl;
covFL<-corFL*.19901*.19980*mean(temp[,1])*mean(temp[,2]);
vcmat<-matrix(c(varf,covFL,covFL,varl),nrow=2);
invvcmat<- ginv(vcmat)#solve(vcmat)
#use residuals with var-cov of observed data...
residstemp<-resids[tdymat[,1]==nt[i]&tdymat[,2]==nd[j],];
testsum<- sum(apply(residstemp,1,function(x){
test<-as.numeric(t(x)%*%invvcmat%*%as.matrix(x))}));
savemat[i,j]<-testsum
}#end dose loop
} #end time loop
return(sum(savemat) )
} #End o'function.
## reweighted OBJECTIVE FUNCTION used in IRLS
w.mult.model.obj.newweightmat <- function(theta,tdymat,w,dosedep=T,
fixedfl=F,fixedlf=F){
#input: theta = parameter estimates, tdymat = DATA... options..
fittedy <- FATmodelY2(theta,tdymat, dosedep=dosedep,
fixedfl=fixedfl,fixedlf=fixedlf) #pred fat
fittedy2<-LivermodelY2(theta,tdymat, dosedep=dosedep,
fixedfl=fixedfl,fixedlf=fixedlf) #pred liver
res.f <- tdymat[,3]-fittedy #fat residuals
res.l<- tdymat[,4]-fittedy2 #liver residuals
resids<-data.frame(res.f,res.l) #dataframe of residuals
nt<-sort(unique(tdymat[,1])) #unique times
nd<-sort(unique(tdymat[,2])) #unique doses
lnd<-length(nd) #number of unique doses
lnt<-length(nt) #number of unique times
savemat<-matrix(0,nrow=lnt,ncol=lnd)
for(i in 1:lnt) { #times loop
for( j in 1:lnd){ #doses loop
temp<-resids[tdymat[,1]==nt[i]&tdymat[,2]==nd[j],];
vcmat<-matrix(unlist(w[i,j]),nrow=2); #get Weight matrix for i,j
and unlist and put into matrix
invvcmat<- ginv(vcmat)#solve(vcmat) # get the sum of the X^{T} *
#W^{-1} * X for all rows in data group i,j
testsum<- sum(apply(temp,1,function(x){
test<-as.numeric(t(x)%*%invvcmat%*%as.matrix(x))}));
savemat[i,j]<-testsum #save results by i and j.
}#end times loop
}#end doses loop
return(sum(savemat) ) # SUM ALL together
} #End o'reweighted objective function!
## function for the Max Element Difference of the weight
#matrices over each iteration.
MaxElementDiff<-function(x,y){#input x old & y new weight matrices
r<-dim(x)[1]; nc<-dim(x)[2]
med<-rep(0,r*nc)
p<-1
for(i in 1:r){
for( j in 1:nc){med[p]<-max(abs(matrix(unlist(x[i,j]),nrow=2)
-matrix(unlist(y[i,j]),nrow=2))); p<-p+1;
} #end row loop } #end col loop.
return(med) }
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#simple SSR###########################
theSSR<- function(theta,tdymat,dosedep=T,fixedfl=F,fixedlf=F){
#input theta = parameter estimates, tdymat = DATA.
if(!dosedep) pke<-1 else pke <-2 #is Ke dose dependent?
if(fixedfl) pkfl<-1 else pkfl<-2 #is Kfl fixed?
if(fixedlf) pklf<-1 else pklf<-2 #is Klf fixed?
p<-pke+pkfl+pklf ; #total number of parameters.
fittedy <- FATmodelY2(theta,tdymat, dosedep=dosedep,fixedfl=fixedfl,
fixedlf=fixedlf) #pred Fat
fittedy2<-LivermodelY2(theta,tdymat, dosedep=dosedep,fixedfl=fixedfl,
fixedlf=fixedlf) #pred Liver
res.f <- tdymat[,3]-fittedy #fat residuals
res.l<- tdymat[,4]-fittedy2 #liver residuals
resids<-data.frame(res.f,res.l) #dataframe of residuals
return(sum(res.f*res.f+res.l*res.l,na.rm=T));
}
###############################################################
#put it all together now.#put it all together now.
HybridIRLSnewweightmat<-function(start.theta,tdymat,
#start.theta = starting param values, tdymat=DATA
dosedep=dosedep,fixedfl=fixedfl,fixedlf=fixedlf, #options
xtol,reltol,pg.tol,fact.r,itermax=50,
#reltol for odiff or vdiff, pg and fact for optim.
criterion=c("vdiff","odiff"), method=c("nlminb", "optim"), trace=6){
# odiff = objective function difference, vdiff = max differenece in
# weight matrices between iter.
if(method=="nlminb"){
unw.fit<-nlminb(start=start.theta,obj=mult.model.obj.newweightmat,
tdymat=tdymat,
dosedep=dosedep,fixedfl=fixedfl,fixedlf=fixedlf,
#lower = start.theta-abs(start.theta)*1.1,
upper =start.theta+abs(start.theta)*1.1,
control=list(iter.max=itermax,x.tol=xtol,rel.tol=reltol))
}
else{ print("optim #1");
LB <- c(max(-6,as.numeric(start.theta[1])-3),-.025,
max(-6,as.numeric(start.theta[3])-3),
-.025,max(-6,as.numeric(start.theta[5])-3),-.025);
UB <- c(min(6,as.numeric(start.theta[1])+3),.025,
min(6,as.numeric(start.theta[3])+3),
.025,min(6,as.numeric(start.theta[5])+3),.025);
unw.fit<-optim(par=start.theta,fn=mult.model.obj.newweightmat,
tdymat=tdymat,
dosedep=dosedep,fixedfl=fixedfl,fixedlf=fixedlf,
#lower = start.theta-abs(start.theta)*1.1,
#upper=start.theta+abs(start.theta)*1.1,
lower = LB ,
upper = UB,
method="L-BFGS-B",
control=list(maxit=2,factr=fact.r,pgtol=pg.tol,trace=trace),hessian=F)
print("NOT REWEIGHTED RESULTS:");
print(unw.fit);
unw.fit.SSR<-theSSR(unw.fit$par,tdymat,dosedep=dosedep,
fixedfl=fixedfl,fixedlf=fixedlf); }
okgo<-0
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#if((unw.fit$convergence%in%c(0,1)&unw.fit$value<1500)){if(okgo==0){
print("DOING IRLS");
p <- length(start.theta)
neww <-newvar.by.dt <-try(newweightmat(unw.fit$par,tdymat,dosedep=dosedep,
fixedfl=fixedfl,fixedlf=fixedlf))
i <- 0
odiff <- 1000 #set large to enter while loop
vdiff <- 100000 #set large to enter while loop.
newtheta <- unw.fit$par # CONVERGED STARTING VALUES!!!
newobjective<-mult.model.obj.newweightmat(newtheta,tdymat,dosedep=dosedep,
fixedfl=fixedfl,fixedlf=fixedlf)
while(eval(as.name(criterion))>reltol & i<=itermax){#While loop for IRLS
i <- i+1
cat("IRLS ITERATION: i =", i, "\n")
if(method=="nlminb"){
w.fit <- nlminb(start=newtheta,obj=w.mult.model.obj.newweightmat,
tdymat=tdymat,w=neww,
dosedep=dosedep,fixedfl=fixedfl,fixedlf=fixedlf,
lower = start.theta-abs(start.theta)*1.1,
upper = start.theta-abs(start.theta)*1.1,
control=list(iter.max=500,x.tol=xtol,rel.tol=reltol))
oldobjective <- newobjective
newobjective <- w.fit$objective
}
else{
LB <- c(max(-6,as.numeric(newtheta[1])-3),-.025,
max(-6,as.numeric(newtheta[3])-3),
-.025,max(-6,as.numeric(newtheta[5])-3),-.025);
UB <- c(min(6,as.numeric(newtheta[1])+3),.025,
min(6,as.numeric(newtheta[3])+3),.025,
min(6,as.numeric(newtheta[5])+3),.025);
w.fit <- try(optim(par=newtheta,fn=w.mult.model.obj.newweightmat,
tdymat=tdymat,w=neww,
dosedep=dosedep,fixedfl=fixedfl,fixedlf=fixedlf,
lower = LB, upper = UB,
method="L-BFGS-B",
control=list(maxit=itermax,factr=fact.r,pgtol=pg.tol,
trace=trace),hessian = F))
if(inherits(w.fit,"try-error")||inherits(w.fit,
"Error in solve.default(vcmat)")){
outlist<-list(NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,
unw.fit$par,unw.fit$convergence, unw.fit$message,
unw.fit$value, unw.fit.SSR) #
names(outlist)<-c("startingvalues",
"parameters", "K",
"objective", "Iterations",
"Message", "call", "convergence",
"weights", "SSR", "RealStartVals",
"conv", "mes",
"unw.obj", "unwSSR")
return(outlist) }
else {
oldobjective <- newobjective #save old objective function values
newobjective <- w.fit$value#save new objective values }
oldtheta <- newtheta #save old parameter estimates
newtheta <- w.fit$par #save new parameter estimates
oldw <- neww #replace weights
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#GET THE NEW WEIGHTS!
neww <-newvar.by.dt<-try(newweightmat(newtheta,tdymat,dosedep=dosedep,
fixedfl=fixedfl,fixedlf=fixedlf))
#objective function difference.
odiff <- abs(newobjective-oldobjective)/oldobjective
oldvar.by.dt <- newvar.by.dt
#difference of var-covar matrices.
vdiff <- max( MaxElementDiff(newvar.by.dt,oldvar.by.dt))
print(vdiff)
} } # end while loop
print("SSR");
SSR<-theSSR(newtheta,tdymat,dosedep=dosedep,fixedfl=fixedfl,
fixedlf=fixedlf);
print(SSR);
K <- if(dosedep) theta2k2(w.fit$par,unique(tdymat[,2]),dosedep=dosedep,
fixedfl=fixedfl,fixedlf=fixedlf) else exp(w.fit$par);
outlist<-list(start.theta,
w.fit$par,
K, switch(method, nlminb=w.fit$objective, optim=w.fit$value),
i+1, w.fit$message,
match.call(), w.fit$convergence,
newvar.by.dt, SSR, unw.fit$par,
unw.fit$convergence, unw.fit$message,
unw.fit$value, unw.fit.SSR) #
names(outlist)<-c("startingvalues",
"parameters", "K",
"objective", "Iterations",
"Message", "call",
"convergence", "weights",
"SSR", "RealStartVals",
"conv", "mes",
"unw.obj", "unwSSR")
}
else { print("SORRY CHARLIE BETTER TASTING TUNA NEXT TIME.");
outlist<-list(NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,
unw.fit$par,
unw.fit$convergence,
unw.fit$message,
unw.fit$value,
unw.fit.SSR) #
names(outlist)<-c("startingvalues",
"parameters",
"K", "objective",
"Iterations", "Message",
"call", "convergence",
"weights", "SSR",
"RealStartVals", "conv",
"mes", "unw.obj", "unwSSR")
}
return(outlist)
}#end o'function.
#######################################################################
# BOOTSTRAPPING!!! for PBPK using IRLS
######################################################################
DDbootstrapPBPK <- function(theta,tdymat,dosedep=FALSE,RANDOMsv=FALSE,
B=1000, start.theta,
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xtol, reltol,pg.tol,fact.r,criterion=c("vdiff","odiff"),
method=c("nlminb", "optim"),trace=0,conf=0.95){
ptm <- proc.time()
datetimestart<-date()
fittedy <- FATmodelY2(theta,tdymat, dosedep=dosedep)
fittedyL<- LivermodelY2(theta,tdymat, dosedep=dosedep)
res <- tdymat[,3]-fittedy
resL <- tdymat[,4]-fittedyL
tn <- table(tdymat[,1]); # time group sample size
print(table(tdymat[,1]));
tp <- as.numeric(names(tn));
xy<-table(tdymat[,2],tdymat[,1])#time and dose group sample size
print(xy);
print(tp);
dn <- table(tdymat[,2]) # group sample size
d <- as.numeric(names(dn))
nd <- length(d)
bootres <- res
bootresL <- resL
boottheta <- matrix(0, nrow=B, ncol=length(theta))
bootresid <- matrix(0, nrow=B, ncol=length(res))
IRLSiter <- rep(0,B)
probs <- c((1-conf)/2, 0.5+conf/2)
startvalues<-start.theta
for(b in 1:B){
cat("b =", b, "\n")
for(i in 1:nd){
for(j in 1:4){ #time loop j
bootres[tdymat[,2]==d[i]&tdymat[,1]==tp[j]]<-sample(res[(tdymat[,2]==d[i]&
tdymat[,1]==tp[j])], size=xy[i,j], replace=TRUE)
bootresL[tdymat[,2]==d[i]&tdymat[,1]==tp[j]]<-
sample(resL[(tdymat[,2]==d[i]&
tdymat[,1]==tp[j])], size=xy[i,j], replace=TRUE)
} } #end of for loop with i
bootresid[b,] <- bootres
boottdymat <- tdymat
boottdymat[,3] <- fittedy+bootres
boottdymat[,4] <- fittedyL+bootresL
if(RANDOMsv==FALSE){startvalues<-start.theta}
else {
if(b==1){startvalues<-start.theta}
else {
if (is.na(boottheta[b-1,1])==TRUE) {startvalues<-start.theta}
else {startvalues<-boottheta[b-1,] } } }
bootfit <-try(HybridIRLSnewweightmat(start.theta =theta,tdymat=boottdymat,
dosedep = T,fixedfl=F,fixedlf=F,
xtol = xtol, reltol = reltol ,fact.r=fact.r,pg.tol=pg.tol,itermax=35,
criterion = criterion, method = method, trace = 2) )
if( inherits(bootfit, "try-error")){boottheta[b,]<-rep(NA,length(theta));
IRLSiter[b]<-rep(NA,1) }
else {boottheta[b,]<-bootfit$par;IRLSiter[b]<-bootfit$Iterations}
}
mean2<-function(x){mean(x,na.rm=T)}
var2<-function(x){var(x,na.rm=T)}
bias <- apply(boottheta, 2, mean2) - theta
se <- sqrt(apply(boottheta, 2, var2))
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output <- list(boottheta=boottheta,IRLSiter=IRLSiter)
quantile2<-function(x,probs){ quantile(x,probs=probs, na.rm = TRUE)}
if(dosedep){
output$k3.3 <- t(apply(boottheta, 1,
function(x){theta2k(x, unique(tdymat[,2]), TRUE)[1,]}))
output$k7.3 <- t(apply(boottheta, 1,
function(x){theta2k(x, unique(tdymat[,2]), TRUE)[2,]}))
output$k15.2 <- t(apply(boottheta, 1,
function(x){theta2k(x, unique(tdymat[,2]), TRUE)[3,]}))
output$k33 <- t(apply(boottheta, 1,
function(x){theta2k(x, unique(tdymat[,2]), TRUE)[4,]}))
output$bias <-bias
output$se<-se
output$pctCIbeta <- apply(boottheta, 2, quantile2, probs=probs)
output$centpctCIbeta <- (matrix(2*theta, nrow=2, ncol=6, byrow=T)
- output$pctCIbeta)[2:1,]
output$normCIbeta <- rbind(theta-output$bias-qnorm(.975)*output$se
theta-output$bias+qnorm(.975)*output$se)
output$pctCIk3.3 <- apply(output$k3.3, 2, quantile2, probs=probs)
output$pctCIk7.3 <- apply(output$k7.3, 2, quantile2, probs=probs)
output$pctCIk15.2 <- apply(output$k15.2, 2, quantile2, probs=probs)
output$pctCIk33 <- apply(output$k33, 2, quantile2, probs=probs)
output$centpctCIk3.3<-(matrix(2*theta2k(theta,unique(tdymat[,2]),
TRUE)[1,], nrow=2, ncol=3, byrow=T)- output$pctCIk3.3)[2:1,]
output$centpctCIk7.3<-(matrix(2*theta2k(theta,unique(tdymat[,2]),
TRUE)[2,], nrow=2, ncol=3, byrow=T)-output$pctCIk7.3)[2:1,]
output$centpctCIk15.2<-(matrix(2*theta2k(theta,unique(tdymat[,2]),
TRUE)[3,], nrow=2, ncol=3, byrow=T)-output$pctCIk15.2)[2:1,]
output$centpctCIk33<-(matrix(2*theta2k(theta,unique(tdymat[,2]),
TRUE)[4,], nrow=2, ncol=3, byrow=T)-output$pctCIk33)[2:1,]
}else{ output$bias <-bias
output$se<-se
output$bootk <- t(apply(output$boottheta, 1, theta2k,
d=unique(tdymat[,2]), dosedep=FALSE))
output$pctCIk <- apply(output$bootk, 2, quantile2, probs=probs)
output$pctCItheta <- apply(output$boottheta, 2,
quantile2, probs=probs)
output$centpctCItheta <- (matrix(2*theta, nrow=2, ncol=3, byrow=T)
- output$pctCItheta)[2:1,]
k <- theta2k(theta, unique(tdymat[,2]), FALSE)
output$centpctCIk <- rbind(2*k - output$pctCIk[2,], 2*k
- output$pctCIk[1,]) }
times<-proc.time() - ptm
output$times<-c(times[3],times[3]/60,times[3]/60/60)
names(output$times)<-c("secs","Mins","Hrs")
output$datetimestart<- datetimestart
output$datetimend<-date()
output$call <- match.call()
return(output)
}#End o'function for bootstrapping.
#PBPK model and MCMC#########################
#NEED TO LOAD LIBARIES#################
library('lattice') #requried for FME
library('coda') #required for FME
library('deSolve') #required for simecol
library('MASS') #required for FME
library('rootSolve') # required for FME
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library('minpack.lm') # required for FME
library('simecol') # NECESSARY!
library('FME') # NECESSARY!
######PBPK model code################
newPBPK<-new("odeModel",
main = function (time, init, parms, loadDose) {
with(as.list(c(parms, init, inputs)), {
######Input:Dose, Dose level, ave body weight####
Dose <- Bio*inputs$Dose(time); #
Doselevel <- inputs$Doselevel(time);
BWt0 <- inputs$Bwt0(time);
######Body weight over time and Cardiac ouput################
Vmax<-exp(Va+Vb*Doselevel*5) # mult by 5
Km<-exp(Ka+ Kb*Doselevel*5) # mult by 5
BWtime<-Wint+Wint*((Vmax*time)/(Km+time)) #grams
Qc <- QCCAR*10080*((BWtime)/1000)^(0.75); # QCCAR is in ml/min/kg
Qli <- Qli0*Qc; #tissue blow flows (fraction of cardiac output) liver=.183
Qf <- Qf0*Qc; #fat = .069
Qr <- Qr0*Qc; #rest o body = .748
Mf <- Mf0*Qf; #Tissue permeabilities.
Mli <- Mli0*Qli;
Mr <- Mr0*Qr;
#######Organ weights as fraction of body weight#####################
LivW<-WLi*BWtime; LivbW<-WLib* LivW
BloodW<-WB*BWtime
FatW<- WF*BWtime; FatbW<- WFb*FatW
RestW<- WR*BWtime; RestbW<- WRb*RestW
#######Elimination term from liver...possibly doselevel dependent######
KLi<-exp(alpha.e+ beta.e*Doselevel*5); #multiply doselevel by 5
# this is the liver elimination (metabolism and elim combined)
#######Elimination term from blood, urinary..possibly doselevel dependent#
Kuri<-exp(KuriA+ KuriB*Doselevel*5); #multiplyby 5; urinary clearance.
#####Gastrointestinal absorption and
#Distribution of TCDD to the portal lymphatic Circulation.
# dAst <- Dose*bio - Kst*Ast; #STOMACH
# dAlum <- Kst*Ast - Kabs*Alum; #LUMAN
#new from closedform solution.
Alum<- (Dose/Kabs) - (Dose/(Kabs-Kst))*exp(-Kst*time) +
((Dose/(Kabs-Kst))-(Dose/Kabs))*exp(-Kabs*time)
#####BLOOD###############################################################
dAb<-Qli*((Alib/LivbW) - (Ab/BloodW)) + Qf*((Afb/FatbW) -
(Ab/BloodW)) + Qr*((Arb/RestbW)
- (Ab/BloodW) ) + a*Kabs*Alum - Kuri*(Ab/BloodW)*BloodW #new
######LIVER###############################################################
Clif<- Cfree2(Ali,LivW,Pli,Ahli,KAhd,Kcyp1a2d) #Free conc in Liver
Alif<-Clif*LivW
if(Alif<0) {Alif<-0}#constraint
dAli <- Mli*((Alib/LivbW)-((Alif/LivW)/Pli)) - KLi*(Alif/LivW)*LivW #LIVER
dAlib <- Qli*((Ab/BloodW)-(Alib/LivbW)) + (1-a)*Kabs*Alum -
Mli*((Alib/LivbW)-((Alif/LivW)/Pli)) #LiverBLood
#####BINDING OF FREE LIVER CONC TO AH receptor and CYP1A2#################
CAhTCDD <- (Ahli*(Alif/LivW)) /(KAhd + (Alif/LivW)) # Ah-TCDD
Acyp1a2<-KACOHCYP*AACOH #linear relationship between ACOH and CYP1a2
CcypTCDD <- ( Acyp1a2*(Alif/LivW)) /(Kcyp1a2d + (Alif/LivW))
denom<-(KAhd + (Alif/LivW))
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########### ACOH Activity in Liver#######################################
#stimulation function
Sacoh<- 1 + InACOH*((CAhTCDD^H)/((CAhTCDD^H)+(IcACOH^H)))
dAACOH<- (K0ACOH*Sacoh - K2ACOH*(AACOH/LivW))*LivW #ACOH amount
SACOHp2<-InACOH*((CAhTCDD^H)/((CAhTCDD^H)+(IcACOH^H)))
########### EROD Activity in Liver#######################################
#stimulation function
Serod<- 1 + InEROD*((CAhTCDD^H)/((CAhTCDD^H)+(IcEROD^H)))
dAEROD<- (K0EROD*Serod - K2EROD*(AEROD/LivW))*LivW #EROD amount
SERODp2<-InEROD*((CAhTCDD^H)/((CAhTCDD^H)+(IcACOH^H)))
#####FAT##################################################################
dAf <- Mf*((Afb/FatbW)-((Af/FatW)/Pf)) #tissue
dAfb<-Qf*((Ab/BloodW) - (Afb/FatbW)) - Mf*((Afb/FatbW) -
((Af/FatW)/Pf)) #conc in Fat bloo
#####REST OF BODY#########################################################
dAr <- Mr*((Arb/RestbW)-((Ar/RestW)/Pr)) #REST OF BOdY
dArb <- Qr*((Ab/BloodW) - (Arb/RestbW)) - Mr*((Arb/RestbW)-
((Ar/RestW)/Pr)) # Rest of body blood
##########################################################################
#Constraints...
if(Ali<0) {Ali<-0};if(Alib<0) {Alib<-0}
if(Af<0) {Af<-0};if(Afb<0) {Afb<-0}
if(Ar<0) {Ar<-0};if(Arb<0) {Arb<-0};if(Ab<0) {Ab<-0}
#########################################################################
list(c(dAli,dAlib,dAf,dAfb,dAr,dArb,dAACOH,dAEROD,dAb) #9
,c(Alum=Alum,Alif=Alif,AhTcddL=CAhTCDD,Cyp=CcypTCDD,KLi=KLi,
Dose=Dose,BWt0=BWt0, #16
BWt=BWtime,Qc=Qc,Qli=Qli,Qf=Qf,Qr=Qr,
Acyp1a2= Acyp1a2,LivW=LivW,
Sacoh=Sacoh,Serod=Serod,Wb=BloodW,#26
LivW=LivW,LivbW=LivbW,BloodW=BloodW,
FatW=FatW,FatbW=FatbW, RestW=RestW,#32
Mli=Mli,Mf=Mf,Mr=Mr,Krui=Kuri)) #36
})},
equations = list(
Cfree2 = function(Ali,LivW,Pli,Ahli,KAhd,Kcyp1a2d){
#uses bisection method to solve
# non linear eq for Free conc in liver.
n<-10
xa<-0
xb<-Ali/LivW
lastv<-.15*(Ali/LivW) #(Alif/(WLi*BWtime))
for(i in 1:n){
testv<-(xa-(1/Pli)*((Ali/LivW)-(Ahli*xa/(KAhd+xa)) -
(Ahli*xa/(Kcyp1a2d+xa))))*(((xa+xb)/2)-(1/Pli)*
((Ali/LivW)-(Ahli*((xa+xb)/2)/
(KAhd+((xa+xb)/2)))-(Ahli*((xa+xb)/2)/(Kcyp1a2d+((xa+xb)/2)))))
if( is.nan(testv)==TRUE) {midpoint<-lastv}
else{
if((xa-(1/Pli)*((Ali/LivW)-(Ahli*xa/(KAhd+xa))-(Ahli*xa/(Kcyp1a2d+xa))))*
(((xa+xb)/2)-(1/Pli)*((Ali/LivW)-(Ahli*((xa+xb)/2)/(KAhd+((xa+xb)/2)))-
(Ahli*((xa+xb)/2)/(Kcyp1a2d+((xa+xb)/2)))))<0) xb<-(xa+xb)/2
else xa<-(xa+xb)/2; }
list(left<-xa,right<-xb, midpoint<-(xa+xb)/2)
midpoint->lastv}
return(midpoint)} ),
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parms =c(Wint= 185.4187, #BW parameters Now in weekly units.
Va= -0.2000187,Vb=-0.0006579897,#BW parameters Now in weekly units.
Ka= 1.861746,Kb=-0.001258892,
Kst = 60.48,#60.48, #gastric nonabsorption constant
Kabs= 33.6,#33.6, # oral absroption constant.
a = .3, #fraction of lymph to blood [[(1 - a) goes to liver]]
alpha.e=2.75,
beta.e= -0.001, #slope and intercept of liver elimination.
Bio = .88, #bioaviablity
QCCAR= 311.4 , #Cardiac output ml/min/kg
Mf0=0.091,#Tissue permeamibity (fraction of tissue blood flow)
Mli0=0.35,#Tissue permeamibity (fraction of tissue blood flow)
Mr0 = .0298, #Tissue permeamibity (fraction of tissue blood flow).
KuriA=.581, KuriB=-0.0004 , #dose dependent urinary clearance
Pf=100 ,Pr=1.5,Pli=6 , #partition coefficients
WB=0.076, #weight proportions Blood
WLi=0.0362,WLib=0.266, #Liver and liver blood
WF=0.069,WFb=0.05, #fat and fat blood
WR=0.729,WRb=.03, #rest of body , rest of body compartment blood.
Qli0=.183, #Blood flow rates as fraction of total caridac output.
Qf0=.069, #fat
Qr0=.748, #rest of body
K0ACOH=1.1, #BASAL ACOH induction rate
K2ACOH=16.8, # degradation rate
InACOH=67.2, # Induction fold
IcACOH=130, # TCDD-Ah-DNA
KAhd=.1, # TCDD-AH Dissociation
Kcyp1a2d=.1, # TCDD-CYP1A2 Dissociation
KACOHCYP=1, #linear relationship between ACOH and CYP1A2
K0EROD = 1100,#BASAL EROD induction rate
K2EROD =16.8,# 1.1from Santostefano# degradation rate EROD 1/hr
InEROD=365,# units fold induction
IcEROD=1300,#
H=.6, #hill coefficient
Ahli=.35 #receptor level
),
inputs=list(Bwt0 = approxfun(0:103, rep(loadDose[1],104), rule=2),
#first element of input vector is body weight,
# SECOND element is time
Doselevel = approxfun(0:103, rep(loadDose[3],104), rule=2),
#3rd element of imput vector.
Dose = approxfun(0:103, loadDose[4:107], rule=2)),
# and 4-107 is the dose.
times = c(0:103),
init = c( Ali = 0, Alib = 0, Af = 0, Afb = 0, Ar = 0 , Arb = 0,
AACOH=.5,AEROD=500, Ab=0),
solver = function (y, times, func, parms, ...) {
lsoda(y, times, func, parms, hmax=1, verbose =T,
maxsteps=50000000,rtol=1e-2, atol=1e-2)
}
)#END OF MODEL CODE!########
########### WEIGHTED COST FUNCTION #############################
weightedcostbyWeek <- function(sim, obs,ttt) {
# print("OBJEcTIVE FUNCTION")
###inputs are simulated values and observed values,
#ttt is a vector of times to repeat the simulated.
names(obs)<-c("Ali","Af","Ab") #subtracts simulated from observed
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#and only uses residuals to compute var covar for the weights.
nr<-dim(obs)[1]
Liv<-unlist(obs[c("Ali")])
Fat<-unlist(obs[c("Af")])
Blood<-unlist(obs[c("Ab")])
sim<-sim[c("Ali","Af","Ab")]
Testdiff<-obs-sim
YminusYhat<- matrix(data = unlist(obs) - unlist(sim) ,
nrow = nr, ncol = 3, byrow = F)
obs.df<-data.frame(Liv,Fat,Blood,ttt)
nt<-sort(unique(ttt))
lnt<-length(nt)
savevec<-rep(0,lnt)
for(i in 1:lnt) {
temp<-obs.df[obs.df$ttt==nt[i],]
tempHat<-YminusYhat[obs.df$ttt==nt[i],]
vcmat<-matrix( #Variance covariance matrix
c(var(tempHat[,1]),
cov(tempHat[,1],tempHat[,2]),
cov(tempHat[,1],tempHat[,3]),
cov(tempHat[,2],tempHat[,1]),
var(tempHat[,2]),
cov(tempHat[,2],tempHat[,3]),
cov(tempHat[,3],tempHat[,1]),
cov(tempHat[,3],tempHat[,2]),
var(tempHat[,3])),nrow=3);
testsum<- sum(apply(tempHat,1,function(x){#print("row");
test<-as.numeric(t(x)%*%ginv(vcmat)%*%as.matrix(x)); #solve(vcmat)
return(test);
})); #multivariate sum of squares
savevec[i]<-testsum
}
return(sum(savevec) )}
ObjectivefuncALLDOSEbyWeekTEF <- function(par) {
OUTCOMES<-TEFoutcomes
DOSES<-FINALavedosebyWeekNg[,49:64]
fave <- function(x2) {
inp <- list(Bwt0 = approxfun(0:103, rep(x2[1],104), rule=2),
#first element of input vector is body weight,
# SECOND time is 2nd
Doselevel = approxfun(0:103, rep(x2[3],104), rule=2),
#3rd element of imput vector.
Dose = approxfun(0:103, x2[4:107], rule=2))
# and 4-731 is the dose.
inputs(newPBPK) <- inp
#cat("DOSE:= ", x2[3], "\n")
if(x2[2]==13) {
times(newPBPK) <-c(0,12); };
#not 13,30,52, and 104 but minus one!dosing starts at time = 0.
if(x2[2]==30) {times(newPBPK) <-c(0,29);};
if(x2[2]==52) { times(newPBPK) <-c(0,51); };
if(x2[2]==104) {times(newPBPK) <-c(0,103);};
info<-out(sim(newPBPK,hmax=1,maxsteps=5000000,rtol=1e-2, atol=1e-2))
info[info<0]<-0.0000001
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dim(info)[1]->rownumber
return(info[rownumber,] ) }
parms(newPBPK)[names(par)] <- par
res <- lapply(DOSES , fave) # Applies simulation to each
# dose vector for each time
print(parms(newPBPK))
es.df<-do.call(rbind,lapply(res,data.frame)) #combine all in a data set.
res.df0<-res.df[c("Ali","Alib","Alif","Af","Afb","Ab")]#choosing cols
res.df <-data.frame(Ali=res.df0$Ali+res.df0$Alib+res.df0$Alif,
Af=res.df0$Af+res.df0$Afb,Ab=res.df0$Ab)
res.df2<-data.frame( #repeat simulated data
rep(res.df$Ali,times=c(10,10,8,10,10,10,8,10,10,10,8,10,10,10,8,8)) ,
rep(res.df$Af,times=c(10,10,8,10,10,10,8,10,10,10,8,10,10,10,8,8)),
rep(res.df$Ab,times=c(10,10,8,10,10,10,8,10,10,10,8,10,10,10,8,8)))
names(res.df2)<-c("Ali","Af","Ab")
obtime<-rep(c(13,30,52,104,13,30,52,104,13,30,52,104,13,30,52,104),
times=c(10,10,8,10,10,10,8,10,10,10,8,10,10,10,8,8))
return(weightedcostbyWeek(res.df2,
OUTCOMES[,c("LIVERamount", "FATamount", "BLOODamount")],obtime))
}
modMCMC(f=ObjectivefuncALLDOSEbyWeekTEF,
p= c(alpha.e=-2.0616721,beta.e= -0.13229725,KuriA=8.3557425,
KuriB=-0.0095490400,Pf= 193.56113,Pli=47.025481),
jump =c(.005, .005 ,.05 ,.001 ,3.3 ,.3),
lower =c(-5 , -1 , 0 ,-4 , 50 ,20),
upper =c( 5, .05 , 9 , 4 ,450 ,180),
prior = Prior ,
var0 = NULL, wvar0 = NULL, n0 = NULL,
niter = 1000,
outputlength =100,
burninlength =0, #updatecov = 2, covscale = (2.4^2)/5,
verbose = TRUE)
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